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(57) ABSTRACT
The present invention relates to a droplet microactuator sys-
tem. According to one embodiment, the droplet microactua-
tor system includes: (a) a droplet microactuator configured to
conduct droplet operations; (b) a magnetic field source
arranged to immobilize magnetically responsive beads in a
droplet during droplet operations; (c) a sensor configured in a
sensing relationship with the droplet microactuator, such that
the sensor is capable of sensing a signal from and/or a prop-
erty of one or more droplets on the droplet microactuator; and
(d) one or more processors electronically coupled to the drop-
let microactuator and programmed to control electrowetting-
mediated droplet operations on the droplet actuator and pro-
cess electronic signals from the sensor.
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DROPLET MICROACTUATOR SYSTEM	 spread of genetic testing and the many advantages that are
associated with it. There is thus a need for new technological
1 RELATED APPLICATIONS	 platforms that allow one to quickly and reliably sequence
nucleic acids at a reasonable cost. The invention described
This application also is related to and incorporates by ref- 5 herein provides an inexpensive, droplet-based sequencing
erence related provisional U.S. Patent Application Nos.	 system.
60/745,058, entitled "Filler Fluids for Droplet-Based Microf-	 Immunoassays are widely used for clinical diagnostics and
luidics" filed on Apr. 18, 2006; 60/745,039, entitled "Appa- 	 constitute more than a $3 billion market in the US alone.
ratus and Methods for Droplet-Based Blood Chemistry," filed 	 Immunoassays are among the most sensitive and specific
on Apr. 18, 2006; 60/745,043, entitled "Apparatus and Meth- io methods that are routinely used in a clinical laboratory.
ods for Droplet-Based PCR," filed on Apr. 18, 2006; 60/745, 	 Immunoassays make use of the high-affinity and specificity in
059, entitled "Apparatus and Methods for Droplet-Based 	 binding between an antigen and its homologous antibody to
Immunoassay," filed on Apr. 18, 2006; 60/745,914, entitled 	 detect and quantify the antigen in a sample matrix. Hetero-
Apparatus and Method for Manipulating Droplets with a 	 geneous immunoassays such as ELISA (Enzyme-Linked
Predetermined Number of Cells" filed on Apr. 28, 2006; 15 Immunosorbent Assay) are among the most sensitive and
60/745,950, entitled "Apparatus and Methods of Sample 	 specific clinical analysis methods, and have been widely used
Preparation for a Droplet Microactuator," filed on Apr. 28,	 for identification of a large class of antigens and antibodies.
2006; 60/746,797 entitled "Portable Analyzer Using Droplet-	 For example, immunoassays are performed, among other
Based Microfluidics," filed on May 9, 2006; 60/746,801, 	 things, for identification of cardiac markers, tumor markers,
entitled "Apparatus and Methods for Droplet-Based 20 drugs, hormones, and infectious diseases. Small sample con-
Immuno-PCR," filed on May 9, 2006; 60/806,412, entitled 	 sumption, faster analysis, and complete automation are three
"Systems and Methods for Droplet Microactuator Opera-	 highly desirable features that require continual improvement
tions," filed on Jun. 30, 2006; and 60/807,104, entitled 	 in any clinical analyzer. Although state-of-the-art laboratory
"Method and Apparatus for Droplet-Based Nucleic Acid
	
immunoassay analyzers offer good automation and through-
Amplification," filed on Jul. 12, 2006. 	 25 put, they require a significant amount of sample per test
(including dead volumes) and lengthy analysis times. The
2 GRANT INFORMATION 	 long assay times and the large size of these analyzers make
them impractical for use in a point-of-sample collection set-
This invention was made with government support under	 ting.
grant no. DK066956 awarded by the National Institutes of 30	 Also, there is considerable variability in the immunoassay
Health, and no. NNJ06JD53C awarded by NASA. The gov- 	 performance, in large part attributed to the techniques being
ernment has certain rights in the invention. 	 operator dependent, resulting in difficulty comparing results
from study to study and even within the same study if more
3 FIELD OF THE INVENTION 	 than one laboratory is used. A fully automated and integrated
35 analyzer that eliminates the operator dependence and stan-
The invention relates to a droplet microactuator and to 	 dardizes results for the immune monitoring assays would
systems, apparatuses and methods employing the droplet 	 considerably improve the interpretation of results from
microactuator for executing various protocols using discrete	 assays.
droplets. More particularly, the invention relates to droplet- 	 Though significant advances have been made in the auto-
based diagnostics. 	 40 mation of immunoassays, these analyzers are prohibitively
expensive and are not affordable in a low-throughput research
4 BACKGROUND OF THE INVENTION	 setting. Lower end systems with automated plate washers,
incubators and integrated optics still require a skilled techni-
The capability to rapidly conduct biochemical and other 	 cian to perform several key steps in an immunoassay such as
assays is critical in a wide variety of fields. For example, rapid 45 preparing microtiter plates with antibodies and loading
and accurate diagnosis of infectious disease is crucial both for	 samples onto the plates. This results in human error due to
the effective management of disease in individual subjects 	 repeated manual intervention and is a major source of inter-
and for ameliorating the public health problems of multi-drug 	 assay and intra-assay variation.
resistant pathogens and community acquired infections.	 There is also a need forpoint of sample collection testing in
Current PCR-based DNA amplification methods suffer 5o a variety of fields, such as medicine, environmental, and
from a number of drawbacks including high reagent costs, 	 bioterrorism-related detection fields. As an example, point-
labor intensity and susceptibility to cross-contamination. 	 of-sample collection (POC) testing forbedside blood analysis
Furthermore, compared to culture, PCR tests are less capable 	 has improvedbut remains a key challenge formodern medical
of simultaneously assaying multiple species, virulence fac- 	 care. Ideally, POC testing would enable the clinicians to
tors, and drug resistant markers. They often lack sensitivity 55 diagnose and implement life-saving technologies in real-time
and cost-effective quantification of the pathogen. There is a 	 by avoiding the need for large laboratory facilities. There
need in the art for improved devices for nucleic acid detection	 remains a need in the art for a lab-on-a-chip that enables
that would overcome these limitations while also miniaturiz-	 simultaneous monitoring of blood gases, metabolites, elec-
ing and automating the technique so that these assays could	 trolytes, enzymes, DNA, proteins, and cells, on low sample
potentially be applied at the point-of-sample collection with 60 volumes at the POC.
minimal training. 	 Microfluidic control of the fluids is an essential require-
Nucleic acid sequencing is becoming increasingly com-	 ment for a successful lab-on-a-chip. Microfluidic systems can
mon in a variety of fields, such as whole genome sequencing, 	 be broadly grouped into continuous-flow and discrete-flow
diagnostics, pharmacogenomics, and forensics. However, the 	 based architectures. As the name suggests, continuous-flow
sequencing field has been hampered by the expensive nature 65 systems rely on continuous flow of liquids in channels
of sequencing machines. The development of inexpensive, 	 whereas discrete-flow systems utilize droplets of liquid either
high-throughput testing systems is critically important to the 	 within channels or in a channel-less architecture. A common
US 7,815,871 B2
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limitation of continuous flow systems is that liquid transport
is physically confined to permanently fixed channels. The
transport mechanisms used are usually pressure-driven by
external pumps or electrokinetically-driven by high-voltages.
These approaches involve complex channeling and require
large supporting systems in the form of external valves or
power supplies. These restrictions make it difficult to achieve
a high degree of functional integration and control in conven-
tional continuous-flow systems, particularly in realizing a
handheld device at the point-of-sample collection. There
remains a need in the art for a point of sample collection
testing system that makes use of droplet manipulations and
especially a system that can accomplish multiple tests or
multiple types of tests on a single chip.
5 BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to droplet-based diagnostics.
According to one embodiment, a droplet microactuator sys-
tem is provided and comprises: (a) a droplet microactuator
configured to conduct droplet operations; and (b) a sensor
configured in a sensing relationship with the droplet micro-
actuator, such that the sensor is capable of sensing a signal
from and/or a property of one or more droplets on the droplet
microactuator.
6 DEFINITIONS
As used herein, the following terms have the meanings
indicated.
"Activate" with reference to one or more electrodes means
effecting a change in the electrical state of the one or more
electrodes which results in a droplet operation.
"Affinity" means the specific or non-specific intramolecu-
lar attraction of one molecule for another molecule or for a
substrate, such as the attraction of an antibody for its corre-
sponding antigen or hapten.
`Analyte," means a target substance for detection which
may be present in a sample. Illustrative examples include
antigenic substances, haptens, antibodies, proteins, peptides,
amino acids, nucleotides, nucleic acids, drugs, ions, salts,
small molecules, cells.
"Antibody" means a polypeptide that has affinity for an
epitope or hapten. An antibody can be a polyclonal antibody,
a monoclonal antibody, an antibody fragment, and/or an engi-
neered molecule capable of binding the corresponding mem-
ber of a specific binding pair. Antibodies may be labeled or
otherwise conjugated to molecules that facilitate direct or
indirect detection of and/or quantification of the antibody.
"Bead," with respect to beads on a droplet microactuator,
means any bead or particle capable of interacting with a
droplet on or in proximity with a droplet microactuator. Beads
may be any of a wide variety of shapes, such as spherical,
generally spherical, egg shaped, disc shaped, cubical and
other three dimensional shapes. The bead may, for example,
be capable of being transported in a droplet on a droplet
microactuator; configured with respect to a droplet microac-
tuator in a manner which permits a droplet on the droplet
microactuator to be brought into contact with the bead, on the
droplet microactuator and/or off the droplet microactuator.
Beads may be manufactured using a wide variety of materials,
including for example, resins, and polymers. The beads may
be any suitable size, including for example, microbeads,
microparticles, nanobeads and nanoparticles. In some cases,
beads are magnetically responsive; in other cases beads are
not significantly magnetically responsive. For magnetically
responsive beads, the magnetically responsive material may
constitute substantially all of a bead or only one component of
a bead. The remainder of the bead may include, among other
things, polymeric material, coatings, and moieties which per-
mit attachment of an assay reagent. Examples of suitable
5 magnetically responsive beads are described in U.S. Patent
Publication No. 2005-0260686, "Multiplex flow assays pref-
erably with magnetic particles as solid phase," published on
Nov. 24, 2005, the entire disclosure of which is incorporated
herein by reference for its teaching concerning magnetically
io responsive materials and beads.
"dNTP" means deoxynucleotidetriphosphate, where the
nucleotide is any nucleotide, such as A, T, C, G or U.
"ddNTP" means dideoxynucleotidetriphosphate, where the
nucleotide is any nucleotide, such as A, T, C, G or U. It will be
15 appreciated that unless otherwise specifically indicated,
ddNTP can be substituted for dNTP, and vice versa.
"Droplet" means a volume of liquid on a droplet microac-
tuator which is at least partially bounded by filler fluid. For
example, a droplet may be completely surrounded by filler
20 fluid or may be bounded by filler fluid and one or more
surfaces of the droplet microactuator. Droplets may take a
wide variety of shapes; nonlimiting examples include gener-
ally disc shaped, slug shaped, truncated sphere, ellipsoid,
spherical, partially compressed sphere, hemispherical, ovoid,
25 cylindrical, and various shapes formed during droplet opera-
tions, such as merging or splitting or formed as a result of
contact of such shapes with one or more surfaces of a droplet
microactuator.
"Droplet operation" means any manipulation of a droplet
30 on a droplet microactuator. A droplet operation may, for
example, include: loading a droplet into the droplet microac-
tuator; dispensing one or more droplets from a source droplet;
splitting, separating or dividing a droplet into two or more
droplets; transporting a droplet from one location to another
35 in any direction; merging or combining two or more droplets
into a single droplet; diluting a droplet; mixing a droplet;
agitating a droplet; deforming a droplet; retaining a droplet in
position; incubating a droplet; heating a droplet; vaporizing a
droplet; cooling a droplet; disposing of a droplet; transporting
4o a droplet out of a droplet microactuator; other droplet opera-
tions described herein; and/or any combination of the fore-
going. The terms "merge," "merging," "combine," "combin-
ing" and the like are used to describe the creation of one
droplet from two or more droplets. It should be understood
45 that when such a term is used in reference to two or more
droplets, any combination of droplet operations sufficient to
result in the combination of the two or more droplets into one
droplet may be used. For example, "merging droplet A with
droplet B," can be achieved by transporting droplet A into
50 contact with a stationary droplet B, transporting droplet B
into contact with a stationary droplet A, or transporting drop-
lets A and B into contact with each other. The terms "split-
ting," "separating" and "dividing" are not intended to imply
any particular outcome with respect to size of the resulting
55 droplets (i.e., the size of the resulting droplets can be the same
or different) or number of resulting droplets (the number of
resulting droplets may be 2, 3, 4, 5 or more). The term "mix-
ing" refers to droplet operations which result in more homog-
enous distribution of one or more components within a drop-
60 let. Examples of "loading" droplet operations include
microdialysis loading, pressure assisted loading, robotic
loading, passive loading, and pipette loading.
"Electronically coupled" is used herein to indicate an elec-
trical or data relationship between two or more components or
65 elements. As such, the fact that a first component is said to be
electronically coupled to a second component is not intended
to exclude the possibility that additional components may be
US 7,815,871 B2
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present between, and/or operatively associated or engaged
with, the first and second components. Further, electrically
coupled components may in some embodiments include
wireless intervening components.
"Highlight" used with reference to a user interface or the
like, such as a droplet microactuator map as described herein,
means that a component of the user interface or map may be
visually differentiated, e.g., by a change in color, brightness,
shading, shape, or by appearance/disappearance of a symbol,
icon, or other visual identifier. For example, mousing over or
selecting a representation of an electrode on the user interface
or may cause the electrode representation to change color.
Sounds may also accompany highlighted items to further
facilitate user interaction with the system.
"Input device" is used broadly to include all possible types
of devices and ways to input information into a computer
system or onto a network. Examples include stylus-based
devices, pen-based devices, keyboard devices, keypad
devices, touchpad devices, touch screen devices, joystick
devices, trackball devices, mouse devices, bar-code reader
devices, magnetic strip reader devices, infrared devices,
speech recognition technologies.
"Magnetically responsive" means responsive to a magnetic
field. Examples of magnetically responsive materials include
paramagnetic materials, ferromagnetic materials, ferrimag-
netic materials, and metamagnetic materials. Examples of
suitable paramagnetic materials include iron, nickel, and
cobalt, as well as metal oxides such as Fe 3O41 BaFe12O19,
CoO, NiO, Mn2O31 Cr2O3 , and CoMnP.
"Output device" is used broadly to include all possible
types of devices and ways to output information or data from
a computer system to a user or to another system. Examples
include visual displays, LEDs, printers, speakers, modems
and wireless transceivers.
"Protocol" means a series of steps that includes, but is not
limited to, droplet operations on one or more droplet micro-
actuators.
"Select" with reference to a user interactive element, such
as icon, field, or virtual button, displayed on a user interface
means to provide input which results in the execution of
instructions associated with the object. Thus, for example,
selection of a representation of an electrode displayed on a
droplet microactuator map by pointing and clicking on the
electrode representation may result in execution of instruc-
tions necessary for activating the actual electrode and/or
instructions necessary for adding a line of code to a set of
instructions which instructs activation of the actual electrode.
Selection may be achieved using any of a variety of input
devices or combination of input devices, such as mouse,
joystick, and/or keyboard.
"Surface" with reference to immobilization of a molecule,
such as an antibody or in analyte, on the surface, means any
surface on which the molecule can be immobilized while
retaining the capability to interact with droplets on a droplet
microactuator. For example, the surface may be a surface on
the droplet microactuator, such as a surface on the top plate or
bottom plate of the droplet microactuator; a surface extending
from the top plate or bottom plate of the droplet microactua-
tor; a surface on a physical object positioned on the droplet
microactuator in a manner which permits it to interact with
droplets on the droplet microactuator; and/or a bead posi-
tioned on the droplet microactuator, e.g., in a droplet and/or in
a droplet microactuator but exterior to the droplet.
"Washing" with respect to washing a surface means reduc-
ing the amount of one or more substances in contact with the
surface or exposed to the surface from a droplet in contact
with the surface. The reduction in the amount of the substance
6
may be partial, substantially complete, or even complete. The
substance may be any of a wide variety of substances;
examples include target substances for further analysis, and
unwanted substances, such as components of a sample, con-
s taminants, and/or excess reagent. The surface may, for
example, be a surface of a droplet microactuator or a surface
of a bead on a droplet microactuator. In some embodiments,
a washing operation begins with a starting droplet in contact
with a surface, where the droplet includes an initial total
io amount of a substance. The washing operation may proceed
using a variety of droplet operations. The washing operation
may yield a droplet in contact with the surface, where the
droplet has a total amount of the substance which is less than
the initial amount of the substance. In another embodiment,
15 the droplet operation may yield the surface in the absence of
a droplet, where the total amount of the substance in contact
with the surface or otherwise exposed to the surface is less
than the initial amount of the substance in contact with the
surface or exposed to the surface in the starting droplet. Other
20 embodiments are described elsewhere herein, and still others
will be immediately apparent in view of the present disclo-
sure.
When a given component such as a layer, region or sub-
strate is referred to herein as being disposed or formed "on"
25 another component, that given component can be directly on
the other component or, alternatively, intervening compo-
nents (for example, one or more coatings, layers, interlayers,
electrodes or contacts) can also be present. It will be further
understood that the terms "disposed on" and "formed on" are
30 used interchangeably to describe how a given component is
positioned or situated in relation to another component.
Hence, the terms "disposed on" and "formed on" are not
intended to introduce any limitations relating to particular
methods of material transport, deposition, or fabrication.
35 When a liquid in any form (e.g., a droplet or a continuous
body, whether moving or stationary) is described as being
"on", "at', or "over" an electrode, array, matrix or surface,
such liquid could be either in direct contact withthe electrode/
array/matrix/surface, or could be in contact with one or more
40 layers or films that are interposed between the liquid and the
electrode/array/matrix/surface.
When a droplet is described as being "on" or "loaded on" a
droplet microactuator, it shouldbe understood that the droplet
is arranged on the droplet microactuator in a manner which
45 facilitates using the droplet microactuator to conduct droplet
operations on the droplet, the droplet is arranged on the drop-
let microactuator in a manner which facilitates sensing of a
property of or a signal from the droplet, and/or the droplet has
been subjected to a droplet operation on the droplet microac-
50 tuator.
7 BRIEF DESCRIPTION OF THE DRAWINGS
55 FIG.1 is a top plan view of a droplet microactuator for usein amplification protocols in accordance with an embodiment
of the present invention;
FIGS. 2A and 2B are top plan views of a droplet microac-
tuator with a single integrated heater and a plurality of inte-
60 grated heaters, respectively, in accordance with various
embodiments of the present invention;
FIG. 3 is a top plan view of a droplet microactuator for use
in nucleic acid sequence analysis in accordance with an
embodiment of the present invention;
65 FIGS. 4 and 5 are illustrations showing reaction steps and
droplet operations of an illustrative embodiment in accor-
dance with the present invention;
US 7,815,871 B2
7
FIG. 6 is a perspective view of a droplet microactuator for
use in conducting immunoassays in accordance with an
embodiment of the present invention;
FIG. 7 is an illustration showing steps for conducting a
droplet-based sandwich affinity-based assay performed on a
droplet microactuator in accordance with an embodiment of
the present invention;
FIG. 8 is an illustration showing steps for conducting a
competitive affinity-based assay performed on a droplet
microactuator in accordance with an embodiment of the
present invention;
FIG. 9 is a perspective view of a biological fluid analyzer in
accordance with an embodiment of the present invention;
FIG. 10 is a side profile view of a droplet microactuator
loading structure in accordance with an embodiment of the
present invention;
FIGS. 11-13 are illustrations showing steps for immobiliz-
ing and freeing magnetically responsive beads using a mag-
netic field in accordance with various embodiments of the
present invention;
FIG. 14 is an illustration showing steps for immobilizing
and freeing beads using a physical obstacle in accordance
with an embodiment of the present invention;
FIG. 15 is an illustration showing steps for washing a
droplet microactuator surface in accordance with an embodi-
ment of the present invention;
FIG. 16A is a side profile view and FIG. 16B is a top plan
view of a droplet microactuator for transporting droplets in
accordance with an embodiment of the present invention;
FIG. 17 is a perspective view of a biological fluid analyzer
in accordance with an embodiment of the present invention;
FIG. 18 is an illustration of droplet microactuator systems
in accordance with an embodiment of the present invention;
FIGS. 19A and 19B are illustrations of a portable hand-
held analyzer in accordance with an embodiment of the
present invention;
FIG. 20 is an illustration of a user interface of a droplet
control system in accordance with an embodiment of the
present invention; and
FIGS. 21A-21D is a side profile view illustrating various
droplet microactuator sensor element configurations in accor-
dance with various embodiments of the present invention.
8 DETAILED DESCRIPTION OF THE
INVENTION
The invention provides methods, devices and systems for
executing one or more droplet-based biochemical assays. For
example, the invention provides methods, devices and sys-
tems for amplifying nucleic acids, analyzing the sequences of
nucleic acids, conducting affinity-based assays, and/or ana-
lyzing components of bodily fluids.
In certain embodiments, a protocol of the system may
involve one or more of the following steps in any order which
achieves the detection end of the invention: extracting sample
from a subject; processing the sample for loading onto a
droplet microactuator; loading the sample onto the droplet
microactuator; dispensing one or more sample droplets of the
sample for transport on the droplet microactuator; loading
one or more reagents onto the droplet microactuator; dispens-
ing one or more reagent droplets for transport on the droplet
microactuator; transporting one or more reagent droplets and/
or one or more sample droplets so as to bring the one or more
reagent droplets into contact with the one or more sample
droplets thereby effecting interaction of the reagent with the
sample; detecting an effect of the interaction of the reagent
with the sample; providing output notifying the user of the
8
results of the detecting step. Examples of biochemical proto-
cols for use with a droplet microactuator of the invention are
discussed in the ensuing sections.
5 8.1 Nucleic Acid Amplification
The invention provides methods, devices and systems for
amplification of nucleic acids in droplets on a droplet micro-
actuator. A large number of copies of one or more nucleic acid
molecules can be made in a single droplet from a small
10 number of copies or even a single copy present in the droplet.
The methods of the invention generally involve combining
the necessary reactants to form an amplification-ready drop-
let and thermal cycling the droplet at temperatures sufficient
15 to result in amplification of a target nucleic acid, e.g., by the
polymerase chain reaction (PCR). In some embodiments, a
droplet including the amplified target nucleic acid may then
be transported into a subsequent process, such as a detection
process, a process for further manipulation of the target
20 nucleic acid, and/or a sequencing process (e.g., as described
in Section 8.2). Amplification devices may include a droplet
microactuator and components sufficient to conduct droplet
operations affecting the methods of the invention when the
droplet microactuator is loaded with appropriate reagents.
25 Systems of the invention may include the droplet microactua-
tor plus system components designed to facilitate software
control of the operation of the droplet microactuator to
execute protocols of the invention.
An illustrative droplet microactuator 100 for use in ampli-
30 fication protocols of the invention is illustrated in FIG. 1. In
this embodiment, multiple fluid ports and/or reservoirs may
be provided, such as sample reservoirs 102, PCR reagent
reservoirs 104, and primer set reservoirs 106. Heating areas
may also be provided, such as lower temperature heating area
35 108 and upper temperature heating area 110. A sample visu-
alization area 112 may also be provided, utilizing, for
example, a microscope or photomultiplier tube (PMT).
In one embodiment, the invention provides a droplet
microactuator and/or system configured and programmed to
40 effect amplification of a sample in a amplification-ready
droplet followed by capture of the amplified nucleic acid. The
amplified nucleic acid may be treated to denature it into
single-stranded nucleic acid before or after it is contacted
with magnetically responsive beads to permit the single-
45 stranded nucleic acid to bind to the magnetically responsive
beads. Binding, for example, may be accomplished using a
biotin-streptavidin system, e.g., in which the single-stranded
nucleic acid is biotinylated, and the surface (e.g., beads or
droplet microactuator surface) is coated with streptavidin
50 covalently bound thereto. Amplification reagents may be
washed away using a washing protocol. Various other meth-
ods, devices, systems, and other aspects of the invention will
be apparent from the ensuing discussion.
It will be appreciated that an important aspect of the inven-
55 tion involves the ability to conduct droplet operations using
each of the nucleic acid amplification reagents and/or
samples on a droplet microactuator. For example, the inven-
tion includes:
60 (1) a droplet microactuator comprising thereon a droplet
comprising any one or more of the reagents and/or samples
described herein for conducting nucleic acid amplification;
(2) a device or system of the invention comprising such drop-
let microactuator;
65 (3) a method of conducting droplet operations on or otherwise
manipulating a droplet making use of such droplet micro-
actuator or system; and/or
US 7,815,871 B2
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(4) a method of conducting an droplet-based sequence analy-
sis protocol making use of such droplet microactuator or
system.
For example, the droplet operations may include one or
more of the following: loading a droplet into the droplet
microactuator; dispensing one or more droplets from a source
droplet; splitting, separating or dividing a droplet into two or
more droplets; transporting a droplet from one location to
another in any direction; merging or combining two or more
droplets into a single droplet; diluting a droplet; mixing a
droplet; agitating a droplet; deforming a droplet; retaining a
droplet in position; incubating a droplet; heating a droplet;
vaporizing a droplet; cooling a droplet; disposing of a droplet;
transporting a droplet out of a droplet microactuator; other
droplet operations described herein; and/or any combination
of the foregoing. Various other methods, devices, systems,
and other aspects of the invention will be apparent from the
ensuing discussion.
8.1.1 Samples and Sample Preparation
The amplification methods of the invention make use of a
sample which includes a nucleic acid template for amplifica-
tion. The nucleic acid template may be of any type, e.g.,
genomic DNA, RNA, plasmids, bacteriophages, and/or arti-
ficial sequences. The nucleic acid template may be from any
source, e.g., whole organisms, organs, tissues, cells,
organelles (e.g., chloroplasts, mitochondria), synthetic
nucleic acid sources, etc. Further, templates may have a wide
variety of origins, e.g., pathological samples, forensic
samples, archaeological samples, etc. Biological specimens
may, for example, include whole blood, lymphatic fluid,
serum, plasma, sweat, tear, saliva, sputum, cerebrospinal
(CSF) fluids, amniotic fluid, seminal fluid, vaginal excre-
tions, serous fluid, synovial fluid, pericardial fluid, peritoneal
fluid, pleural fluid, transudates, exudates, cystic fluid, bile,
urine, gastric fluids, intestinal fluids, fecal samples, and
swabs or washes (e.g., oral, nasopharangeal, optic, rectal,
intestinal, vaginal, epidermal, etc.) and/or other biological
specimens.
Various sample processing steps may be accomplished to
prepare the nucleic acid template. In some cases, such as
amplification from plasmids or bacteriophages, crude sample
will suffice. In other cases, such as amplification of large
fragments from genomic DNA, highly purified template is
preferred. Sample preparation steps may take place on or off
the droplet microactuator.
The system of the invention may be configured and pro-
grammed to permit processing of a biological sample to pre-
pare a droplet including a nucleic acid template for amplifi-
cation. Some portion or all of this processing may be effected
on or off the droplet microactuator, e.g., using beads having
reagents bound thereto with affinity for target organisms to
isolate the target organisms from a biological sample. The
droplet microactuator may process the sample by dividing it
into one or more discrete droplets for subsequent operations
on the droplet microactuator.
Specimens may, in some instances, be treated to change
reduce viscosity during subsequent droplet operations. For
example, samples can be prepared on the droplet microactua-
tor or off the droplet microactuator by mixing with an alkaline
solution (for example, 10% KOH) or reducing agents such as
dithiothreitol (DTT) or dithioerythritol (DTE) to liquefy the
sample and render it sufficiently fluid to facilitate droplet
operations on a droplet microactuator. Other examples of
suitable sample preparation techniques are described in U.S.
10
Patent Application No. 60/745,950, entitled "Apparatus and
Methods of Sample Preparation for a Droplet Microactuator,"
filed on Apr. 28, 2006.
A droplet including the nucleic acid template may be com-
5 bind with amplification reagents to provide an amplifica-
tion-ready droplet, e.g., combined with PCR reagents to yield
a PCR-ready droplet. Depending on the reagents selected, the
amplification-ready droplet may be isothermally amplified or
thermal cycled to effect amplification of a target nucleic acid.
io Amplified product may be detected and/or quantified in real-
time on a droplet microactuator. In this manner, the invention
provides on-chip, real-time, quantitative amplification to
detect and quantify a target nucleic acid in a sample.
As nearly 100% of the sample can be utilized for analysis
15 (there is no requirement for priming of channels or pumps),
very small sample volumes (e.g., less than about 100 µL or
less than about 50 µL or less than about 25 µL) can be
analyzed. Many tests can be performed using a single, small
sample, and reagent costs can be minimized.
20 8.1.2 Reagents
In the amplification protocols of the invention, various
reagents may be combined with a nucleic acid template to
yield an amplification-ready droplet, such as a PCR-ready
25 droplet. PCR reagents typically include primers, nucleotides,
polymerase, and buffers. These input reagents may be pro-
vided as individual reagents loaded separately onto the drop-
let microactuator and combined using droplet operations on
the droplet microactuator. Moreover, some or all of the
30 reagents may be provided as reagent mixes that are loaded
onto the droplet microactuator in a premixed form. In one
embodiment, all amplification reagents are combined into a
single droplet that must only be combined with a sample
droplet in order to yield an amplification-ready droplet, e.g.,
35 a PCR-ready droplet.
8.1.2.1 Buffer
Reagents will typically include a buffer. The buffer is
selected to facilitate the amplification reaction. Any buffer
which fulfills this function is suitable. Magnesium ions are
40 usefully included in the buffer where the nucleic acid being
amplified is a DNA.
In one embodiment, the buffer includes KCl, Tris and
MgCl2- Other suitable buffers are described in Chamberlain
et al., Nucleic Acid Research 16:11141-11156 (1988). For
45 example, the buffer may comprise about 500 mM KCl, about
100 mM Tris-HCl (pH 8.3), and about 15 mM MgCl2- In
another example, the buffer may comprise about 83 mM
(NH4)2 SO4, about 335 mM Tris-HCl (pH8.8), about 33.5 mM
MgCl2, about 50 mM P-Mercapthoethanol, and about 34 mM
5o EDTA. The buffer may also include primers and/or poly-
merases.
In one embodiment, PCR may be performed sequentially
or in parallel in several droplets in which the concentration of
one or more buffer components is systematically varied (e.g.,
55 in a series of droplets) in order to improve or optimize the
buffer for a specific reaction. Thus, for example, any one or
more of the following buffer components may be varied: KCl;
Tris; MgCl2; (NH4)2SO4; P-Mercaptoethanol; EDTA. Once
the best of the tested buffer conditions is identified, PCR can
60 proceed using the best buffer system or further optimization
may be conducted around the best of the tested buffer sys-
tems.
The invention includes a droplet microactuator including a
droplet thereon which is a buffer or which comprises a buffer
65 component, as well as systems and/or devices including such
a droplet microactuator, and methods of conducting droplet
operations on or otherwise manipulating such droplet on a
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droplet microactuator. Thus, for example, the invention
includes a droplet microactuator comprising a droplet
thereon, which droplet comprises one or more of the follow-
ing components: KCl, Tris, MgCl2; (NH4)2 SO4; R -Mer-
capthoethanol; EDTA.
Further, the invention includes a droplet microactuator
comprising a droplet thereon, which droplet comprises one or
more of the foregoing components at a concentration suffi-
cient to facilitate amplification of a target nucleic acid. More-
over, the invention includes such a droplet along with a poly-
merase, nucleotides and/or one or more primers at a
concentration sufficient to facilitate amplification of a target
nucleic acid. The invention also includes a method of con-
ducting droplet operations on or otherwise manipulating any
of the droplets described in this section using the droplet
microactuator, device, and/or system. For example, the drop-
let operation may include one of more the following: loading
a droplet into the droplet microactuator; dispensing one or
more droplets from a source droplet; splitting, separating or
dividing a droplet into two or more droplets; transporting a
droplet from one location to another in any direction; merging
or combining two or more droplets into a single droplet;
diluting a droplet; mixing a droplet; agitating a droplet;
deforming a droplet; retaining a droplet in position; incubat-
ing a droplet; heating a droplet; vaporizing a droplet; cooling
• droplet; disposing of a droplet; transporting a droplet out of
• droplet microactuator; other droplet operations described
herein; and/or any combination of the foregoing.
8.1.2.2 Primers
Reagents used in the amplification methods of the inven-
tion will include one or more primers. In typical methods, two
primers are used to define the region of the nucleic acid
template that will be amplified. Primers will typically have a
sequence and a length which is selected to ensure efficient
replication with few mistakes. Such primers are often in the
range of about 18-24 bases long. Other requirements for
selection of effective primers are known. Examples of suit-
able primer properties include lack of internal secondary
structure, 40-60% G/C content, balanced distribution of G/C
and A/T rich domains, and lack of complementary at the 3'
ends to avoid formation of primer dimers. Though not spe-
cifically required, primers with one or more of these proper-
ties may be suitably employed in the practice of the invention.
Additionally, the melting temperature (Tm) for primers is
typically selected to permit annealing temperatures of about
55 to about 65° C., or about 62 to about 65° C. A variety of
publicly available computer programs exist to help identify
primers with properties suitable for use in amplification set-
tings. Where two primers are used, they are typically provided
in equal concentrations. Primers may not be necessary in
cases in which the nucleic acid being amplified is an RNA.
In some embodiments, degenerate mixtures of primers are
used. For example, since a given amino acid sequence may be
encoded by several possible codons, the mixture may include
all possible sequences covering all codon combinations for a
target polypeptide. The degenerate primer mixture may be
simplified by identifying codon bias for the organism in ques-
tion, and including only primers commonly used by the
organism.
Primers are provided at any concentration which facilitates
amplification of the target nucleic acid. Concentrations
should be low enough to avoid an undue amount of misprim-
ing, accumulation of non-specific product, and/or primer-
dimer formation. Primer concentration should be high
enough to avoid exhaustion of primer prior to completion of
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the amplification reaction. In some embodiments, concentra-
tions range from about 0.1 µM to about 1 µM or from about
0.1 µM to about 0.6 µM.
Primers may also be labeled. For example, labels may be
5 selected to facilitate detection, localization, quantification,
and/or isolation of PCR product. For example, biotinylation
can be used to facilitate detection and/or purification using
streptavidin to capture biotinylated PCR product on surface.
10 Further, streptavidin can be associated with magnetically
responsive beads for capture of biotinylated PCR product.
Digoxigenin can also be used for detection of PCR product.
Primers may, for example, be labeled at their 5' ends and/or
internally, and further, labeled nucleotides may be incorpo-
15 rated into the PCR product for detection, localization, quan-
tification, and/or isolation.
The invention includes a droplet microactuator including a
droplet thereon which includes labeled and/or unlabeled
primers (e.g., at concentrations ranging from about 0.1 µM to
20 about 1 µM or from about 0.1 µM to about 0.6 µM) for
amplification of a target nucleic acid in a concentration suf-
ficient to facilitate the amplification reaction, as well as sys-
tems and/or devices including such a droplet microactuator,
and methods of conducting droplet operations or otherwise
25 manipulating such droplet on a droplet microactuator. As
another example, the invention includes a droplet microac-
tuator including a droplet thereon including labeled and/or
unlabeled primers at a low enough concentration to reduce or
eliminate mi spriming and accumulation of non-specific prod-
30 uct and a high enough concentration to avoid exhaustion of
primer prior to completion of the amplification reaction. In
yet another example, the invention includes a droplet micro-
actuator comprising a droplet thereon including labeled and/
or unlabeled primers at a concentration ranging from about
35 0.1 µM to about 1 µM or from about 0.1 µM to about 0.6 µM.
Further, the invention includes such a droplet along with a
polymerase, nucleotides and/orbuffer components at concen-
trations selected to facilitate amplification of a target nucleic
acid. Moreover, the invention includes a method of conduct-
40 ing droplet operations on or otherwise manipulating any of
the droplets described in this section using the droplet micro-
actuator, device, and/or system. For example, the droplet
operation may include one of more the following: loading a
droplet into the droplet microactuator; dispensing one or
45 more droplets from a source droplet; splitting, separating or
dividing a droplet into two or more droplets; transporting a
droplet from one location to another in any direction; merging
or combining two or more droplets into a single droplet;
diluting a droplet; mixing a droplet; agitating a droplet;
50 deforming a droplet; retaining a droplet in position; incubat-
ing a droplet; heating a droplet; vaporizing a droplet; cooling
• droplet; disposing of a droplet; transporting a droplet out of
• droplet microactuator; other droplet operations described
herein; and/or any combination of the foregoing.
55
8.1.2.3 Nucleotides
Reagents used in the amplification methods of the inven-
tion will include nucleotides. Stock solutions of dNTPs are
commercially available from a variety of sources. Stock solu-
60 tions are typically provided at concentrations of 100-300
mM. Stock solutions can be diluted prior to introduction to
the droplet microactuator and/or on the droplet microactuator
using droplet operations to combine the stock solutions with
one or more buffer solutions. Final concentrations in the
65 PCR-ready droplet will typically range from about 50 µcool to
about 200 µcool. The four dNTPs are typically provided in
equimolar concentrations.
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A variety of modified nucleotides may be employed in the
practice of the invention. Examples include nucleotides
designed to reduce secondary structure resolution, prevent
contamination, as well as radiolabeled nucleotides, non-ra-
dioactive labeled nucleotides, and nucleotides designed to
promote random mutagenesis. For examples, see McPherson
et al., PCR, Taylor and Francis Group, 2006 (the entire dis-
closure which is incorporated herein by reference).
The invention includes a droplet microactuator including a
droplet thereon which includes nucleotides for amplification
of a target nucleic acid in a concentration sufficient to facili-
tate the amplification reaction, as well as systems and/or
devices including such a droplet microactuator, and methods
of conducting droplet operations on or otherwise manipulat-
ing such a droplet on a droplet microactuator. Thus, for
example, the invention includes a droplet microactuator com-
prising a droplet thereon including one or more nucleotides in
a concentration ranging from about 100 mM to about 300 mM
(stock concentration) or from about 50 µmol to about 200
µmol (operating concentration). In another example, the
invention includes a droplet microactuator comprising a
droplet thereon including 1, 2, 3 or 4 nucleotides, each in a
concentration ranging from about 100 mM to about 300 mM
or from about 50 µM to about 200 µM. The system of the
invention may be configured and programmed to execute a
protocol for diluting stock nucleotide concentrations to pro-
vide droplets comprising operating nucleotide concentra-
tions. For example, the system of the invention may be con-
figured and programmed to execute a protocol diluting stock
nucleotide concentrations ranging from about 100 mM to
about 300 mM to provide operating solutions ranging from
about 50 µmol to about 200 µcool. Further, the invention
includes nucleotide-containing droplets along with poly-
merase(s), primer(s) and/or buffer components in concentra-
tions selected to provide conditions that facilitate amplifica-
tion of a target nucleic acid. Moreover, the invention includes
a method of conducting droplet operations on or otherwise
manipulating any of the droplets described in this section
using the droplet microactuator, device, and/or system. For
example, the droplet operation may include one of more the
following: loading a droplet into the droplet microactuator;
dispensing one or more droplets from a source droplet; split-
ting, separating or dividing a droplet into two or more drop-
lets; transporting a droplet from one location to another in any
direction; merging or combining two or more droplets into a
single droplet; diluting a droplet; mixing a droplet; agitating
a droplet; deforming a droplet; retaining a droplet in position;
incubating a droplet; heating a droplet; vaporizing a droplet;
cooling a droplet; disposing of a droplet; transporting a drop-
let out of a droplet microactuator; other droplet operations
described herein; and/or any combination of the foregoing.
8.1.2.4 PCR Polymerases
A variety of PCR polymerases may be used in the droplet-
based PCR protocols of the invention. Suitable polymerases
will often have optimal activity at about 75' C. and the ability
to retain that activity after prolonged incubation, e.g., at tem-
peratures greater than 95° C. Useful polymerases may, for
example, include DNA-dependent DNA polymerases and/or
RNA-dependent DNA polymerases (reverse transcriptases).
Various thermostable polymerases, such as Taq DNA poly-
merases, may be used. Suitable examples include Ampli-
Taq®, AmpliTaq Gold®, the Stoffel fragment ofAmpliTaq®,
and others. Examples of thermostable polymerases with
proofreading capability include Vent®, Th, DeepVent(k, Pfu,
Pwo, U1Tma®, Accuzyme®, and KOD Hifi, DNA poly-
merases, as well as various exo - versions of the foregoing.
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Polymerase preparations may in some cases include dyes for
determining or confirming concentrations of PCR reagents.
In some cases, the system is configured and programmed to
detect such dyes and calculate reagent concentrations based
5 on colorimetric measurements. In some cases, the invention
makes use of droplets including a combination of a thermo-
stable polymerase (e.g., Taq DNA Polymerase) and a proof-
reading polymerase (e.g., Pwo DNA Polymerase).
The invention includes a droplet microactuator including a
10 droplet thereon which includes one or more polymerases at
concentrations sufficient to facilitate the amplification reac-
tion, as well as systems and/or devices including such a drop-
let microactuator, and methods of conducting droplet opera-
tions or otherwise manipulating such droplet on a droplet
15 microactuator. Moreover, the invention includes a method of
conducting droplet operations on or otherwise manipulating
any of the droplets described in this section using the droplet
microactuator, device, and/or system. For example, the drop-
let operation may include one of more the following: loading
20 a droplet into the droplet microactuator; dispensing one or
more droplets from a source droplet; splitting, separating or
dividing a droplet into two or more droplets; transporting a
droplet from one location to another in any direction; merging
or combining two or more droplets into a single droplet;
25 diluting a droplet; mixing a droplet; agitating a droplet;
deforming a droplet; retaining a droplet in position; incubat-
ing a droplet; heating a droplet; vaporizing a droplet; cooling
a droplet; disposing of a droplet; transporting a droplet out of
a droplet microactuator; other droplet operations described
30 herein; and/or any combination of the foregoing. Further, the
invention includes polymerase-containing droplets on a drop-
let microactuator of the invention along with nucleotides,
primer and/or buffer in concentrations selected to provide
conditions sufficient to facilitate amplification of a target
35 nucleic acid.
8.1.2.5 Detection of Amplified Product
In some embodiments, amplified nucleic acid will be
detected after some number of amplification cycles. For
40 example, amplified nucleic acid may be quantified during or
after each cycle, or after some predetermined number of
cycles, e.g., after each set of 2, 3, 4, 5, 6, 7, 8, 9, or 10 cycles.
Detection generally involves using droplet operations to
transport the droplet into detection zone in which a sensor
45 measures some aspect of the droplet, such as a physical,
chemical or electrical aspect, which correlates with amplifi-
cation. The system may be programmed so that amplification
cycles may be continued until detection reveals that a desired
level of signal has been achieved. In one embodiment, the
50 detection method for amplification is a fluorescence tech-
nique.
Further, in some embodiments, a droplet comprising
amplified nucleic acid may be transported for further process-
ing/detection. For example, in diagnostic embodiments, a
55 droplet including amplified nucleic acid may be transported
for detection of the presence of a target diagnostic nucleic
acid. The target nucleic acid may, for example, include a
nucleic acid from the pathogenic organism, such as a DNA or
RNA associated with a parasite, bacteria, fungus or virus. The
60 droplet microactuator may be provided as a component of an
integrated and portable diagnostic platform. The system may
provide for fully automated, rapid detection of a panel of
infectious diseases by real-time PCR. The system may be
used at the bedside, stat laboratory, physician's office, or in
65 the field.
Fluorescence detection is suitable for detection of ampli-
fied nucleic acid. Light emitting diodes (ZEDS) and laser
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diodes are suitable as excitation sources because of their
small physical size, low power requirements and long life.
LEDs are appealing because of their low cost and laser diodes
because of their narrow spectral width, and the fact that they
can be focused to small spot sizes without discarding a sub-
stantial amount of light.
In addition to the reagents already discussed, reagents use-
fully employed in nucleic acid amplification protocols of the
invention include various detection reagents, such as fluores-
cent and non-fluorescent dyes and probes. For example, the
protocols may employ reagents suitable for use in a TagMan
reaction, such as a TagMan probe; reagents suitable for use in
a SYBR® Green reaction, such as SYBR® Green; reagents
suitable for use in a molecular beacon reaction, such as a
molecular beacon probe; reagents suitable for use in a scor-
pion reaction, such as a scorpion probe; reagents suitable for
use in a fluorescent DNA-binding dye-type reaction, such as
a fluorescent probe; and/or reagents for use in a LightUp
protocol, such as a LightUp probe.
The invention includes a droplet microactuator including a
droplet thereon which includes one or more detection
reagents, such as any one or more of the aforementioned
probes, at concentrations sufficient to facilitate detection of
the amplification reaction, as well as systems and/or devices
including such a droplet microactuator, and methods of con-
ducting droplet operations or otherwise manipulating such
droplet on a droplet microactuator. Moreover, the invention
includes a method of conducting droplet operations on or
otherwise manipulating any of the droplets described in this
section using the droplet microactuator, device, and/or sys-
tem. For example, the droplet operation may include one of
more the following: loading a droplet into the droplet micro-
actuator; dispensing one or more droplets from a source drop-
let; splitting, separating or dividing a droplet into two or more
droplets; transporting a droplet from one location to another
in any direction; merging or combining two or more droplets
into a single droplet; diluting a droplet; mixing a droplet;
agitating a droplet; deforming a droplet; retaining a droplet in
position; incubating a droplet; heating a droplet; vaporizing a
droplet; cooling a droplet; disposing of a droplet; transporting
a droplet out of a droplet microactuator; other droplet opera-
tions described herein; and/or any combination of the fore-
going. Further, the invention includes nucleotide-containing
droplets on a droplet microactuator of the invention along
with a nucleotides, primer, detection probe and/or buffer in
concentrations selected to provide conditions sufficient to
facilitate amplification of a target nucleic acid.
Furthermore, the invention includes methods of detecting
and/or quantifying amplification which methods include
measuring a signal (e.g., a fluorescent signal) from droplet on
a droplet microactuator. Thus, for example, the method may
employ exposure of a droplet potentially including a fluores-
cent dye (such as SYBR® Green) to a light source at a
wavelength selected to cause the compound to fluoresce and
measuring the resulting fluorescence. Fluorescence emitted
from the droplet can be tracked during an amplification reac-
tion to permit monitoring of the reaction, e.g., using a
SYBR® Green-type compound. A system of the invention
may, for example, be programmed to detect such fluorescence
and to display a corresponding graph or other output permit-
ting a user to track the progress of a PCR reaction in real-time.
In another example, the invention includes a method of
detecting and/or quantifying the presence of a target nucleic
acid by including a probe with specificity for a target nucleic
acid (e.g., a TagMan-type probe) in an amplification-ready
droplet potentially including the target nucleic acid, thermal
cycling the amplification-ready droplet, and detecting any
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fluorescence signal caused by degradation of the probe,
where a fluorescent signal is indicative of the presence of the
target nucleic acid in the droplet. The invention includes
corresponding methods using other target-specific probes,
5 such as scorpion probes and molecular beacons.
8.1.3 Thermal Cycling
In the practice of the invention, a PCR-ready droplet is
thermal cycled in order to effect an amplification of a target
to nucleic acid. Tight control of thermal cycling may be neces-
sary for effective amplification of certain nucleic acids.
Examples of structures designed to provide controlled ther-
mal cycling on a droplet microactuator are discussed in Sec-
tion 8.8.6 below. Typically, each thermal cycle will involve at
15 least two steps:
(1) heating the droplet to a temperature sufficient to denature
double stranded nucleic acid in the droplet into single-
stranded DNA (typically about 90-100° C.); and
(2) lowering the droplet temperature to permit primers to
20	 anneal to their complementary sequences on the nucleic
acid template strands (typically about 50-75° C.).
In some cases a thermal cycle may also involve a third step:
(3) adjusting the droplet temperature to facilitate extension of
the double stranded segment of the nucleic acid to be
25	 extended by incorporation of additional nucleotides (typi-
cally about 70-75° C.).
Depending on the reagents selected, incorporation of addi-
tional nucleotides may be accomplished at the same tempera-
ture at which the primers are permitted to anneal to the nucleic
30 acid template strands, and thus the temperature adjustment of
the third step may not be necessary. Additional thermal
cycling steps may also be incorporated in various protocols of
the invention.
The invention permits multiple droplets to be thermal
35 cycled in parallel. Thus, in various embodiments, more than
2, 3, 4, 5, 10, 20, 30, 40, 50, 100, or 1000 amplification-ready
droplets are thermal cycled in parallel on a single droplet
microactuator. In some embodiments, detection of amplifica-
tion in these droplets is measured in parallel in real time.
40 In one embodiment, each droplet undergoing thermal
cycling is positioned in proximity to a sensor, or is transported
into proximity with a sensor, so that a signal from the droplet
correlating with amplification can be monitored in real time.
The system may output real-time information accessible to a
45 user which is indicative of the progress of the amplification
process. Further, the system may be arranged to permit such
output when thermal cycling multiple droplets in parallel,
e.g., more than 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, or 1000
amplification-ready droplets are thermal cycled in parallel on
5o a single droplet microactuator and the system outputs real-
time information is indicative of the progress of the amplifi-
cation process
The methods of the invention may include a temperature
optimization step or protocol for optimizing temperatures
55 and/or times for denaturation, annealing, and/or extension. In
this step, one or more heating zones is used to vary the
temperature of one of more heating steps. For example, the
methods may include an optimization step or protocol for
optimization of annealing temperature. A series of droplets
60 may be thermal cycled using varied annealing temperatures
followed by detection to quantify amplification and thereby
determine which of the tested annealing temperatures pro-
duces the best results. Subsequent thermal cycling can be
conducted at the selected temperature. Similarly a series of
65 droplets may be cycled through annealing temperatures for
different periods of time followed by detection to quantify
amplification and thereby determine which of the tested time
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periods produces the best results at a given temperature. Sub-
sequent thermal cycling can be conducted using the selected
time period. Further, such optimization protocols can be
executed sequentially or simultaneously in order to determine
both the optimum temperature and the optimum time period.
Similar protocols may be executed for optimizing tempera-
tures and/or time periods for denaturation and/or extension
steps.
In one embodiment, thermal cycling is accomplished by
heating and cooling the entire droplet microactuator. This
embodiment generally involves the following steps:
(1) heating the droplet microactuator to a temperature suffi-
cient to denature the double-stranded DNA (present in a
droplet on the droplet microactuator) into single-stranded
DNA;
(2) lowering the temperature of the droplet microactuator to a
temperature sufficient to permit primers (present in a drop-
let on the droplet microactuator) to anneal to their comple-
mentary sequences on the nucleic acid template strands;
(3) optionally, adjusting the temperature of the droplet micro-
actuator to facilitate extension of the double stranded seg-
ment of the nucleic acid (present in a droplet on the droplet
microactuator) by incorporation of additional nucleotides.
The thermal cycling protocols of the invention may be
conducted without significant loss of water or other compo-
nents of the PCR-ready droplet. Further, the thermal cycling
protocols may be conducted without significant cross-con-
tamination between droplets. Moreover, the thermal cycling
may be conducted without significant disruption in the capa-
bility of the droplet microactuator to continue conducting
droplet operations. For example, droplet operations may in
some cases continue to be conducted at the various denatur-
ation, annealing, and/or extension temperatures.
In a related embodiment, thermal cycling is accomplished
by heating and cooling a section or region of the droplet
microactuator. This approach generally involves the follow-
ing steps:
(1) heating a section or region of the droplet microactuator to
a temperature sufficient to denature the double-stranded
DNA (present in a droplet on the droplet microactuator)
into single-stranded DNA;
(2) lowering the temperature of a section or region of the
droplet microactuator to a temperature sufficient to permit
primers (present in a droplet on the droplet microactuator)
to anneal to their complementary sequences on the nucleic
acid template strands;
(3) optionally, adjusting the temperature of a section or region
of the droplet microactuator to facilitate extension of the
double stranded segment of the nucleic acid (present in a
droplet on the droplet microactuator) by incorporation of
additional nucleotides.
In one embodiment, this approach is conducted using a
droplet microactuator with a single integrated heater 202, as
illustrated in FIG. 2A.
In another embodiment, regions of the droplet microactua-
tor may be maintained at the required temperatures, and the
droplets may be transported through the appropriate tempera-
ture regions in order to accomplish the thermal cycling. This
approach generally involves the following steps:
(1) transporting an amplification-ready droplet to a region of
the droplet microactuator that is maintained at a tempera-
ture appropriate to cause denaturation of double-stranded
DNA in the droplet into single-stranded DNA;
(2) transporting the amplification-ready droplet to a region of
the droplet microactuator that is maintained at a tempera-
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ture sufficient to permit primers in the droplet to anneal to
their complementary sequences on the nucleic acid tem-
plate strands; and
(3) optionally, transporting an amplification-ready droplet to
s	 a region of the droplet microactuator that is maintained at
a temperature sufficient to facilitate or optimize extension
of the double-stranded segment of the nucleic acid in the
droplet by incorporation of additional nucleotides.
In this embodiment, thermal cycling is accomplished by
io repeating the transporting steps to move the droplets from
zone to zone. In one embodiment, the droplet microactuator
includes only one thermal zone for each required tempera-
ture, and thermal cycling is accomplished by rotating each
droplet through the appropriate thermal zones. In another
15 embodiment, the droplet microactuator includes two or more
of each of the thermal zones. In yet another embodiment, the
droplet microactuator includes two or more of one or more of
the thermal zones. Further, the droplet microactuator may
include 2, 3 or more thermal zones, each of which may be
20 heated to a different specified temperature. In one embodi-
ment, this approach is conducted using a droplet microactua-
tor with a plurality of integrated heaters 204, as illustrated in
FIG. 2B.
Further, one or more heaters may be used to establish a
25 continuous thermal gradient across a region of the droplet
microactuator. In this embodiment, an electrode matrix, elec-
trode path or series of electrode paths may be employed to
locate the droplet in the appropriate temperature zone to
effect the required thermal cycling steps. Thermal cycling
30 may thus be accomplished by transporting the droplet to an
electrode at the appropriate position within the thermal gra-
dient to achieve the target temperature. Variations in tempera-
ture, e.g., to optimize any of the various denaturing, annealing
and/or extension steps, may be effected by simply varying the
35 location of the droplet within the thermal zone.
Thermal cycling may involve the use of various heating
and/or cooling modalities to establish target temperature
zones for denaturation, annealing and/or extension. These
heating and cooling modalities may be arranged to facilitate a
40 suitable temperature ramp between the target temperature
zones. The ramp may be controlled by changing the tempera-
ture of a specific heating and/or cooling modality and/or by
selecting heating and cooling modalities at distances selected
to effect target temperature zones with suitable temperature
45 ramps. The droplet microactuator may have heating and/or
cooling modalities with temperature ranges and spacing
selected to create a predetermined set of potential target tem-
perature zones and temperature ramps. Various heating and/
or cooling modalities may be included between target tem-
50 perature zones to adjust the ramp between zones.
In one embodiment, the droplet microactuator includes a
series of independently adjustable heating elements. The tem-
perature of each heating element may be adjusted to provide
for an appropriate heating ramp as droplets pass from one
55 target temperature zone to the next. Further, distance between
heating elements at target temperatures may be selected to
facilitate an appropriate temperature ramp and/or to prevent
overheating caused by interaction between closely situated
heating elements. Such approaches provide flexibility in
60 working with a variety of protocols each requiring different
target temperature zones and ramp profiles. For example, in a
series or matrix of heating elements, target temperature zones
may be at adjacent heating elements and/or may be separated
by one or more heating elements such that they are separated
65 by a greater distance. In this way, distances may be varied to
account for temperature requirements of a variety of protocol
requirements. A system of the invention may select optimal
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heating elements for establishing target temperature zones
with appropriate or optimal temperature ramps between the
heating zones.
The methods of the invention may include a temperature
optimization step or protocol for optimizing temperatures
and/or times for the denaturation, annealing, and/or extension
phases of the thermal cycle. As an example, the methods may
include an optimization step or protocol for optimization of
annealing temperature. A series of heating zones may be
established in which amplification-ready droplets are cycled
through different annealing temperatures to determine which
annealing temperature produces optimum results. Subse-
quent thermal cycling can be conducted at the optimum tem-
perature. Similarly a series of amplification-ready droplets
may be cycled using a protocol in which the time of the
annealing phase is systematically varied to determine which
time period produces optimum results at a given temperature.
Subsequent thermal cycling can be conducted using the opti-
mum time period. Further, such protocols can be executed
sequentially or simultaneously in order to determine both the
optimum temperature and the optimum time period. Similar
protocols may be executed for optimizing denaturation and/
or extension steps. Optimization protocols my run sequen-
tially or in parallel.
Similarly, the methods of the invention may include a
temperature optimization step or protocol using multiple
independently heated thermal zones for optimizing tempera-
tures and/or times for denaturation, annealing, and/or exten-
sion. For example, a series of heating zones may be estab-
lished through which amplification-ready droplets are
transported. The zones may include temperatures targeted to
promote denaturation, annealing, and/or extension. In a spe-
cific droplet set, the temperature of one of the denaturation,
annealing and/or extension zones may be systematically var-
ied for a set of PCR-ready droplets, while the other two
temperatures remain constant. Multiple droplet sets can be
tested so that each of the temperature parameters may be
varied as needed. One or more of the multiple droplet sets
may be tested sequentially and/or in parallel. Variations in
heating zone temperature may, for example, be controlled by
the processor (e.g., controlling the temperature of a heating
element and/or controlling a location of a droplet within a
heating gradient) via software pre-programmed to execute an
optimization protocol and/or via software controlled by a user
via a user interface. The timing of each of the phases of the
thermal cycle may be optimized in like manner. Optimization
protocols my run sequentially or in parallel.
Moreover, the invention includes a method of conducting
one or more droplet operations using a PCR-ready droplet on
a droplet microactuator at an elevated temperature, e.g., at a
temperature which is greater than about 70, 75, 80, 85, 90, 95,
or 100° C. For example, the droplet operation may include:
loading a droplet into the droplet microactuator; dispensing
one or more droplets from a source droplet; splitting, sepa-
rating or dividing a droplet into two or more droplets; trans-
porting a droplet from one location to another in any direc-
tion; merging or combining two or more droplets into a single
droplet; diluting a droplet; mixing a droplet; agitating a drop-
let; deforming a droplet; retaining a droplet in position; incu-
bating a droplet; heating a droplet; vaporizing a droplet; cool-
ing a droplet; disposing of a droplet; transporting a droplet out
of a droplet microactuator; other droplet operations described
herein; and/or any combination of the foregoing. Still further,
the invention includes a method of heating and/or cooling a
droplet by transporting the droplet between two or more
temperature zones on a droplet microactuator. Further, the
invention includes a method of heating and/or cooling a drop-
let by transporting the droplet between two or more tempera-
ture zones on a droplet microactuator when the temperature
zones range from about 40° C. to about 120° C. The invention
also includes a method of heating and/or cooling a droplet by
5 transporting the droplet between two or more temperature
zones on a droplet microactuator when the temperature zones
range from about 40° C. to about 120° C. to achieve target
temperatures at least some of which are at a temperature
which is greater than about 70, 75, 80, 85, 90, 95, or 100° C.
10 The invention includes a droplet microactuator or droplet
microactuator system having one or more input reservoirs
loaded with reagents for conducting biochemical reactions,
such as the reagents described for use in nucleic acid ampli-
fication protocols, affinity-based assay protocols, sequencing
15 protocols, and protocols for analyses of biological fluids. For
example, one or more reservoirs may include reagents for
providing buffer, primers, nucleotides, polymerases, and
other reagents for conducting a PCR reaction. In one embodi-
ment, one or more reservoirs includes a buffer which includes
20 two or more reagents for conducting a PCR reaction, where in
the reagents are selected from primers, nucleotides, poly-
merases, and other PCR reagents. In another embodiment,
one or more of the reservoirs includes a droplet including all
reagents required for conducting a PCR reaction, such that
25 when combined with a sample droplet including a nucleic
acid template, the result is a droplet which is ready for PCR
thermal cycling. The invention also includes a droplet micro-
actuator or droplet microactuator system, having one or more
input reservoirs loaded with a sample for conducting a PCR
30 reaction.
8. 1.4 Amplification Protocols
It will be appreciated by one of skill in the art in light of the
present disclosure that many variations are possible within
35 the scope of the invention. In general, the protocols involve
combining two or more droplets comprising PCR reagents
and template to yield a PCR-ready droplet, and thermal
cycling the PCR-ready droplet at temperatures selected to
facilitate amplification of a target nucleic acid.
40 Upstream, the protocol may involve various sample pro-
cessing steps in order to provide a nucleic acid template that
is ready for PCR amplification. For example, reverse tran-
scription of RNA may be usedprior to PCR to provide a stable
DNA nucleic acid template for amplification. Thus, in one
45 embodiment, the invention provides a method of preparing a
droplet comprising a DNA nucleic acid template, wherein the
method includes performing droplet-based reverse transcrip-
tion of RNA to yield the nucleic acid template.
A "Hot Start" approach can be used to minimize the for-
50 mation of primer-dimers during reaction preparation. By lim-
iting polymerase activity prior to PCR cycling, non-specific
amplification is reduced and target yield is increased. Com-
mon methods for Hot Start PCR include chemical modifica-
tions, wax-barrier methods, and inhibition by a Taq-directed
55 antibody.
Downstream, the protocol may involve various subsequent
steps, such as sequencing of an amplified nucleic acid, e.g.,
using a pyrosequencing approach or separation of amplified
fragments using capillary electrophoresis,
60 Various specialized techniques may also be used during the
PCR process. For example, primers with sequences not com-
pletely complementary to the nucleic acid template can be
used for droplet-based in vitro mutagenesis. Thus, for
example, the invention may include a method of accomplish-
65 ing in vitro mutagenesis in a droplet on a droplet microactua-
tor, when the method involves combining two or more drop-
lets including PCR reagents and primers selected for
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mutagenesis in quantities sufficient to facilitate amplification
of a mutated version of the target nucleic acid. Further, the
mutated version of the target nucleic acid may be transported
for downstream processing, e.g., sequencing of the mutated
version of the target nucleic acid to confirm the desired muta-
tion.
In a medical diagnostic aspect of the invention, molecular
tags, such as digoxigenin (DIG) or biotin-labeled dUTP can
be used to permit detection of specific sequences. The labeled
PCR products may, for example, be used as hybridization
probes or detected by use of capture probes.
In many protocols, it will be desirable to simultaneously
process one or more control droplets to determine the quality
or fidelity of the reaction. Thus, for example, in order to
ensure that contamination has not occurred one or more PCR-
ready droplets without the sample template may be thermal
cycled and otherwise processed in the same manner as drop-
lets including the sample template. Detection of amplified
nucleic acid in the control droplets would be indicative of
contamination. Other control droplets may include known
quantities or concentrations of template material, or known
quantities or concentrations of fluorescent dye. Control drop-
lets may be processed on the same droplet microactuator as
the sample droplets, simultaneously with, before and/or after,
processing of the actual sample droplet.
The system provides the possibility of independent soft-
ware-based customization of reaction protocols and condi-
tions for each sample or assay. This, combined with the scal-
ability of the platform ensures that the capabilities of the
system can be extended to include a wide range of nucleic
acid targets.
The invention includes methods of conducting droplet
operations on amplification reagents. For example, the inven-
tion includes a method of conducting one or more droplet
operations on a droplet including buffer, primers, nucleotides,
polymerases, and/or other PCR reagents. The invention also
includes a method of conducting one or more droplet opera-
tions using a buffer droplet on a droplet microactuator includ-
ing one or more primers. The invention also includes a
method of conducting one or more droplet operations using a
buffer droplet on a droplet microactuator including one or
more nucleotides. The invention also includes a method of
conducting one or more droplet operations using a buffer
droplet on a droplet microactuator including one or more
polymerases, e.g., DNA polymerases. The invention also
includes a method of conducting one or more droplet opera-
tions using a buffer droplet on a droplet microactuator includ-
ing one of more reverse transcriptases. In another embodi-
ment, the invention includes a method of conducting one or
more droplet operations using a buffer droplet on a droplet
microactuator which includes 2, 3, 4 or more PCR reagents
selected from the categories including primers, nucleotides,
polymerases, and other PCR reagents. Further, the invention
includes a method of conducting one or more droplet opera-
tions using a PCR-ready droplet including one or more buff-
ers, primers, nucleotides, polymerases, and nucleic acid tem-
plates including a target nucleic acid sequence.
The droplet-based amplification protocols are also useful
for analyzing RNA content. In some embodiments, RNA will
be the initial target nucleic acid. A two buffer system may be
used to provide one buffer for the reverse transcription (RT)
step that creates cDNA from the viral RNA, and a different
buffer selected to facilitate the DNA amplification step. In a
related embodiment, a single buffer method is used in which
a buffer is provided that is compatible for both reactions but
not necessarily optimal for either.
In one embodiment, a droplet-based PCR can be executed
on a droplet microactuator to quantitate the changes in gene
expression levels for relevant cancer biomarkers, e.g., vascu-
lar endothelial growth factor (VEGF) and the cyclin-depen-
5 dent kinase inhibitors p2l(Cipl) and p27(Kipl). For
example, cells in a droplet, whether suspended or bound to a
surface, can be lysed. Freed poly(A) mRNA can be captured
in droplets using beads, such as oligo (H) magnetically
responsive beads. Reagents are available from Dynal Biotech
io in its mRNA DIRECT Micro Kit. Mixing or agitation of
droplets may be used to enhance cell lysis and enhance cap-
ture of poly (A) mRNA onto beads. mRNA from oligo (H)
magnetically responsive beads can be eluted by thermally
melting the RNA-DNA duplex. The appropriate temperature
15 depends on the length of the strand. Beads can be washed
using droplet-based washing protocols as described else-
where herein. PCR (e.g., qRT-PCR) can be performed using a
droplet-based protocol on the droplet microactuator with the
appropriate primers for the gene targets (e.g., VEGF, p21
20 (Cipl) and p27(Kipl)). Droplet-based RNA amplification
may also be accomplished using the Van Gelder and Eber-
wine technique.
The invention provides droplet-based rolling circle ampli-
fication for DNA. In the rolling circle approach, a buffer
25 droplet including a dsDNA his heated on a droplet microac-
tuator to a temperature sufficient to result in denaturation of
the dsDNA (typically about 95° C.). Incubation time may in
some instances range from about 1 to about 10 minutes. A
droplet including a circularizable probe is combined with the
3o droplet including the denatured DNA to anneal and ligate the
circularizable probe to the target dsDNA at an effective tem-
perature (e.g., about 60° C.) in buffer with a polymerase (e.g.,
T. flavus DNA polymerase) and an appropriate ligase (e.g.,
Ampligase DNA ligase). Incubation may in some cases be
35 less than about 45 minutes. The resulting droplet is combined
with rolling circle primer, buffer, 029 DNA polymerase, at a
decreased temperature (e.g., about 31° C.). Incubation time
may in some cases range from about 2 to about 30 minutes.
Biotin may be incorporated with the 029 DNA polymerase to
40 capture the amplicon on a streptavidin bead or surface and
visualized with a fluorescent probe.
The invention provides droplet-based strand displacement
amplification (SDA) for DNA. In this embodiment, a buffer
droplet including a dsDNA fragment with target specific
45 amplification primers is heated on a droplet microactuator to
a temperature sufficient to result in denaturation of the
dsDNA (typically about 95° C.). Incubationtime may in some
instances be for less than about 4 minutes. The droplet is then
cooled to an annealing temperature (e.g., about 37° C.) to
5o result in annealing. Annealing time may in some cases be for
less than about 4 minutes. The droplet is combined using
droplet operations with a droplet including a restriction endo-
nuclease and exo(minus) Klenow polymerase. The resulting
droplet is isothermally incubated on the droplet microactua-
55 for at a temperature sufficient to result in DNA amplification
(e.g., about 37° C.). Incubation time may in some cases be
from about 1 to about 5 hours. Amplification can be detected
using, for example, a fluorescent probe or a strand specific
molecular beacon
60 The invention provides droplet-based transcription medi-
ated amplification or NASBA for RNA. In this embodiment,
a droplet including a target nucleic acid is heated on the
droplet microactuator to a temperature sufficient to denature
the target (e.g., about 95' C.). Denaturation time may in some
65 cases be less than about 4, 3, or 2 minutes. The droplet is then
cooled to an appropriate temperature (e.g., about 41' C.), and
combined using droplet operations with a droplet including
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add T7 RNA polymerase promoter-target primer 1 and target
primer 2. The resulting droplet is combined using droplet
operations with a droplet including reverse transcriptase,
RNAse H and T7 RNA polymerase. The droplet temperature
is then adjusted to a temperature sufficient to result in ampli-
fication of RNA amplicons. Amplification time may in some
cases last for about 60 minutes.
One aspect of the invention is a droplet microactuator
having a substrate for immobilization of a nucleic acid. In one
aspect, the substrate is a gold substrate. Another aspect is a
droplet microactuator including a substrate for immobiliza-
tion of a nucleic acid and reagents for immobilizing the
nucleic acid to the substrate. Yet another aspect is a droplet
microactuator including a substrate for immobilization of a
nucleic acid, reagents for immobilizing the nucleic acid to the
substrate, and a nucleic acid sample. These reagents and
samples, may for example, be stored in reservoirs on the
droplet microactuator and/or in reservoirs or other containers
off the droplet microactuator (e.g., in a cartridge). In yet
another aspect, the invention involves a method of immobi-
lizing a nucleic acid sample on a substrate comprising execut-
ing droplet operations to bring a droplet comprising the
nucleic acid sample into contact with the substrate and
thereby deposit in the nucleic acid sample on the substrate.
8.1.5 Downstream Analysis
In some embodiments, a droplet comprising amplified tar-
get nucleic acid may be transported downstream for further
analysis. For example, the droplet may be transported and
stream for analysis by micro gel electrophoresis. The micro
gel electrophoresis may take place on or off the droplet micro-
actuator.
In one embodiment, a two dimensional micro gel electro-
phoresis device, such as the device described by Mohanty et
al. and the American Electrophoresis Society Annual Meet-
ing (see http://aiche.confex.com/aiche/2005/techprogram/
P30621.HTM).
In some embodiments, droplets including amplified
nucleic acids are contacted with droplets including reagents
sufficient to clone the amplified nucleic acids into suitable
vectors. Vectors may be selected, for example, for use in gene
libraries, and/or expression in cells.
8.2 Nucleic Acid Sequence Analysis
The invention provides methods, devices and systems for
droplet-based nucleic acid sequence analysis on a droplet
microactuator system which, among other things, avoids
problems associated with the increasingly complex mixtures
required by the approaches of the prior art.
FIG. 3 illustrates an illustrative droplet microactuator 300
suitable for nucleic acid sequence analysis. In this embodi-
ment, multiple fluid ports or reservoirs may be provided such
as DNA input reservoir 302, DNA reagents reservoir 304,
primer set reservoirs 306, nucleotide (e.g., dA, dC, dG, and
dT) reservoirs 308, and pyrosequencing primer reservoir 310.
Wash buffer reservoir 312 may also be provided, as well as
waste area 314, thermal cycling area 316, and imaging area
318. Various thermal cycling area embodiments may employ
a variety of heater configurations such as those described
elsewhere herein. Imaging area 318 may utilize, for example,
a photomultiplier tube (PMT).
FIGS. 4 and 5 illustrate reaction steps and droplet opera-
tions of an illustrative embodiment of the invention. A nucleic
acid sample may be amplified as needed (on or off the droplet
microactuator) to obtain a sufficient concentration of nucleic
acid for analysis. The nucleic acid sample may be introduced
to a droplet microactuator where it is immobilized on a solid
support. Reagents for denaturing the nucleic acid to single
24
strand, priming and stepwise extension of the double stranded
portion, may be transported to the immobilized nucleic acid
using droplet microactuation techniques. Importantly, drop-
lets including reaction products may be transported away
5 from the immobilized nucleic acid, e.g., for further process-
ing, analysis, and/or waste disposal. Importantly, detection
may in some embodiments be conducted separately in time
and space relative to the extension synthesis reactions.
Among other things, this capability reduces or eliminates the
io build-up of certain degradation byproducts causedby existing
methods. A further advantage of the invention is that detec-
tion can occur in proximity to a sensor to improve the effi-
ciency of light collection and thus the sensitivity of the analy-
sis.
15 The invention may include a droplet microactuator or drop-
let microactuator system having one or more input reservoirs
loaded with reagents for conducting sequencing protocols.
For example, one or more reservoirs may include reagents for
conducting a pyrosequencing protocol. The invention also
20 may include a droplet microactuator or droplet microactuator
system, having one or more input reservoirs loaded with a
sample for conducting a pyrosequencing protocol.
It will be appreciated that an important aspect of the inven-
tion involves the ability to conduct droplet operations using
25 each of the sequence analysis reagents and/or samples on a
droplet microactuator. For example, the invention may
include:
(1) a droplet microactuator comprising thereon a droplet
comprising any one or more of the reagents and/or samples
so	 described herein for conducting sequence analyses;
(2) a device or system of the invention comprising such drop-
let microactuator;
(3)a method of conducting droplet operations on or otherwise
35	 manipulating a droplet making use of such droplet micro-
actuator or system; and/or
(4) a method of conducting an droplet-based sequence analy-
sis protocol making use of such droplet microactuator or
system.
40 For example, the droplet operations may include one or
more of the following: loading a droplet into the droplet
microactuator; dispensing one or more droplets from a source
droplet; splitting, separating or dividing a droplet into two or
more droplets; transporting a droplet from one location to
45 another in any direction; merging or combining two or more
droplets into a single droplet; diluting a droplet; mixing a
droplet; agitating a droplet; deforming a droplet; retaining a
droplet in position; incubating a droplet; heating a droplet;
vaporizing a droplet; cooling a droplet; disposing of a droplet;
50 transporting a droplet out of a droplet microactuator; other
droplet operations described herein; and/or any combination
of the foregoing. Various other methods, devices, systems,
and other aspects of the invention will be apparent from the
ensuing discussion.
55
8.2.1 Sample Amplification
Nucleic acid sequence analysis typically begins with a
sample including an amplified nucleic acid analyte or with a
sample that includes a nucleic acid analyte for amplification.
6o For the latter, amplification can be performed using standard
techniques and/or using droplet-based amplification on a
droplet microactuator as described in Section 8.1. Amplifica-
tion may be conducted on the same droplet microactuator
used to conduct sequence analysis protocols and/or on a sepa-
65 rate droplet microactuator. In some embodiments, a second
droplet microactuator and is coupled in fluid communication
with a sequence analysis droplet microactuator.
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8.2.2 Nucleic Acid Immobilization
As illustrated in FIG. 4, the amplified nucleic acid sample
may be immobilized within the droplet microactuator so that
reagent droplets may be brought into contact with the immo-
bilized nucleic acid. Immobilization may be on a surface of
the droplet microactuator or on other surfaces within the
microactuator, such as beads made from polymers, polymeric
resins, and optionally including magnetically responsive
materials.
Useful substrates for such attachment include glass, gold,
polyacrylamide gels, polypyrrole, Teflon, and optical fibers.
Materials may, for example, be provided as films, particles,
matrices or beads. In one embodiment, the substrate includes
magnetically responsive beads. The droplet microactuator
can include a magnet or electromagnet for producing a mag-
netic field to manipulate (e.g., immobilize, release, or move)
the magnetically responsive beads. For example, magneti-
cally responsive beads can be agitated and immobilized on
the microactuator using a magnetic field to enhance washing
steps (see Section 8.6).
A wide variety of techniques may be used to immobilize
molecules, such as DNA, to surfaces. Examples include those
chemistries used to attach oligonucleotides to the surface of
microarrays and chemistries used in solid phase synthesis
techniques.
Nucleic acid samples may be thiolated and adsorbed to a
gold substrate. Nucleic acids maybe thiolated, for example,
by substituting a non-bridging internucleotide oxygen of a
phosphodiester moiety with sulfur, e.g., as described in U.S.
Pat. No. 5,472,881, by Beebe et al., entitled "Thiol Labeling
of DNA for Attachment to Gold Surfaces," the entire disclo-
sure of which is incorporated herein by reference. One or
more droplets including the thiolated nucleic acid can be
transported on the droplet microactuator to a gold surface
where the thiolated nucleic acid sample will be deposited on
the gold surface. The droplet including the thiolated DNA is
brought into contact with the gold surface for a sufficient time
for covalent bonds to form between the sulfur and the gold.
Electroactuation techniques may be employed to increase the
surface area of the droplet with the gold surface.
DNA sample can be biotinylated at the 5'-ends using a
water soluble biotin ester or using a biotinyl phosphoramidite
reagent. Biotinylated DNA can be captured on streptavidin
coated substrates. Thus, a droplet including biotinylated
DNA sample can be transported into contact with the strepta-
vidin surface where the DNA will be captured and immobi-
lized.
Chemistry has been described for immobilization of single
stranded DNA on a substrate (S. Taira et al., "Immobilization
of single-stranded DNA by self-assembled polymer on gold
substrate for a DNA chip," Biotechnol Bioeng. 2005 Mar.
30;89(7):835-8). In this approach, thioctic acid (TA) is
covalently attached to poly(allylamine hydrochloride) (PAH)
in sidechains to immobilize the polymer on a gold surface by
self-assembly. N-hydroxysuccinimide-ester terminated
probe single-stranded (ss) DNA is easily covalently immobi-
lized onto a TA-PAH-coated gold surface. The surface may be
covered with polyacrylic acid, which forms ion complexes
with the TA-PAH, to reduce the cationic charge.
As illustrated in step 3 of FIG. 4, double stranded nucleic
acid is treated with a denaturing reagent, such as NaOH
solution, in order to yield single stranded sample. This step is
illustrated as occurring after the immobilization step; how-
ever, it will be appreciated that denaturation may be effected
by transporting a denaturing reagent into contact with the
double stranded nucleic acid sample, before, during or after
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immobilization. Denaturation may also be performed by
heating the sample to thermally melt the double-stranded
complex.
One aspect of the invention is a droplet microactuator
5 having a substrate for immobilization of a nucleic acid.
Another aspect is a droplet microactuator including a sub-
strate for immobilization of a nucleic acid and reagents for
immobilizing the nucleic acid to the substrate. Yet another
10 
aspect is a droplet microactuator including a substrate for
immobilization of a nucleic acid, reagents for immobilizing
the nucleic acid to the substrate, and a nucleic acid sample.
These reagents and samples, may for example, be stored in
reservoirs on the droplet microactuator and/or in reservoirs or
other containers off the droplet microactuator (e.g., in a car-
15 tridge). In one embodiment of a reservoir loading assembly,
reagent and/or sample reservoirs (e.g., in vials or syringes)
may be coupled in fluid communication with droplet micro-
actuator reservoirs so that fluid from the vials may flow or be
20 forced directly into the droplet microactuator reservoirs. This
aspect of the invention is scalable, such that the number of
reservoirs and reservoir loading assemblies maybe increased
as needed to include slots for as many reagents as required to
conduct a desired protocol. Reagent/sample reservoirs and
reagent/sample loading are discussed further in Sections
25 8.8.4 and 8.8.5.1.
8.2.3 Polymerase Facilitated Nucleotide Incoroporation
As illustrated in steps 4 and 5 of FIG. 4, the immobilized,
single stranded nucleotide sample is primed to yield a double
so stranded segment. Priming may, for example, be achieved by
transporting a droplet comprising primer into contact withthe
immobilized sample.
The primed sample is reacted with a deoxynucleotide
35 triphosphate (dNTP) in the presence of a polymerase. This
reaction may be achieved by transporting one or more drop-
lets including a deoxynucleotide triphosphate (dNTP) and a
polymerase into contact with the immobilized sample. If the
dNTP is complementary to the first base in the single stranded
40 portion of the nucleic acid sample, the polymerase catalyzesits incorporation into the DNA strand. Each incorporation
event is accompanied by release of pyrophosphate (PPi) in a
quantity corresponding to the quantity of incorporated nucle-
otide. Incorporation events can thus be determined by mea-
45 during the PPi released. Addition of dNTPs is typically per-
formed one at a time, each in a separate buffer. Nucleotide
incorporation proceeds sequentially along each immobilized
template as each nucleotide is made available in a preselected
or programmed order.
50 A variety of native and modified polymerases may be used.
Modified polymerases include, for example, native
sequences with additions, insertions or replacements, that
result in a polymerase that retains the capacity to facilitate
incorporation of a nucleotide into a primed sample. The poly-
55 merase may be an exonuclease deficient polymerase. The
large or Klenow fragment of DNA polymerase may also be
used.
A dATP or ddATP analogue may be selected which does
not interfere in the enzymatic PPi detection reaction but
60 which nonetheless may be incorporated by a polymerase into
a growing DNA chain without interfering with proper base
pairing. Examples of suitable analogues include [1-thio]
triphosphate (or a-thiotriphosphate) analogues of deoxy or
dideoxy ATP, e.g., deoxyadeno sine[ 1-thio]tripho spate, or
65 deoxyadenosine a-thiotriphosphate (dATPoLS) as it is also
known. These and other analogues are described in U.S. Pat.
No. 6,210,891, by Nyren, et al., entitled "Method of sequenc-
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ing DNA," the entire disclosure of which is incorporated
herein by reference for its teaching concerning such ana-
logues.
Single stranded binding protein may be included to extend
the length of sequences that may be sequenced by reducing
folding of the single stranded sample. Thus, for example, the
invention includes a droplet microactuator including a droplet
including single stranded binding protein. The droplet may be
an amplification-ready droplet including single stranded
binding protein. The invention includes methods of conduct-
ing droplet operations on a droplet including single stranded
binding protein.
8.2.4 Detection of Nucleotide Incorporation
Determination of whether a specific base has incorporated
at the target site may involve quantification of PPi released
during the incorporation reaction. As each dNTP is added to
a growing nucleic acid strand during a polymerase reaction, a
PPi is released. PPi released under these conditions can be
detected enzymatically e.g. by the generation of light in the
luciferase-luciferin reaction (discussed further below). As the
process continues, the complementary strand is assembled,
and the nucleotide sequence is determined from the signal
peaks. The system may produce a program, as illustrated in
FIG. 5.
8.2.4.1 Conversion of PPi to ATP
In some cases, PPi released during an incorporation event
may be detected indirectly. PPi quantification may, for
example, be accomplished by quantifying ATP produced
from APS in the presence of an enzymatic catalyst. ATP
sulfurylase quantitatively converts PPi to ATP in the presence
of adenosine 5' phospho sulfate (APS). Thus, in one embodi-
ment, PPi can be converted to ATP, and the quantity of ATP
can be measured to determine the quantity of dNTP incorpo-
rated during the reaction.
8.2.4.2 Quantification of ATP
Once PPi is converted to ATP, the ATP can be quantified to
measure the incorporation of dNTP. As illustrated in FIG. 5,
ATP drives the luciferase-mediated conversion of luciferin to
oxyluciferin that generates visible light in quantities that are
proportional to the quantity of ATP. The light produced in the
luciferase-catalyzed reaction may be detected, e.g., by a
charge coupled device (CCD) camera, photodiode and/or
photomultiplier tube (PMT). Light signals are proportional to
the number of nucleotides incorporated. Detected signal can
be translated into a system output corresponding to the results
which is viewable by a user.
Luciferin-luciferase reactions to detect the release of PPi
have been described. For example, a method for continuous
monitoring of PPi release based on the enzymes ATP sul-
phurylase and luciferase referred to as Enzymatic Lumino-
metric Inorganic Pyrophosphate DetectionAssay ("ELIDA")
has been described by Nyren and Lundin (Anal. Biochem.,
151, 504-509, 1985, the entire disclosure of which is incor-
porated herein by reference.) The use of the ELIDA method to
detect PPi in a droplet on a droplet microactuator is one aspect
of the present invention. The method may however be modi-
fied, for example by the use of a more thermostable luciferase
(Kaliyama et al., 1994, Biosci. Biotech. Biochem., 58, 1170-
1171, the entire disclosure of which is incorporated herein by
reference). Examples of suitable detection enzymes for the
PPi detection reaction are ATP sulphurylase and luciferase.
In certain prior art applications, a nucleotide degrading
enzyme, such as apyrase, is used to degrade unincorporated
dNTPs and excess ATP. When degradation is complete,
another dNTP is added. Since the reaction takes place in a
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single solution, waste products continue to build up as
sequencing proceeds. An important aspect of the present
invention is that it avoids the requirement for a nucleotide
degrading step. Thus, while in some aspects of the invention,
5 a nucleotide degrading step may be included, in other aspects,
the systems and methods of the invention specifically omit a
nucleotide degrading step. Thus, for example, the analysis
may be accomplished in the absence of a substantial amount
of nucleotide degrading enzyme, e.g., in the absence of a
io substantial amount of apyrase.
Further, the inventors believe that conducting the incorpo-
ration/conversion/detection reactions in the absence of sub-
stantial build-up of byproducts will produce a more predict-
able result. Thus, for example, where single nucleotide
15 stretches are present in the sample, it is traditionally difficult
to distinguish the specific number of incorporations as the
length of the single nucleotide stretch increases. The inven-
tors believe that the clean nature of the reaction of the present
invention will lead to greater accuracy and reproducibility for
20 longer single nucleotide stretches. Thus, for example, the
inventors believe that the method of the invention can accu-
rately detect single nucleotide stretches having 6, 7, 8, 9 10,
11, 12, 13, 14, 15 or more nucleic acids with 90, 95, 99 or
99.9% accuracy.
25
8.2.5 Droplet Operation Protocols
It will be appreciated that, in addition to the protocols
described above, a variety of droplet operation protocols may
be utilized in order to carry out the sequence analyses of the
30 invention. Thus, for example, conversion to ATP can be
accomplished in a single reaction along with the dNTP incor-
poration reaction, or the reactions can be performed stepwise:
(1) incorporation of dNTP to release PPi, followed by (2)
conversion of PPi to ATP. Where the incorporation and con-
35 version steps are performed together, the system may trans-
port a single droplet including the required reagents (dNTP,
polymerase, ATP sulfurylase, and APS). Thus, all reagents
required to incorporate a dNTP into the immobilized sample,
release PPi, and react the PPi with APS to yield ATP may be
40 included in a reservoir on the droplet microactuator as a single
source reagent for each nucleotide. The source reagent for
each nucleotide may be successively brought into contact
with the immobilized sample so that the reactions may take
place, yielding ATP in the presence of a complimentary
45 dNTP.
Where the incorporation and conversion steps are per-
formed separately, the primer, polymerase, dNTP, sulfury-
lase, and APS may be provided from separate sources as
separate reagent droplets which are merged together to per-
50 form the reactions of the invention. Alternatively, some or all
of these reagents may be provided from a single source as a
pyro sequencing reagent droplet which is brought into contact
with the immobilized sample in order to conduct the reactions
of the invention. For example, a droplet including the dNTP
55 and polymerase may be brought into contact with the immo-
bilized sample, so that the base will incorporate if compli-
mentary, thereby releasing PPi. The droplet potentially
including the PPi may then be transported away from the
immobilized sample and combined with a droplet including
60 the ATP sulfurylase andAPS to produce ATP. Alternatively, a
droplet including the ATP sulfurylase and APS may be com-
bined with the droplet potentially including the PPi in the
presence of the immobilized sample to produce ATP.
Further, while FIG. 4 illustrates the priming step 4 and
65 incorporation/conversion steps 5 as occurring sequentially, it
will be appreciated that they can be separated out further or
they can all be incorporated into a single step. In other words,
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each specific reagent may be added to the reaction at the
appropriate time in one or more droplets or any combination
of multiple reagents may be provided together in a single
droplet or series of droplets. Thus, in one embodiment, the
droplet microactuator transports one or more droplets into
contact with the single stranded sample, wherein one or more
droplets together include the following reagents (or their
functional equivalents) provided together or in separate drop-
lets: primer, polymerase, and dNTP in any combination and
in any order producing the result that the primer hybridizes
with the sample to form a double stranded portion, the poly-
merase catalyzes incorporation of any complimentary dNTP
into a target site at the first single stranded base position
adjacent to the double stranded portion, thereby releasing
PPi.
In another embodiment, the droplet microactuator trans-
ports one or more droplets into contact with the single
stranded sample, and the one or more droplets together
include the following reagents (or their functional equiva-
lents): primer, polymerase, dNTP, sulfurylase, and APS, in
any combination and in any order producing the result that the
primer hybridizes with the sample to form a double stranded
portion, the polymerase catalyzes incorporation of any com-
plimentary dNTP into a target site at the first single stranded
base position adjacent to the double stranded portion, thereby
releasing PPi, and the ATP sulfurylase converts any PPi to
ATP in the presence ofAPS. Base incorporation is determined
by quantifying the quantity of PPi released.
The droplet potentially comprisingATP may be merged via
droplet microactuation techniques with a droplet comprising
reagents, such as luciferase and luciferin, for facilitating
detection of any ATP. Similarly, a droplet including luciferin
and potentially comprising ATP may be merged via droplet
microactuation techniques with a droplet including luciferase
for detection of any ATP. Further, a droplet including
luciferase and potentially comprisingATP may be merged via
droplet microactuation techniques with a droplet including
luciferin for detection of any ATP.
Droplets for the detection reaction may be merged in the
presence of or apart from the immobilized sample. For
example, a luciferase/luciferin droplet may be merged with
the droplet potentially including ATP in the presence of the
immobilized sample. Alternatively, the droplet potentially
including ATP may be separated from the immobilized
sample to be merged with a luciferase/luciferin droplet. In
either case, the merging of droplets including reagents that
produce a light signal may be accomplished in proximity to
the sensor in order to maximize the amount of light detected.
When the droplet potentially including ATP is transported
away from the immobilized sample to be merged with a
luciferase droplet, the transport step may include an incuba-
tion step in order to maximize the production of ATP for
detection in the fluorescence reaction. In other words, this
incubation may be accomplished during transport, or the
droplet may be temporarily stored for incubation prior to the
fluorescence reaction. The droplet microactuator may include
an incubation zone for this purpose. The incubation zone may
or may not include a heating element to control temperature in
the zone. The incubation zone may or may not include a wall
separating the zone from the remainder of the droplet micro-
actuator. The incubation zone may include an array of elec-
trodes to facilitate transport of droplets into and out of the
zone. The zone is scalable and may include electrodes for
transporting and storing tens, hundreds or more droplets
within the incubation zone.
In the practice of the invention, one or more detection
reagents may be specifically excluded from the polymerase
30
reaction step so that any signal will not be emitted during the
polymerase reaction. For example, in one embodiment, a
detection enzyme is not added to the reaction mix for the
polymerase step. Instead, the droplet used to conduct the
5 polymerase step is transported away from the immobilized
sample, then merged with a droplet including the detection
enzyme in range of a sensor for detecting signal from any
resulting reaction.
The reaction mix for the polymerase reaction may thus
io include at least one dNTP, polymerase, APS, and ATP sulfu-
rylase, and may optionally include luciferin, while lacking
any significant amount of luciferase. In this way, the dNTP
incorporation reaction may be separated from the detection
reaction. The detection reaction may thus be conducted in the
15 presence of the sensor, e.g., as illustrated in FIG. 5, in order to
maximize the detection signal. For example, where the detec-
tion signal includes light, the detection reaction may be com-
pleted in range of a sensor for detecting light emitted from any
resulting light-producing reaction.
20 Further, a detection reaction and a subsequent incorpora-
tion reaction may be conducted in parallel, thereby expediting
sequencing speed. Similarly, an incorporation reaction may
be conducted, the output of a previous incorporation reaction
may be incubated, and the output of a previous incubation
25 may be subjected to detection all in parallel in separate drop-
lets, thereby expediting sequencing speed.
Unlike certain processes of the prior art, the droplet micro-
actuator approach of the present invention avoids mass trans-
port effects. Reagents may be brought directly into contact
30 with each sample, without requiring a flow of reagents across
multiple samples. Where magnetically responsive beads are
used, they may be maintained in place using a magnetic field
and/or they may be transported from place-to-place in drop-
lets. Reagents may be transported from a reagent source
35 directly to a sample without coming into contact with other
samples and potentially causing cross-contamination. Diffu-
sion of byproducts is avoided by isolation of droplets in the
filler fluid. Wells packed with beads, e.g., stabilizing beads,
which may interfere with light detection may also be avoided.
40 A wash containing apyrase may be used between applications
of nucleotides, but its use is not necessary in the practice of
the invention, and in some embodiments, it is specifically
avoided.
Between applications of each new set of reagents to the
45 immobilized sample, it may be washed, e.g., with a buffer
solution. Various surface washing protocols are described in
Section 8.6.
8.2.6 Applications
50 The nucleic acid amplification and sequencing methods,
devices and systems of the invention are useful in a wide
variety of settings, such as scientific research, medical and
veterinary diagnostics, phramacogenomics, genomic
sequencing, gene expression profiling, detection of sequence
55 variation, forensics, and environmental testing. Due to the
portable size enabled by the droplet microactuator of the
invention, sequencing for the applications described herein
can, if desirable, be accomplished at the point-of-sample
collection.
60 In one embodiment, the invention may provide an influ-
enza test panel. In this embodiment, the system may accept a
biological sample as input, process the sample to prepare
target influenza virus nucleic acids for amplification, conduct
amplification using the protocols of the invention, and detect
65 the presence of target influenza nucleic acids. The biological
sample may, for example, be collected from a nasopharyngeal
swab.
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	In another embodiment, the invention may provide a res- 	 confirm treatment decisions. Infectious organisms may, for
	
piratory infection panel. In this embodiment, the system may 	 example, include viruses, bacteria, parasites or fungi. The
	
accept a biological sample as input, process the sample to	 invention provides, for example, a system and method for
	
prepare nucleic acids from common respiratory pathogens,	 quick, inexpensive detection of drug resistant strains of bac-
such as bacteria, viruses and/or fungi, for amplification, con- 5 terial or viruses (e.g., new strains of drug-resistant HIV)
	
duct amplification using the protocols of the invention, and 	 which is a critical component of combating these disease
	
detect the presence of target respiratory pathogen nucleic 	 causing organisms.
	
acids. In an extended version of the respiratory infection 	 The systems and methods of the invention may be
	
panel, the panel may include testing for atypical infections 	 employed for genetic testing, e.g., to identify DNA segments
such as those affecting immuno -compromised patients. The io in a subject that play a role in a specific disease or DNA
	
biological sample may, for example, be provided by or 	 segments which may be predictive of a specific disease. For
	
obtained from a nasopharyngeal swab. Examples of respira-	 example, linkage may be demonstrated when, within fami-
	
tory pathogens suitable for detection using a respiratory 	 lies, one form of the marker is found in those with the disease
	
infection panel of the invention include S. pneumoniae, H.	 more often than in blood relatives in whom the disease is
influenzae, Legionella, Chlamydia, Mycoplasma; viruses 15 absent. Such methods have proved successful in Huntington
	
such as influenza, RSV, coronavirus, parainfluenzae, aden- 	 disease, cystic fibrosis, breast cancer, and other disorders.
	
ovirus, metapneumovirus, bocavirus, hantavirus; and fungi	 Thus, for example, the systems and methods of the invention
such as Pneumocystis, Aspergillus, Cryptococcus. 	 may be used to identify mutations in a gene that are only
	
For sequencing lengthy nucleic acids, e.g., whole 	 present (in gene dosage sufficient to cause disease) in subj ects
genomes, samples may be broken into smaller overlapping 20 with disease or subjects predisposed to develop the disease. In
	
fragments (e.g., 100-1000 bp, 200-900 by or 300-800 bp), 	 another embodiment, the systems and methods of the inven-
	
e.g., by digestion with restriction enzymes. The smaller frag- 	 tion are used to identify genetic variations for which (1) there
	
ments may be analyzed using the systems and methods of the	 is a statistically significant probability that the sequence will
	
invention. Results may be assembled and edited to recon- 	 be present in people with the disease, and (2) there is a
struct the longer sequence, e.g., by identifying and matching 25 statistically significant probability that the sequence will not
	
overlaps in the sequenced fragments. Analysis of the frag- 	 be present in people without the disease. Similarly, the sys-
	
ments may proceed in a parallel manner, in order to expedite	 tems and methods of the invention are used to identify genetic
	
the sequencing. Each template may be sequenced multiple 	 variations for which there is a statistically significant prob-
	
times to enhance accuracy. In this way, entire chromosomes 	 ability that people with positive test results will get the dis-
or even entire genomes may be accurately sequenced. 	 30 ease and that people with negative results will not get the
	
Genes transcribed in a given set of tissues can be deter- 	 disease. Further, the systems and methods of the invention
	
mined from mRNA extracted from cells or tissue. mRNA 	 may be used to sequence a segment of DNA to identify one or
	
may be copied into DNA (cDNA) using reverse transcriptase. 	 more SNPs.
	
The resulting cDNAs may be cloned, and the clone ends from	 The systems and methods of the invention may be used in
a cDNA library may be sequenced according to the methods 35 a clinical trial setting. For example, nucleic acids from per-
	
of the invention to generate EST, which provide an expression 	 sons participating in a trial may be sequenced, and adverse
	
profile for the tissue from which the mRNA was extracted.	 events may be compared with genetic variation in the trial
	
RNA patterns may in some cases be correlated with disease 	 group to identify a subset of participants with increased sus-
	
states and may be sequenced as a diagnostic tool. RNA 	 ceptibility to one or more adverse events. Depending on the
viruses may also be sequenced. 	 40 severity of the particular adverse event in question, subjects
	
Once a reference sequence has been obtained for a region 	 with the associated genetic variation may, for example, be
	
of interest (e.g., a gene believed to be involved with a disease), 	 watched more closely, receive further protective treatment,
	
variations of the sequence as found in different individuals or	 and/or removed from the trial altogether. Similarly, efficacy
	
closely related species can be identified by selectively rese- 	 may be compared with genetic variation in the trial group to
quencing a small portion of known sequence. Variations may, 45 identify a subset of participants with increased likelihood to
	
for example, occur as SNPs; size differences (insertions/de- 	 positive treatment outcomes. Target populations can be
	
letions); copy number differences (duplications) and rear- 	 defined based on positive outcomes and/or lack of unduly
rangements (inversions, translocations). 	 adverse events. Products can be labeled accordingly. Physi-
	
Populations of organisms can be sequenced, e.g., from 	 cians can test their patients for the associated genetic varia-
water, soil and/or atmospheric samples. For example, most 50 tion and can prescribe products only to the population subset
	
current knowledge of microbiology still is derived from indi- 	 for which treatment is pharmaceutically acceptable.
	
vidual species that either cause disease or grow readily as 	 The invention is also useful for forensic evaluations, such
	
monocultures under laboratory conditions and are thus easy 	 as: identifying potential suspects whose DNA may match
	
to study. Sequencing can be used to study the organization, 	 evidence left at crime scenes; exonerating persons wrongly
membership, functioning, and relationship of such organ- 55 accused of crimes; identifying crime and catastrophe victims;
	
isms. Qualitative analysis of sequence and gene diversity can 	 establishing paternity and other family relationships; identi-
	
thus be obtained from organisms that cannot be cultured using 	 fying endangered and protected species as an aid to wildlife
conventional techniques.	 officials; detecting bacteria and other organisms that may
	
The systems and methods of the invention may also be used	 pollute air, water, soil, and food; matching organ donors with
to provide genomically specific diagnostics and treatment. 6o recipients in transplant programs; determining pedigree for
	
For example, the systems may be used to identify genotypic	 seed or livestock breeds; and authenticating consumables
	
traits that are associated with more or less favorable treatment 	 such as caviar and wine; identifying genetically modified
	
outcomes. Results may be used to guide treatment decisions. 	 foods.
	
Similarly, the systems and methods of the invention can be 	 Other examples of applications include: testing for asso-
used to identify identifying mutations in infectious organisms 65 ciations between genetic variations and subject outcomes,
	
or genetically damaged or altered cells, such as cancers and 	 e.g., efficacy, side effect profile, pharmacokinetics, and/or
	
other neoplasms, and this information can be used to guide or 	 pharmacodynamics, in the drug discovery process; analyzing
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a subject's genetic profile to differentiate between potential
drug therapies based on genotypic variation; screening for
predisposition for disease so that a subject can take steps to
monitor, treat, avoid or lessen the severity of a genetic dis-
ease; screening to decrease the number of adverse drug reac-
tions in a patient population; screening to enable the use of a
drug which is not safe in a genetically identifiable population
subset; and monitoring of gene therapies.
8.3 Affinity-Based Assays
The invention provides methods, devices and systems for
conducting droplet-based, affinity-based assays, such as
affinity-based assays. These assays include any assay in
which a compound having a binding affinity for an analyte is
contacted with the analyte or a sample potentially including
the analyte using droplet operations. For example, the com-
pound having a binding affinity for an analyte may be pro-
vided in a droplet and transported into contact with an analyte
which is present in another droplet on a droplet microactuator
or is immobilized on a surface of a droplet microactuator. As
another example, the compound having binding affinity for
the analyte may itself be immobilized on the surface of a
droplet microactuator and/or on the surface of beads included
on a droplet microactuator, and a droplet including the analyte
or potentially including the analyte may be brought into con-
tact with the immobilized antibody.
It will be appreciated that a wide variety of affinity-based
assay protocols are possible within the scope of the invention.
Examples of affinity-based assay formats include direct affin-
ity-based assays, indirect affinity-based assays, and competi-
tive affinity-based assays. The assays may be employed to
detect the presence of a target analyte, and may also in some
cases be used to quantify the target analyte present in a
sample. In a competitive assay, a droplet including a sample
antibody and labeled antibody is contacted with a surface.
The sample antibody competes with labeled antibody for
binding to antigen adsorbed onto the surface. A variant of this
approach involves linking the antigen to the surface via an
intermediary linker. For example, the linker may be an anti-
body. The capture bridge assay uses a droplet including a
sample antibody to link antigen adsorbed to the surface with
antigen in solution. Another approach involves the use of
biotinylated antigen and a streptavidin coated solid phase.
Another approach involves binding the sample antibody to
antigen immobilized on the solid phase. The bound antibody
may be detected with isotype specific labeled second anti-
body. Excess antibody can be washed off using the droplet
protocols of the invention.
It will be appreciated that an important aspect of the inven-
tion involves the ability to conduct droplet operations using
each of the required affinity-based assay reagents and/or
samples on a droplet microactuator. For example, the inven-
tion includes:
(1) a droplet microactuator comprising thereon a droplet
comprising any one or more of the reagents and/or samples
described herein for conducting affinity-based assays;
(2) a device or system of the invention comprising such drop-
let microactuator;
(3) a method of conducting droplet operations on or otherwise
manipulating a droplet making use of such droplet micro-
actuator or system; and/or
(4) a method of conducting an droplet-based affinity-based
assay making use of such droplet microactuator or system.
For example, the droplet operations may include one or
more of the following: loading a droplet into the droplet
microactuator; dispensing one or more droplets from a source
droplet; splitting, separating or dividing a droplet into two or
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more droplets; transporting a droplet from one location to
another in any direction; merging or combining two or more
droplets into a single droplet; diluting a droplet; mixing a
droplet; agitating a droplet; deforming a droplet; retaining a
5 droplet in position; incubating a droplet; heating a droplet;
vaporizing a droplet; cooling a droplet; disposing of a droplet;
transporting a droplet out of a droplet microactuator; other
droplet operations described herein; and/or any combination
of the foregoing. Various other methods, devices, systems,
io and other aspects of the invention will be apparent from the
ensuing discussion.
8.3.1 Samples and Sample Preparation
The invention provides droplet-based affinity-based assays
which are useful for detection of a wide variety of analytes.
15 For example, any analyte that can bind with specificity to an
affinity molecule, such as an antibody, is suitable for detec-
tion using the systems of the invention. A single sample may
be analyzed for one or more target analytes. Analytes may, for
example, be biological analytes or synthetic analytes.
20 Examples include analytes in the following categories: ana-
lytes from human sources, analytes from animal sources,
analytes from plant sources, analytes from bacterial sources,
analytes from viral sources, and analytes from spore sources.
25 Analytes may, for example, include proteins, peptides, small
molecules, and various biomolecules, such as carbohydrates,
lipids, and the like. In one embodiment, samples are con-
tacted with immobilized antibody (e.g., antibody immobi-
lized on beads), prior to introduction of the immobilized
30 antibody onto the droplet microactuator.An illustrative droplet microactuator 600 suitable for con-
ducting immunoassays is illustrated in FIG. 6. This embodi-
ment may employ two substrates, a first substrate 601a and a
second substrate 601b spaced apart in a substantially parallel
35 fashion to provide an intervening space. Multiple fluid ports
or reservoirs may be provided in the intervening space, such
as wash buffer reservoirs 602, sample reservoir 604, primary
antibody reservoir 606, secondary antibody reservoir 608,
and immobilized antibody (e.g., antibody immobilized on
40 
beads) reservoir 610. Waste areas 612 may also be provided,
as well as a magnet 614 positioned in a manner which permits
interaction between the magnet's magnetic field and magneti-
cally responsive components located in the intervening space.
In this particular embodiment, transport electrodes 616 are
45 
provided on the first substrate.
8.3.2 Sandwich Affinity-Based Assay
In one embodiment, the invention provides a droplet-based
sandwich affinity-based assay performed on a droplet micro-
actuator. It will be appreciated that a wide variety of protocols
5o are possible within the scope of the invention for conducting
sandwich affinity-based assays. The following droplet-based
protocol, which is based on the FIG. 7 illustration, is provided
as one example only and is not intended to be limiting of the
scope of the invention:
55 (1) immobilizing on a surface an antibody (primary) with
specificity for a target analyte;
(2) washing the immobilized antibody, e.g., using a droplet-
based washing protocol, to remove excess antibody;
(3) using droplet operations to expose the immobilized anti-
60	 body to a sample droplet potentially including the target
analyte with binding affinity for the immobilized antibody;
(4) washing the immobilized antibody-target analyte com-
plex, e.g., using a droplet-based washing protocol, to
remove unbound components of the sample droplet;
65 (5) exposing the immobilized antibody (now potentially
including the target analyte bound thereto) to a droplet
including a reporter (secondary) antibody;
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(6)washing away excess reporter antibody, e.g., using a drop-
let-based washing protocol;
(7) optionally, performing additional steps to provide a mea-
surable parameter or signal;
(8) measuring the measurable parameter or signal; and
(9) providing an output indicative of the signal.
Any one or more of the foregoing steps can be performed
using droplet operations on a droplet microactuator as
described herein.
8.3.2.1 Immobilizing Antibody
A primary antibody is immobilized on a surface. The sur-
face may, for example, be a surface of the droplet microac-
tuator, or the surface of beads, such as magnetically respon-
sive beads, non-magnetically responsive beads, or particles,
such as nanoparticles.
Immobilization of the antibody to the surface can be
accomplished on the droplet microactuator using droplet-
based protocols. For example, reagents for immobilizing an
antibody to a surface may be introduced to the droplet micro-
actuator, dispensed as discrete droplets and transported into
contact with the surface for deposition. Where the surface in
question is the surface of one or more beads, the beads may be
introduced to the droplet microactuator, dispensed as buffer
droplets, transported on the droplet microactuator, and
merged with one or more droplets including reagents for
immobilizing the droplets on the surface of the beads.
Alternatively, the antibodies may be immobilized off the
droplet microactuator. For example, antibodies may be
immobilized on beads prior to introduction to the droplet
microactuator. A variety of protein-coated (e.g., streptavidin)
and antibody-coated beads are commercially available. In
another embodiment, antibodies may be immobilized on a
surface of the droplet microactuator, e.g., during manufacture
of the droplet microactuator.
Further, surfaces may be prepared for immobilization of
antibodies. For example, a surface may be provided including
moieties which have an affinity for an antibody or a binding
moiety coupled to an antibody. The antibody, optionally
including the binding moiety, may be brought into contact
with the surface thereby immobilizing the antibody on the
surface. For example, beads pre-coated with streptavadin
may be introduced to the droplet microactuator. Droplet
operations may be conducted with droplets including the
streptavadin-coated beads, and may be employed to bring
such bead-containing droplets into contact with one or more
droplets including biotinylated antibody to thereby couple the
antibody to the beads. As another example, the droplet micro-
actuator may include a streptavidin coated surface on a drop-
let microactuation path, such that droplet operations may be
employed to bring a droplet including biotinylated antibody
into contact with the streptavidin coated surface and thereby
immobilize the antibody on the surface. In a yet another
example, capture antibodies can be selectively immobilized
onto the surface of the droplet microactuator, e.g., by pattern-
ing the surface to enable immobilization of antibodies or by
coupling photoactive species directly to the antibodies or to
streptavidin and then immobilizing the antibody selectively
by using a direct-write light system or using an optical mask
or using other means to selectively expose light.
A wide variety of techniques are available for binding
antibodies to surfaces. For example, the surface may be acti-
vated with Protein G to enable the binding of antibody mol-
ecules via their Fc domain, leaving the variable region avail-
able for target capture. Antibody may be covalently bound to
latex surfaces by reaction of activated antibody with 1,3-
diaminopropane coupled, polystyrene aldehyde/sulfate latex.
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Surfactant-free sulfate white polystyrene latex beads may be
coated with antibody by incubation with antibody and con-
jugation buffer (30 mM Na2CO3, 70 mM NaHCO31 pH 9.5).
Biotinylated antibody can be captured on streptavidin coated
s substrates. Antibodies may be covalently bound to a modified
surface of the droplet microactuator such as a silane or thi-
olated layer. Antibodies may be covalently bound to a modi-
fied surface of the droplet microactuator (e.g., during assem-
bly or using droplet operations to deposit the antibodies on the
io surface), such as a surface modified with silane or a thiolated
surface.
8.3.2.2 Binding Target Analyte to Immobilized Antibody
A sample droplet is contacted with the immobilized anti-
body to permit any target analyte present in the sample to bind
15 with the immobilized antibody. This step may be accom-
plished using droplet operations to transport a sample droplet
into contact with the surface on which the antibody is
attached, e.g., a droplet including antibody coated beads or a
surface of the droplet microactuator on which the antibody is
20 immobilized. In an alternative embodiment, the surface is a
beads surface, and the bead is contacted with the sample prior
to introduction into the droplet microactuator. The bead may
also be washed prior to introduction into the droplet micro-
actuator. The antibody binds to analyte from the sample drop-
25 let. The binding process may be expedited by increasing the
speed of mass-transport. A few examples of accelerating
mass transport include transport of the droplets at a high
speed to enable thorough mixing of the beads with antibodies
and the target analyte or to replenish the surface of immobi-
30 lized antibody with target analytes. Other means include agi-
tating the incubated droplet in-place by electrically manipu-
lating the droplet or by a number of external means such as
piezoelectric methods of actuation. In absence of any means
ofmass transport, the binding events occurbased on diffusion
35 and it could take longer times thereby prolonging the assay
times. The immobilized antibody (e.g., the beads or the sur-
face) may in some embodiments be subjected to a washing
protocol on the droplet microactuator, e.g., as described in
Section 8.6, to remove excess sample or other materials.
40
8.3.2.3 Binding Reporter Antibody to Target Analyte
After washing (e.g., the beads or the surface), a droplet
comprising a reporter antibody having affinity for a different
epitope on the analyte may be brought into contact with the
45 washed immobilized antibody potentially having the cap-
tured analyte. The labeled antibody conjugate includes an
antibody coupled to a reporter molecule, such as a radioactive
molecule, an enzyme capable of catalyzing a detectable reac-
tion (e.g., a color change, chemiluminescence, fluorescence,
50 chemiluminescence, or electrochemical), a chemilumines-
cent molecule, or a fluorescent molecule. Depending on the
reporter used, the immobilized antibody (e.g., beads or other
surface) including the analyte and reporter antibody may then
subjected to a washing protocol, e.g., as described in Section
55 8.6, to remove excess reporter antibody.
8.3.2.4 Producing and Detecting Measurable Parameter
Bound reporter antibody may be quantified by detecting a
signal facilitated by the reporter antibody. For example, the
signal may be radioactivity, color change, luminescence,
60 fluorescence, luminescence, Raman spectra, light scattering
approaches, particle/bead aggregation, surface plasmon reso-
nance, Raman spectroscopic effect and the like. The detection
may be direct or indirect, by detecting the quantity of anti-
body coupled to the analyte or by detecting the quantity of
65 unbound antibody.
For approaches requiring further reaction to produce a
signal, e.g., conversion of a non-fluorescent product to a
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fluorescent product, a droplet including the additional
required reactants can be brought into contact with antibody-
antigen-antibody complex in order to facilitate the further
reaction.
Once the reporter antibody has been permitted to bind to
the analyte, excess reporter antibody can be washed away
using a washing protocol, and droplet operations can be used
to bring a droplet including the required reporter reactants
into contact with the immobilized antibody. In one embodi-
ment, the reporter antibody is labeled with an enzyme (e.g.,
horseradish peroxidase (HRP) or alkaline phosphatase
(ALP)) capable of catalyzing a reaction which produces a
measurable parameter. For example, HRP can be used to
catalyze hydrogen peroxide to generate an electrochemical
signal which can be detected by measuring the current or
voltage. Detection of bound antibody can be achieved by a
fluorescence reaction catalyzed by the HRP using Amplex
Red and hydrogen peroxide as substrates. Another example
employs an alkaline phosphatase mediated conversion of
NBT to violet formazan, which can be detected in a droplet
colorimetrically. In another approach, a chemiluminescence
substrate such as luminol or Ps-atto from Lumigen could be
catalyzed by HRP to generate a chemiluminescence signal.
Other examples of suitable detection approaches are dis-
cussed elsewhere herein (e.g., see 8.3.5).
In one embodiment, the detection step is performed in a
droplet on the droplet microactuator in the presence of a
sensor in order to enhance or maximize capture of signal from
the reaction. In another embodiment, the reaction is per-
formed away from a sensor, and the droplet is transported
using droplet operations into the presence of a sensor for
detection purposes.
8.3.2.5 Alternative Sandwich Assay Approaches
It will be appreciated that a variety of alternative
approaches are possible. For example the steps need not be
performed in the order described above, e.g., the reporter
antibody may be bound to the analyte prior to or at the same
time the analyte is exposed to the immobilized antibody. In
another approach, binding of capture antibody, analyte, and
reporter antibody can all be performed simultaneously and
then presented to a capture site and then washed. In some
approaches, such as surface enhanced resonance Raman scat-
tering, washing may not be required.
8.3.3 Competitive Affinity-Based Assay
In one embodiment, the invention provides a competitive
affinity-based assay performed on a droplet microactuator.
Analytes for detection by competitive affinity-based assay are
typically those that are too small for binding two antibodies as
required by a sandwich assay. It will be appreciated that a
wide variety of protocols are possible within the scope of the
invention for conducting competitive affinity-based assays.
The following droplet-based protocol, which is based on the
FIG. 8 illustration, is provided for illustration only and is not
intended to be limiting of the scope of the invention:
(1) immobilizing on a surface an antibody with specificity for
a target analyte;
(2) washing the immobilized antibody, e.g., using a droplet-
based washing protocol, to remove excess antibody;
(3) providing a sample droplet potentially including target
analyte and including a reporter analyte;
(4) exposing the immobilized antibody to the combined target
analyte/reporter analyte droplet so that the reporter analyte
competes with any target analyte for binding sites;
(5) washing the substrate to remove unbound analyte and
reporter analyte;
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(6) optionally, performing additional steps to yield a measur-
able parameter or signal; and
(7) quantifying bound reporter analyte, wherein the quantity
of reporter analyte is inversely proportional to the quantity
5	 of target analyte.
Any one or more of the foregoing steps can be performed
using droplet manipulation techniques on a droplet microac-
tuator as described herein. Each of the steps is discussed in
further detail in the ensuing sections.
10 8.3.3.1 Immobilizing Antibody
The antibody may be immobilized as described above in
Section 8.4.1.1.
8.3.3.2 Competitive Binding
15 A droplet including the sample potentially including a
target analyte is combined with a droplet including the
reporter analyte, and the combined droplet is brought into
contact with the immobilized antibody. Alternatively, the
mixture of target and reporter is accomplished during loading
20 of the droplet microactuator.
The reporter analyte may be made by coupling the reporter
nucleic acid to the analyte using any of a variety of conjuga-
tion methods. In one embodiment, the analyte portion is
modified with a molecule, such as biotin, which generates a
25 secondary capture site for immobilizing a streptavidin sensor
DNA complex. The coupling of biotin to the analyte must not
unduly interfere with its binding to the capture antibody. The
biotinylated material may in some cases compete equally
with the analyte from the test sample. Coupling of the bioti-
3o nylated analyte to a reporter molecule can occur before or
after the biotinylated analyte is captured by the immobilized
antibody.
For example, in one embodiment, the assay is performed
by mixing a droplet with a known quantity of biotinylated
35 analyte with the sample droplet potentially containing an
unknown quantity of unmodified analyte. A droplet including
the biotinylated analyte is combined with a droplet poten-
tially including the target analyte. The combined droplet is
contacted with the immobilized antibody so that the biotiny-
40 lated analyte and the target analyte (if any) compete for bind-
ing to the immobilized antibody. The quantity of biotinylated
analyte bound is inversely proportional to the quantity of
analyte in the test droplet. The immobilized antibody (e.g.,
the beads or the surface) may then be subjected to a washing
45 protocol, e.g., as described in Section 8.6, to remove excess
reporter analyte.
8.3.3.3 Detecting the Reporter Analyte
After washing, a droplet with a streptavidin-biotin-reporter
50 
complex is added to a droplet including the washed beads or
otherwise brought into contact with a surface including the
immobilized antibody. The streptavidin-biotin-reporter com-
plex binds to any biotinylated analyte that was capturedby the
antibody on the bead.
55 8.3.3.4 Alternative Competitive Assay Approaches
The competitive affinity-based assay described here is only
one example of a droplet microactuator protocol suitable for
execution on the droplet microactuator of the invention. A
variety of alternatives are possible within the scope of the
60 invention. For example, the steps are not limited to the order
given. The antibody can be bound to the target analyte/re-
porter analyte before it is immobilized by combining a drop-
let including the free antibody with one or more droplets
including the target analyte/reporter analyte, after which the
65 antibody may be brought into contact with the surface for
immobilization. The reporter analyte may be conjugated with
the reporter nucleic acid on the droplet microactuator by
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combining droplets including the two reagents. A droplet
including the reporter analyte may be combined with a drop-
let including the reporter nucleic acid to affect conjugation
before or after the reporter analyte is exposed to the captured
antibody.
In another embodiment, a competitive assay is performed
by mixing a droplet with a known amount of enzyme-labeled
analyte with a sample droplet containing the target analyte
which is then further mixed with a droplet containing anti-
bodies. Competition ensues for binding sites between the
labeled and target analytes. The activity of the enzyme is
reduced upon binding of the enzyme-labeled analyte with the
antibody and this can be monitored through a number of
different types of transduction events, e.g., absorbance, in
order quantify the concentration of the target analyte in the
sample. For example, a droplet containing Uancomycin
labeled with glucose-6-phophate dehydrogenase (G6P-DH)
can be mixed with a sample droplet containing unlabelled
Uancomycin which can be further mixed with a droplet con-
taining antibodies reactive to Uancomycin, glucose-6-phos-
phate, and nicotinamide adenine dinucleotide (NAD). The
activity of G6P-DH is reduced upon binding to an antibody.
G6P-DH converts NAD' to NADH, resulting in an absor-
bance change that is measured spectrophotometrically at 340
mu. Once a calibration has been performed within the droplet
microactuator, the Uancomycin concentration in each
unknown sample can be determined using the stored calibra-
tion curve and the measured absorbance obtained in the assay
of the sample. Other analytes that can be detected using the
same method includes Valproic acid, Tobramycin, Gentami-
cin, and Caffeine.
8.3.4 Other Affinity-Based Assay Protocols
The competitive affinity-based assay described here is only
one example of a droplet microactuator protocol suitable for
execution on the droplet microactuator of the invention. A
variety of alternatives are possible within the scope of the
invention. For example, the droplet microactuator system of
the invention enables multiple affinity-based assays to be
simultaneously performed on a single sample or a single
affinity-based assay to be performed on multiple samples or a
combination thereof. Further, affinity-based assays may be
performed along with other tests, such as PCR and/or
immuno-PCR.
A variety of alternative assay types may be executed using
droplet-based protocols in light of the instant specification.
Examples include immunoprecipitation assays; immunoradi-
ometric assays; heterogeneous enzyme labeled affinity-based
assays in which the quantitation of the antibody bound and
unbound fractions requires a physical separation of these two
fractions; homogeneous (non-separation) enzyme labeled
affinity-based assays which do not require a physical separa-
tion of these two fractions because the unbound and antibody
bound fractions can be distinguished functionally. For immu-
noprecipitation assays, droplets including reagents for con-
ducting the immunoprecipitation assays are combined on a
droplet microactuator to conduct the immunoprecipitation
assay. Immunoprecipitation may be detected using a light
scattering detector.
While most of the approaches discussed thus far involve
immobilization of the antibody or the analyte, immobiliza-
tion is not required in all droplet-based immunoassays of the
invention. For example, the invention includes a homogenous
droplet-based enzyme-multiplied immunoassay in which the
labeled antibody includes an enzyme that is inactivated when
bound to the primary antibody. Enzymatic activity is approxi-
mately proportionate to the analyte concentration. The
40
approach generally includes combining on a droplet micro-
actuator droplets for conducting the droplet-based enzyme-
multiplied immunoassay and measuring the resulting enzy-
matic activity.
5 In another method, the light scattering properties of the
antigen/antibody complex will be altered upon a binding
event, and this change can be monitored by detecting light
scattering changes in the reaction droplet on the droplet
to microactuator, such as turbidity measurements, to identify
and/or quantitate the capture events. For example, a physi-
ological sample droplet on the droplet microactuator contain-
ing immunoglobulins such as IgA, IgG, and IgM (after
sample preparation including dilution and addition of poly-
15 mers) or apolipoproteins such as ApoAl, ApoB (after sample
preparation including dilution and addition of polymers or
surfactants) can be combined using droplet operations with a
droplet containing respective antibodies that, upon occur-
rence of binding events, results in a change in the turbidity of
20 the combined droplet which can be monitored spectrophoto-
metrically. A few examples of other analytes that can be
measured using this technique include a i -antitrypsin (AAT),
transferrin, prealbumin, haptoglobin, complement C3, and
complement C4.
25 Another class of immunoassays suitable for use in the
present invention include agglutination assays which can also
be performed in the droplet format. A droplet containing the
analyte is mixed with a droplet containing particles, for
example latex particles, with the capture antibody or antigen
30 bound to the particles. If the target analyte is present in the
sample, the latex particles start to agglutinate together and it
can be quantified by measuring the absorbance.
The system provides multiplexed affinity-based assays. In
35 one embodiment, the system has the ability to detect 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,
41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more analytes using
immunoassays. In some high throughput settings, the system
40 provides for multiplexed detection of 96, 384, 1536, or higher
number of analyses either in serial fashion on in parallel
fashion. The analytes may, for example, include analytes
from natural or non-natural sources. In another embodiment,
the invention has the ability to execute affinity-based assay
45 protocols for detecting one or more analytes from any 2, 3, 4
or 5 the following categories: analytes from bacterial sources,
analytes from viral sources, analytes from fungal sources,
protein toxin analytes, and small molecule toxin analytes.
The system may be programmed to repeat assays as needed
50 to increase confidence for a single target result. Importantly,
the droplet microactuator system can be programmed to
effect confirmatory re-testing of positives to reduce the pos-
sibility of false positives. The system may also be pro-
grammed and configured to permit storage of tested samples
55 on the droplet microactuator for subsequent additional labo-
ratory testing.
An important advantage of the invention is the capability of
the droplet microactuator to quickly and accurately produce
calibration curves. The droplet microactuator can accurately
6o and reproducibly dispense droplets of a solution of known
concentration of control analyte and can dilute such droplets
by combining them with buffer droplets to provide a series of
control droplets having varied concentrations of control ana-
lyte. These control droplets can be taken through the same
65 protocol as sample droplets to produce a calibration curve.
The calibration curve can be used to determine quantities of
analyte in sample droplets.
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8.3.5 Other Detection Approaches for Affinity-based Assays
A wide variety of detecting approaches are available for
use in the droplet-based affinity-based assays of the inven-
tion. The selected approach will be capable of directly or
indirectly producing a signal in a droplet-based affinity-based
assay. The signal may be detectable by a sensor positioned in
contact with or in close proximity with the droplet. Examples
of signals suitable for use in the affinity-based assays include
signals produced from radioisotopic labels, fluorescent
labels, luminescent labels, electroluminescent labels micro-
particles, nanoparticles, enzymatic reactions, aggregation
compounds, Raman-active dyes, electroactive labels, and
labels affecting conductivity. Examples of suitable radioiso-
topic labels include s'Co, 3H 35P 35 S, and 125 1. In one
embodiment, radioisotopic labels are used in a scintillation
proximity assay (SPA) on a droplet microactuator. SPA's
enable detection of binding events without requiring a wash-
ing step. The radiolabel may, for example, be incorporated
into a competitive analyte in a competition assay or in a
secondary antibody in a sandwich assay. Radiolabels that
emit alpha or weak beta particles are preferred. The SPA is
conducted in proximity to a fluorophore that emits light upon
exposure to a radiolabel. For example, the fluorophore may be
provided in a bead, in a surface of the droplet microactuator to
which an antigen or primary antibody is bound, or in nano-
particle coupled to an antigen or primary antibody. Examples
of suitable luminescent labels include acridinium ester,
rhodamine, dioxetanes, acridiniums, phenanthridiniums and
various isoluminol derivatives. Examples of suitable fluores-
cent labels include fluorescein and Eu 3+ . Examples of suit-
able enzymatic labels include those which produce visible,
colored, fluorescent and/or luminescent products from suit-
able substrates. For example, suitable enzymes may include
penicillinase, horseradish peroxidase, (3-galactosidase, ure-
ase, deaminases and alkaline phosphatase. Examples of suit-
able nanoparticles include metal nanoparticles. Further infor-
mation about detection approaches suitable for affinity-based
assays of the invention is provided in Section 8.11.
8.3.6 Sample Size and Assay Speed
Implementation on a digital microfluidic platform will dra-
matically reduce the equipment size and cost, primarily by
miniaturizing all liquid handling functions. Assays can, in
some embodiments, be performed on less than 100th or 1000th
of the sample and reagent volumes currently used with equal
sensitivity and specificity. In one embodiment, the system
will typically perform affinity-based assays using samples at
droplet volumes of 1 µL or less, or 100 nanoliters or less.
Other advantages include reduced time to results due to
faster kinetics in the miniaturized format for the assays and
higher throughput due to multiplexing. For example, in one
embodiment, the system executes affinity-based assay proto-
cols for detecting 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14,15, 16,
17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
or more analytes in less than about 60, 50, 40, 30, 20, 15, 10,
5 or 2 minutes.
8.3.7 Applications of Droplet-Based, Affinity-Based Assays
As noted above, the affinity-based assays of the invention
are useful for detecting a wide variety of molecules. Any
molecule which binds with affinity to an affinity molecule,
such as an antibody, is a suitable analyte. Analytes may, for
example, include biological molecules or synthetic mol-
ecules. Biological molecules may, for example, include mol-
ecules from plants, animals, microbes, and viruses. Synthetic
molecules may, for example, include industrial byproducts,
pollutants, and pharmaceuticals. Analytes may include toxins
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or analytes indicative of the presence of specific biological
organisms, e.g., infectious diseases, or toxins that are
employed in bioterrorism or biological warfare. Examples of
such organisms include anthrax, avian influenza, botulism,
5 hantavirus, legionnaires' disease, pneumonic plague, small-
pox, tularemia, and viral hemorrhagic fevers (VHFs). Other
examples include analytes associated with monitoring the
immunogenicity of vaccines targeting cancer, chronic infec-
tious diseases (e.g., HIV, malaria, hepatitis C, candidemia),
io immunology (e.g., allergy, autoimmunity), endocrinology
(thyroid, non-thyroid), drug testing (e.g., drugs of abuse,
therapeutic drugs) and detection ofbioterrorism agents (e.g.,
anthrax, smallpox).
In one embodiment, immunoassay technique is used to test
15 a sample for the presence of a biological organism, such as a
bacteria or a virus. In some embodiments, the system can
achieve extremely sensitive detections even down to a single
cell. Further, some embodiments may include PCR bacterial
typing or variance.
20 The affinity-based assays of the invention are also useful
for detecting chemical, biological or explosive threats. For
example, antibody to explosives can be used to detect the
presence of trace amounts of explosive in a sample. Thus, the
invention also provides a method of screening an area for
25 chemical or biological analytes indicative of the presence of
biological, chemical, or explosive weapons.
In one embodiment, the invention provides the capability
of detecting multiple analytes in a single droplet. One way to
achieve this result according to the invention involves the use
30 of different antibodies for different analytes at spatially sepa-
rated locations on the droplet microactuator. For example, the
droplet microactuator may include multiple surfaces, each
comprising a specific antibody. A single sample droplet may
be manipulated to come into contact with these antibodies all
35 at once, or sequentially, as the droplet is transported across the
antibody regions. Affinity-based assay protocols of the inven-
tion may be employed to detect the presence of analyte bound
to the antibody in any of the various regions. Similarly, mul-
tiple analytes can be detected in a single droplet by using
40 different labels to simultaneously detect different analytes in
the same spatial area. In another embodiment, the droplet
microactuator includes spatially separated beads, each bead
or set of beads having a unique antibody or set of antibodies.
Sample droplets and/or bead containing droplets may be
45 manipulated using droplet operations in order to contact a
sample droplet with each of the beads or sets of beads.
8.4 Immuno PCR
The invention provides a droplet-based immuno PCR
50 (pick) for sensitively detecting analytes that are available only
at trace levels. This invention combines the various means of
affinity-based assays using a detector antibody on a droplet-
based platform and utilizes a nucleic acid strand as a label.
This nucleic acid strand is amplified using amplification tech-
55 mques (e.g., see Section 8.1).
It will be appreciated that an important aspect of the inven-
tion involves the ability to conduct droplet operations using
each of the required iPCR reagents and/or samples on a drop-
let microactuator. For example, the invention includes:
60 (1) a droplet microactuator comprising thereon a droplet
comprising any one or more of the reagents and/or samples
described herein for conducting iPCR protocols;
(2) a device or system of the invention comprising such drop-
let microactuator;
65 (3) a method of conducting droplet operations on or otherwise
manipulating a droplet making use of such droplet micro-
actuator or system; and/or
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(4) a method of conducting an droplet-based affinity-based
assay making use of such droplet microactuator or system.
For example, the droplet operations may include one or
more of the following: loading a droplet into the droplet
microactuator; dispensing one or more droplets from a source
droplet; splitting, separating or dividing a droplet into two or
more droplets; transporting a droplet from one location to
another in any direction; merging or combining two or more
droplets into a single droplet; diluting a droplet; mixing a
droplet; agitating a droplet; deforming a droplet; retaining a
droplet in position; incubating a droplet; heating a droplet;
vaporizing a droplet; cooling a droplet; disposing of a droplet;
transporting a droplet out of a droplet microactuator; other
droplet operations described herein; and/or any combination
of the foregoing. Various other methods, devices, systems,
and other aspects of the invention will be apparent from the
ensuing discussion.
8.4.1 Sandwich iPCR
In one embodiment, the invention provides a droplet-based
sandwich iPCR performed on a droplet microactuator. In
general, the sandwich iPCR involves:
(1) immobilizing on a surface an antibody with specificity for
a target analyte;
(2) washing the immobilized antibody, e.g., using a droplet-
based washing protocol;
(3) exposing the immobilized antibody to a sample droplet
potentially including the target analyte;
(4) washing the immobilized antibody, e.g., using a droplet-
based washing protocol;
(5) exposing the immobilized antibody (now potentially
including the target analyte bound thereto) to a droplet
including a second antibody conjugated to a nucleic acid
molecule;
(6) washing the immobilized antibody, e.g., using a droplet-
based washing protocol;
(7) amplifying the nucleic acid and detecting the amplifica-
tion (if any) to determine the presence and quantity of
captured target analyte.
Any one or more of the foregoing steps can be performed
using droplet manipulation techniques on a droplet microac-
tuator as described herein. Each of the steps is discussed in
further detail in the ensuing sections.
8.4.1.1 Immobilizing Antibody
A primary antibody is immobilized on a surface. The sur-
face may, for example be a surface of the droplet microactua-
tor, or the surface of beads, such as magnetically responsive
beads. Immobilization of the antibody to the surface can be
accomplished on the droplet microactuator using droplet-
based protocols. For example, reagents for immobilizing an
antibody to a surface may be introduced to the droplet micro-
actuator, dispensed as discrete droplets and transported into
contact with the surface for deposition. Where the surface in
question is the surface of one or more beads, the beads may be
introduced to the droplet microactuator, dispensed as droplets
in a buffer, transported, and merged with one or more droplets
including reagents for immobilizing the droplets on the sur-
face of the beads.
A wide variety of techniques are available for binding
antibody to surfaces. For example, the surface may be acti-
vated with Protein G to enable the binding of antibody mol-
ecules via their Fc domain, leaving the variable region avail-
able for target capture. Antibody may be covalently bound to
latex surfaces by reaction of activated antibody with 1,3-
diaminopropane coupled, polystyrene aldehyde/sulfate latex.
Surfactant-free sulfate white polystyrene latex beads may be
coated with antibody by incubation with antibody and con-
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jugation buffer (30 mM Na2CO3, 70 mM NaHCO31 pH 9.5).
Biotinylated antibody can be captured on streptavidin coated
substrates. Light-directed immobilization can also be per-
formed, e.g., as described elsewhere in the present disclosure.
5 8.4.1.2 Binding Target Analyte to Immobilized Antibody
A sample droplet is contacted with the immobilized anti-
body to permit any target analyte present in the sample to bind
with the immobilized antibody. This step may be accom-
10 plished by transporting a sample droplet into contact with a
surface of the droplet microactuator on which the antibody is
immobilized. In another embodiment, the step may be
accomplished by merging a sample droplet with a droplet
including beads on which the antibody has been immobilized.
15 The antibody binds to the analyte from the sample droplet.
The immobilized antibody (e.g., the beads or the surface) may
be subjected to a washing protocol, e.g., as described in
Section 8.6.
8.4.1.3 Binding Antibody-NA to Target Analyte
20 After washing (e.g., the beads or the surface), a droplet
comprising an antibody-NA conjugate having affinity for a
different epitope on the analyte may be brought into contact
with the washed immobilized antibody potentially having the
captured analyte. The antibody-NA conjugate includes a
25 nucleic acid molecule coupled to the antibody. The nucleic
acid molecule serves as the nucleic acid template for ampli-
fication. The immobilized antibody (e.g., the beads or the
surface) are then subjected to a washing protocol, e.g., as
described in Section 8.6.
30
8.4.1.4 Amplifying the Nucleic Acid
The nucleic acid is amplified, e.g, as described in Section
8.1. The quantity of amplified product produced is measured,
e.g., using real time fluorescence detection, electrochemical
35 and/or electrochemiluminescent detection. The quantity of
PCR product produced correlates with the quantity of bound
antibody-DNA, which depends in turn on the quantity of
analyte present in the sample droplet.
40 8.4.1.5 Alternative Approach
In an alternative embodiment, the order of these steps is
generally reversed to perform nucleic acid amplification fol-
lowed by an affinity-based assay that results in an optical or
electrical signal. In this sequence, an immunoassay would be
45 performed to monitor nucleic acid amplification.
8.4.2 Competitive iPCR
In one embodiment, the invention provides a competitive
iPCR performed on a droplet microactuator. Analytes for
detection by competitive iPCR are typically those that are too
so small for binding two antibodies as required by a sandwich
assay. In general, the competitive iPCR involves:
(1) immobilizing on a surface an antibody with specificity for
a target analyte;
55 (2) combining a sample droplet potentially including target
analyte with a droplet including a reporter analyte;
(3) exposing the immobilized antibody to the combined target
analyte/reporter analyte droplet so that the reporter analyte
competes with any target analyte for binding sites;
60 (4) washing the substrate to remove unbound analyte;
(5) coupling the bound reporter analyte to a reporter nucleic
acid; and
(6) amplifying the reporter nucleic acid and monitoring the
progress of the amplification to determine the quantity of
65 unbound reporter analyte, which for the bound reporter
analyte is inversely proportional to the quantity of target
analyte in the sample.
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the reporter analyte is exposed to the captured antibody. A
variety of alternatives is possible within the scope of the
invention.
5 8.4.3 Samples and Sample Preparation
A wide variety of analytes may be detected using droplet-
based iPCR protocols of the invention. A single sample may
be analyzed for one or more target analytes. Analytes may, for
example, be biological analytes or synthetic analytes. For
8.4.2.2 Competitive Binding 	
10 example, in one embodiment, the analytes are selected fromA droplet including the sample potentially including a 	 following categories: analytes from bacterial sources, ana-
target analyte is combined with a droplet including the 	 lytes from viral sources, analytes from spore sources, protein
reporter analyte, and the combined droplet is brought into	 toxin analytes, and small molecule toxin analytes. In one
contact with the immobilized antibody. 	 embodiment, the target analytes include toxins or analytes
The reporter analyte may be made by coupling the reporter 15 indicative of the presence of specific biological organisms,
nucleic acid to the analyte using any of a variety of conjuga- 	 e.g., infectious diseases, or toxins that are employed in biot-
tion methods. In one embodiment, the analyte portion is 	 errorism or biological warfare. Examples of such organisms
modified with a molecule, such as biotin, which generates a 	 include anthrax, avian influenza, botulism, hantavirus,
secondary capture site for immobilizing a streptavidin-DNA 	 legionnaires' disease, pneumonic plague, smallpox, tulare-
complex. The coupling of biotin to the analyte must not 20 mia, and viral hemorrhagic fevers (VHFs).
unduly interfere with its binding to the primary capture anti-
body. The biotinylated material may in some cases compete
equally with the analyte from the sample. Coupling of the
biotinylated analyte to the reporter nucleic acid can occur
before or after the biotinylated analyte is captured by the 
25immobilized antibody.
For example, in one embodiment, the assay is performed
by mixing a droplet with a known quantity of biotinylated
analyte with the sample droplet potentially containing an
unknown quantity of unmodified analyte. A droplet including so
the biotinylated analyte is combined with a droplet poten-
tially including the target analyte. The combined droplet is
contacted with the immobilized antibody so that the biotiny-
lated analyte and the target analyte (if any) compete for bind-
ing to the immobilized antibody. The quantity of biotinylated 35
analyte bound is inversely proportional to the quantity of
analyte in the sample droplet.
8.4.2.3 Coupling the Nucleic Acid Reporter
After washing, a droplet with a streptavidin-biotin-reporter
nucleic acid complex is added to a droplet including the
washed beads or surface. The streptavidin-biotin-reporter
nucleic acid complex binds to any biotinylated analyte that
was captured by the antibody on the bead.
8.4.2.4 Amplifying the Nucleic Acid
After washing, the quantity of a streptavidin-biotin-re-
porter nucleic acid complex immobilized is determined by
amplification of the reporter nucleic acid. The amplification
signal is an inverse measure of the quantity of analyte in the
original sample. Amplification may proceed as described in
Section 8.1. The presence and quantity of amplified product
produced is measured, e.g., using real time fluorescence
detection. The quantity of reporter analyte that was displaced
is proportional to the quantity of target analyte in the sample.
8.4.2.5 Alternative Approaches
The steps are not limited to the order given. For example,
the antibody can be bound to the target analyte/reporter ana-
lyte before it is immobilized by combining a droplet includ-
ing the free antibody with one or more droplets including the
target analyte/reporter analyte, after which the antibody may
be brought into contact with the surface for immobilization. 	 8.4.5 Applications
The reporter analyte may be conjugated with the reporter	 The iPCR assays provided by the invention are useful for
nucleic acid on the droplet microactuator by combining drop- 	 detecting a wide variety of molecules present in extremely
lets including the two reagents. A droplet including the 65 small quantities. Among other things, the system is useful for
reporter analyte may be combined with a droplet including 	 surveillance for a chemical, biological or explosive threat. For
the reporter nucleic acid to affect conjugation before or after 	 example, antibody to explosives can be used to detect the
45
Any one or more of the foregoing steps can be performed
using droplet manipulation techniques on a droplet microac-
tuator as described herein. Each of the steps is discussed in
further detail in the ensuing sections.
8.4.2.1 Immobilizing Antibody
The antibody may be immobilized as described above in
Section 8.4.1.1.
40
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8.4.4 Immuno-PCR Protocols
The system of the invention enables multiple immuno-
PCR tests to be simultaneously performed on a single sample.
Further, immuno-PCR tests may be performed along with
other tests, such as PCR and/or affinity-based assays.
The system provides multiplexed detection. In one
embodiment, the system has the ability to detect 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47, 48, 49, 50 or more analytes. The
analytes may, for example, include analytes from natural or
non-natural sources. In another embodiment, the invention
has the ability to detect one or more analytes from any 2, 3, 4
or 5 the following categories: analytes from bacterial sources,
analytes from viral sources, analytes from spore sources,
protein toxin analytes, and small molecule toxin analytes.
The system may be programmed to implement additional
tests as needed to increase confidence for a single target
result. Importantly, the droplet microactuator system can be
programmed to effect confirmatory re-testing of positives to
reduce the possibility of false positives. The system may also
be programmed and configured to permit storage of tested
samples on the droplet microactuator for subsequent addi-
tional laboratory testing.
In operation, the system performs analysis and provides
results extremely quickly. For example, in one embodiment,
the system has the ability to detect 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, 50 or more analytes in less than about 60, 50,
40, 30, 20, 15 or 10 minutes. In another embodiment, the
system has the ability to detect 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,
47, 48, 49, 50 or more analytes from any 2, 3, 4 or 5 the
following categories: analytes from bacterial sources, ana-
lytes from viral sources, analytes from spore sources, protein
toxin analytes, and small molecule toxin analytes, and all
tests are completed in less than about 60, 50, 40, 30, 20, 15 or
10 minutes.
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presence of trace amounts of explosive in a sample. Thus, the
invention also provides a method of screening an area for
chemical or biological analytes indicative of the presence of
biological, chemical, or explosive weapons.
In one embodiment, iPCR technique is used to test a
sample for the presence of a biological organism, such as a
bacteria or a virus. In some embodiments, the system can
achieve even single-organism detection. Further, some
embodiments may include PCR bacterial typing or variance.
8.5 Analysis of Biological Fluids
The invention provides methods, devices and systems for
analysis of blood, various components of blood, and other
biological fluids. Illustrative designs for a biological fluid
analyzer are shown in FIGS. 9 and 17.
FIG. 9 illustrates one embodiment of a biological fluid
analyzer 900. In this embodiment, various modules may be
provided for conducting biological fluid analysis, such as, for
example, detection of metabolites (e.g., glucose, lactate,
blood urea nitrogen, and creatinine), electrolytes (e.g., K',
Cl-, and Na'), proteins, and enzymes. These various modules
may include amperometric module 902, potentiometric mod-
ule 904, optical module 906, and conductometric module
908.
Another embodiment of a biological fluid analyzer 1700 is
illustrated in FIG. 17. In this embodiment, multiple fluidports
or reservoirs may be provided such as antibody reservoirs
1701 (such as for bacteria antibodies, spore antibodies, bac-
teria AB-DNA, spore AB-DNA, protein toxin antibodies,
small molecule antibodies, proteinAB-DNA, and small mol-
ecule SB-A DNA), PCR primer reservoirs 1702, and PCR
reagents reservoirs 1703. Sample port 1704 may also be pro-
vided, as well as sample reservoir 1705, wash solution area
1706, and waste reservoir 1707. Other areas that may be
provided include hot temperature area 1708, cold temperature
area 1709, and detector area 1710.
It will be appreciated that an important aspect of the inven-
tion involves the ability to conduct droplet operations using
each of the required biological fluid analysis samples and
reagents on a droplet microactuator. For example, the inven-
tion includes:
(1) a droplet microactuator comprising thereon a droplet
comprising any one or more of the reagents and/or samples
described herein for conducting such biological fluid
analysis;
(2) a device or system of the invention comprising such drop-
let microactuator;
(3) a method of conducting droplet operations on or otherwise
manipulating a droplet making use of such droplet micro-
actuator or system; and/or
(4) a method of conducting an droplet-based affinity-based
assay making use of such droplet microactuator or system.
For example, the droplet operations may include one or
more of the following: loading a droplet into the droplet
microactuator; dispensing one or more droplets from a source
droplet; splitting, separating or dividing a droplet into two or
more droplets; transporting a droplet from one location to
another in any direction; merging or combining two or more
droplets into a single droplet; diluting a droplet; mixing a
droplet; agitating a droplet; deforming a droplet; retaining a
droplet in position; incubating a droplet; heating a droplet;
vaporizing a droplet; cooling a droplet; disposing of a droplet;
transporting a droplet out of a droplet microactuator; other
droplet operations described herein; and/or any combination
of the foregoing. Various other methods, devices, systems,
and other aspects of the invention will be apparent from the
ensuing discussion.
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8.5.1 Sample and Sample Preparation
Examples of suitable samples for use with the droplet
microactuator of the invention include whole blood, serum,
and plasma, and various components thereof. Venous, arte-
5 rial, or capillary blood can be used. Examples of other
samples usefully analyzed according to the present invention
include cerebrospinal fluid (CSF), urine, saliva, sweat, tears,
amniotic fluid, pleural fluid, milk, cystic fluid, synovial fluid,
stool, and semen.
10 Serum and/or plasma may be extracted from whole blood
on the droplet microactuator and/or prior to introduction into
the droplet microactuator. An example of a loading structure
1000 provided for this purpose is provided in FIG. 10. In this
embodiment, fluid is flowed from a reservoir 1002 through a
15 sealing means 1004 into a loading chamber 1006 where it
comes into contact with a membrane 1008. Permeate passes
into a permeate flow channel 1010 through which it flows into
droplet microactuator reservoir 1012, assisted by pressure
source 1014 which applies pressure via channel 1016.
20 The small size of the device dramatically reduces the vol-
ume of sample required for routine testing, which is an impor-
tant concern in many settings. For example, typical sample
sizes will have a volume which is in one embodiment from
about 1 nL to about 100 mL, or about 10 nL to about 10 mL,
25 or about 1 µL to about 10 µL.
8.5.2 Analytes
The invention provides a versatile droplet microactuator
system capable of performing an array of tests on a single
30 sub-microliter droplet of blood or any physiological sample
of about -0.5 µL. Examples of suitable tests include metabo-
lites (e.g., glucose, creatinine, lactate, blood urea nitrogen),
electrolytes/elements (e.g., K+, Na+, Cl-, P, Mg, Li, Ca, Fe),
gases (e.g., pH, pCO 2, NH3), enzymes (alkaline phosphatase
35 (ALP), aspartate aminotransferase (AST), alaaine ami-
notransferase (ALT), lactate dehydrogenase (LDH), Lipase,
Creatine Kinase, Creatine Kinase MB), proteins (albumin,
c-reactive protein (CRP), urine microalbumin, urine protein,
cerebrospinal fluid protein, serum total protein), and hemat-
40 ocrit. Other analytes include glycated hemoglobin (Alc),
hemoglobin, uric acid, triglycerides, cholesterol, high density
lipoprotein (HDL) and low density lipoprotein (LDL).
8.5.2.1 Metabolites
The invention is useful in conducting a variety of enzyme-
45 coupled assays, such as for glucose, blood urea nitrogen,
creatinine, and lactate based on electrochemical or optical
detection. In some embodiments, glucose, lactate, and crea-
tinine are measured through the amperometric detection of
H2O2 in an enzyme-coupled assay performed on the droplet
50 microactuator.
In some embodiments, the invention includes an electro-
chemistry module with electrodes for amperometric and/or
potentiometric detection of metabolites (e.g., glucose, lac-
55 
tate, blood urea nitrogen, creatinine).
8.5.2.2 Electrolytes
For quantifying various ions (e.g., ammonia, bromide, cad-
mium, calcium, chloride, copper, cyanide, fluoride, fluorbo-
rate, iodide, lead, nitrate, perchlorate, potassium, silver/sul-
60 fide, magnesium, iron, lithium, phosphorus, sodium,
surfactant, thiocyanate) in a sample, such as a processed
biological sample, the droplet microactuator may be modified
to include an ion-selective electrode (ISE). A sample droplet
may be transported into contact with the ISE for detection of
65 the desired ion. Further, prior to detection, standard droplets
may be brought into contact with the ISE for the purpose of
calibration. In some embodiments, the invention includes an
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electrochemistry module with electrodes for amperometric,
potentiometric, and/or conductometric detection of electro-
lytes (e.g., K', Cl-, Na').
ISEs can be included in the droplet microactuator for
detecting electrolytes. ISEs can, for example, be included as
components of a top and/or bottom substrate and/or as com-
ponents exposed to a space between a top and/or bottom
substrate or associated with a single substrate droplet micro-
actuator. They can be integrated with transport electrodes.
The ISEs are generally arranged so that droplet operations
can be employed to bring a droplet on the droplet microac-
tuator into contact with an ISE. Various techniques can be
used to make ion selective electrodes on the droplet microac-
tuator. Examples include screen printing, as well as photoli-
thography, etching, and lift-off.
As a specific non-limiting example, Ag/AgCl canbe screen
printed to provide working and reference electrodes with a
KCl salt bridge. Examples of suitable ionophores in PVC for
the fabrication of ion-selective membranes include methyl
monensin for Na+, valinomycin for K+, quaternary ammo-
nium chloride for Cl-, and tridodecyl amine for pH. The
ion-selective membranes can be made by micro dispensing
and/or spray-coating (e.g., thermal/ultrasonic printing).
Electrolytes can be detected in any biological sample. Spe-
cific non-limiting examples include whole blood, plasma and
serum, as well as the examples provided elsewhere in this
disclosure.
8.5.2.3 Gases
For quantifying the presence of gasses (e.g., pCO21 pOz) or
pH, various specialized electrodes may be used. As a non-
limiting example, a carbon dioxide microprobe may be incor-
porated into a droplet microactuator of the invention for
detection and/or quantification of carbon dioxide. The micro-
probe may be arranged so that droplet operations can be
employed to bring a droplet on the droplet microactuator into
contact with the microprobe. Further, prior to detection, stan-
dard droplets may be brought into contact with the carbon
dioxide microprobe, using droplet operations, for the purpose
of calibration. Corresponding approaches are suitable for
detecting oxygen and/or determining pH. In some embodi-
ments, the droplet microactuator may include electrodes for
amperometric, potentiometric, and/or conductometric detec-
tion of blood gases (e.g., pCO21 pOz, pH).
As a specific non-limiting example, a Severinghaus-type
CO2 sensor can be made with the pH electrode made of
gold-quinhydrone electrode immersed with the internal solid
electrolyte made of NaHCO 3 , NaCl, and a sucrose binder. A
gas permeable membrane of polydimethylsiloxane can be
deposited thereon. Digital conditioning electronics (e.g., high
input impedance amplifiers) can be used to interface with the
potentiometric electrodes.
Gasses can be detected in any droplet on the droplet micro-
actuator. Specific non-limiting examples include droplets
including whole blood, plasma, and/or serum, as well as the
biological samples described elsewhere in this disclosure.
8.5.2.4 Enzyme
In some embodiments, the invention includes chemilumi-
nescence assays for detection of enzymes, such as liver
enzymes. Using a series of droplet-based multiple enzymatic
steps, the ALT and AST assays can be reduced to a final step
that produces hydrogen peroxide which can be measured
quantitatively by absorbance, luminescence, fluorescence, or
electrochemically.
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8.5.2.5 Serum Protein
A colorimetric assay may be utilized for detection of total
protein in a sample. Examples of suitable colorimetric meth-
ods include: the Biuret method, the Lowry method, the bicin-
5 choninic acid (BCA) assay, and Bradford assay. The Biuret
method generally involves contacting a sample droplet with a
droplet comprising cupric ions. The cupric ions form a col-
ored complex with proteins. The Lowry reaction approach is
based on the amplification of the biuret reaction by combin-
io ing with a Folin reagent droplet. A variation of the Lowry
assay uses a Bicinchoninic acid (BCA) droplet to permit
detection of the cuprous ions generated from cupric ions by
reaction with protein in a droplet under alkaline conditions.
The Bradford assay approach involves combining the sample
15 with a droplet comprising Coomassie Blue dye to form a
colored complex. In each case, an LED/photodiode setup,
e.g., as shown in FIG. 21A, can be used for monitoring the
absorbance. Total protein can be detected in any sample drop-
let using techniques described herein, including optical sens-
20 ing methods based on fluorescence and/or chemilumines-
cence, as well as using the affinity-based assay techniques
disclosed herein. Specific non-limiting examples of useful
samples for determining total proteins include biological
samples, such as whole blood, plasma and serum, as well as
25 the samples described elsewhere in this disclosure.
8.5.2.6 Hematocrit
Red blood cells can be quantified in a sample droplet using
a variety of techniques. For example, the hemoglobin content
can be calculated by measuring absorbance at 805 nun. Oxy-
so hemoglobin can then be calculated by measuring the absor-
bance at 650 nun. Results may be obtained by comparing the
absorbance measurements for samples to the absorbance
measurements for a series of known standards.
35 In some embodiments, the invention includes an electro-
chemistry module with electrodes for amperometric, poten-
tiometric, and/or conductometric detection of hematocrit.
The droplet microactuator may include a conductometric cell
with a pair of electrodes forAC conductometric measurement
40 
of hematocrit. For a two-substrate droplet microactuator, the
electrodes may be located on one or both substrates. The
electrodes are arranged so that arranged so that droplet opera-
tions can be employed to bring a droplet on the droplet micro-
actuator into contact with the electrodes.
45 8.5.3 Multi-Analyte Analyzer
Examples of suitable analytes are glucose, creatinine, lac-
tate, BUN, Kam , Nam, Cl-, pH, pCO2, ALP, total protein, and
hematocrit. In one embodiment, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
or more analytes are analyzed on a single droplet microac-
50 tuator. Preferably, these analytes are selected from glucose,
creatinine, lactate, BUN, Kam , Nam, Cl-, pH, pCO2, ALP, total
protein, and hematocrit. In one embodiment, glucose, creati-
nine, lactate, BUN, Kam , Nam, Cl-, pH, pCO2, ALP, total pro-
tein, and hematocrit are analyzed on a single droplet micro-
55 actuator. Other examples of suitable analytes include
calcium, bilirubin, albumin, clotting time, ALT, and AST.
In some embodiments, assays 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
or more analytes are processed in parallel on a droplet micro-
actuator system of the invention, i.e., one or more processing
6o and/or detecting steps for such analyte are accomplished
simultaneously with one or more processing and/or detecting
steps for another analyte on a single droplet microactuator. A
droplet microactuator system may execute 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12 or more colorimetric assays for detection of the
65 same or different analyte types in parallel. The droplet micro-
actuator system may execute 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or
more chemiluminescence assays for detection of the same or
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different analyte types in parallel. The droplet microactuator
may execute 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more ampero-
metric assays for detection of the same or different analyte
types in parallel. The droplet microactuator may execute 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12 or more potentiometric assays for
detection of the same or different analyte types in parallel.
The droplet microactuator may execute 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12 or more fluorescence assays for detection of the same
or different analyte types in parallel. The droplet microactua-
tor may include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more
conductometric assays for detection of the same or different
analyte types run in parallel. The droplet microactuator will
include droplets or reservoirs including reagents for execut-
ing each of the protocols. The droplet microactuator device
and/or system will include detection components as needed
for executing detection steps of the protocols.
Moreover, the droplet microactuator may include 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12 or more analytes that are processed in
parallel, and the system may execute 1, 2, 3, 4, 5, 6 or more
assay protocols on these analytes. The droplet microactuator
may include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more analytes
that are processed in parallel, and execute 1, 2, 3, 4, 5, 6 or
more assay protocols on these analytes, where the assays are
selected from colorimetric assays, chemiluminescence
assays, fluorescence assays, amperometric assays, potentio-
metric assays and conductometric assays. The droplet micro-
actuator will include droplets or reservoirs including reagents
for executing each of the protocols. The droplet microactuator
device and/or system will include detection components as
needed for executing detection steps of the protocols.
Furthermore, various protocols for nucleic acid amplifica-
tion, nucleic acid sequencing, affinity-based assays, cell han-
dling, bead handling and washing, and analyte detection pro-
tocols may also be readily integrated into a single droplet
microactuator system. In one embodiment, a single droplet
microactuator includes reagents and detection components
for conducting nucleic acid amplification and nucleic acid
sequencing. In another embodiment, a single droplet micro-
actuator includes reagents and detection components to con-
duct nucleic acid amplification for detection of a blood-borne
pathogen and reagents and detection components for con-
ducting one or more other assays from those assay types
and/or for analyte types as described herein. In another
embodiment, a droplet microactuator includes components
for manipulating cells along with components and reagents
for conducting affinity-based assays.
In short, the invention enables a droplet microactuator
system that not only performs the routine operations of a
central lab-based chemistry analyzer at higher throughput
with dramatically lower sample volumes, but also offers bet-
ter functionality by integrating hematology, pathology,
molecular diagnostics, cytology, microbiology, and serology
onto the same platform.
In one embodiment, the invention provides a droplet
manipulation module integrated with an optical detection
module and an electrochemical detection module for analyz-
ing blood gases, electrolytes, enzymes, proteins, and metabo-
lites.
One embodiment of the invention employs a modular
design to partition independently optimized fabrication pro-
cesses. For example, all the electrochemical components can
be fabricated on a substrate, all the microfluidic electrodes
can be fabricated on another substrate, and all the electronics
can be fabricated on yet another substrate. A disposable sand-
wich droplet microactuator can be formed between the elec-
trochemical module and the droplet manipulation module
which can be coupled to a reusable electronics module for
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data acquisition and analysis. Optical detection modules can
be constructed in the analyzer.
8.5.4 Biological Fluid Analysis Detection
The biological fluid analyses described herein make use of
5 
a variety of detection approaches, e.g., as described in Sec-
tions 8. 1, 8. 2, 8.3, 8.4, 8.5, and 8.11.
8.6 Surfaces and Surface Washing Protocols
Various protocols of the invention require surfaces for
io immobilization of reactants. For example, surfaces may be
used to capture or immobilize target components of a droplet,
such as cells, other beads, microparticles, nanoparticles, anti-
bodies, proteins, peptides, nucleic acids, small molecules
and/or other chemical components. Surfaces used for such
15 purposes may, for example, include surfaces of beads, micro-
particles, nanoparticles, membranes, physical objects, and/or
droplet microactuator surfaces. Various protocols require
washing step in which unbound materials are removed from
one or more surfaces.
20 A sample droplet including one or more target components
for capture may, using droplet operations, be contacted with a
surface having affinity for such targets. Washing protocols of
the invention may be used to remove from the surface
unbound components of the sample droplet. For example, a
25 droplet protocol may be used to bring one or more droplets
including one or more target components into contact with
one or more surfaces so that the one or more target compo-
nents may be immobilized or captured on the one or more
surfaces. A washing protocol may be executed to remove
30 unbound substances from the one or more surfaces. Similarly,
a droplet protocol may be used to bring one or more droplets
including one or more target components into contact with
one or more beads so that the one or more target components
may be immobilized or captured on the one or more beads. A
35 washing protocol may be executed to separate unbound sub-
stances from the one or more beads.
Washing generally involves bringing one or more washing
droplets into contact with the immobilized surface. Washing
may involve agitation of the droplets while in contact with the
40 surface. Washing droplets may, for example, include water,
deionized water, saline solutions, acidic solutions, basic solu-
tions, detergent solutions and/or buffers.
Washing protocols of the invention result in highly efficient
removal of unbound substances from the surface. In one
45 embodiment, the invention provides method of providing a
droplet in contact with a surface with a reduced concentration
of a substance. This method may generally include providing
a surface in contact with a droplet comprising a starting
concentration of the substance and having a starting volume;
50 conducting one or more droplet operations to merge a wash
droplet with the droplet to yield a combined droplet; and
conducting one or more droplet operations to divide the com-
bined droplet to yield a set of droplets including: (i) a droplet
in contact with the surface having a decreased concentration
55 and decreased quantity of the substance relative to the starting
concentration; and (ii) a droplet which is separated from the
surface.
The method of the invention may yield a droplet in contact
with the surface having a decreased quantity or substantially
6o decreased quantity of the substance relative to the starting
concentration. The resulting droplet may in some embodi-
ments have a volume which is approximately the same as the
starting volume. In some embodiments, the washing steps
may be repeated until a predetermined maximum quantity of
65 the one or more components is met or exceeded in the result-
ing droplet. The predetermined amount may represent a sub-
stantial reduction relative to the starting concentration. In
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some cases, the resulting droplet may be substantially free of
the components. For example, in some embodiments, the
reduction in amount exceeds 99, 99.9. 99.99, 99.999,
99.9999, 99.99999, 99.999999 percent on a molar basis.
The method of the invention may yield a droplet in contact
with the surface having a decreased concentration or substan-
tially decreased concentration of the substance relative to the
starting concentration. The resulting droplet may in some
embodiments have a volume which is approximately the
same as the starting volume. In some embodiments, the wash-
ing steps may be repeated until a predetermined maximum
concentration of the one or more components is met or
exceeded in the resulting droplet. The predetermined concen-
tration limit may represent a substantial reduction relative to
the starting concentration. In some cases, the resulting droplet
may be substantially free of the components. For example, in
some embodiments, the reduction in concentration exceeds
99, 99.9. 99.99, 99.999, 99.9999, 99.99999, 99.999999 per-
cent.
8.6.1 Washing Beads
For protocols making use of beads, droplet with beads can
be combined using droplet operations with one or more wash
droplets. Then, while retaining the beads (e.g., physically or
magnetically), the merged droplet may be divided using drop-
let operations it into two or more droplets: one or more drop-
lets with beads and one or more droplets without a substantial
amount of beads. In one embodiment, the merged droplet is
divided using droplet operations into one droplet with beads
and one droplet without a substantial amount of beads.
Generally, each execution of a washing protocol results in
retention of sufficient beads for conducting the intended assay
without unduly detrimental effects on the results of the assay.
In certain embodiments, each division of the merged droplet
results in retention of more than 90, 95, 97, 98, 99, 99.1, 99.2,
99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99, 99.9. 99.99, 99.999,
99.9999, 99.99999, or 99.999999 percent of beads. In other
embodiments, each execution of a washing protocol to
achieve a predetermined reduction in the concentration and/
or amount of removed substance results in retention of more
than 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99, 99.9.
99.99, 99.999, 99.9999, 99.99999, or 99.999999 percent of
beads. In still other embodiments, the amount of retained
beads is calculated and the results are adjusted accordingly.
In some embodiments, beads can be washed in reservoirs
in which the bead-containing droplet and wash droplets are
combined, beads are retained (for example by a magnet, by
physical structures, electrostatic forces), and droplets lacking
beads are dispensed from the reservoir using droplet opera-
tions. For example, beads can be washed by dilute-and-dis-
pense strategy whereby a wash buffer is added to the reservoir
to dilute the contents, magnetically responsive beads are
localized within the reservoir with a magnet and most of the
solution is dispensed from the reservoir, and this cycle is
repeated till acceptable levels of washing are achieved.
8.6.1.1 Washing Magnetically Responsive Beads
A non-limiting example, illustrated in FIG. 11, involves
immobilizing magnetically responsive beads using a mag-
netic field. Immobilized magnetically responsive beads may
be freed by reduction or elimination of the magnetic field.
Washing magnetically responsive beads may generally
include the following steps:
(1) using droplet operations to position a droplet 1101 com-
prising magnetically responsive beads 1102 and unbound
substances 1103 in proximity with a magnet 1104;
54
(2) using droplet operations to combine a wash droplet 1106
with the droplet 1101 comprising the magnetically respon-
sive beads 1102;
(3) immobilizing the beads 1102 by application of a magnetic
5	 field;
(4) using droplet operations to remove some or all of the
droplet surrounding the beads to yield a droplet 1108 com-
prising the beads with a reduced concentration of unbound
target substance and a droplet 1110 comprising unbound
to	 target substance;
(5) releasing the beads 1102 by removing the magnetic field;
(6)repeating steps (2) to (3) or (2) to (4) until a predetermined
degree of purification is achieved.
In this manner, unbound substances, such as contaminants,
15 byproducts or excess reagents, can be separated from the
beads. Each cycle produces a droplet including the beads but
with a decreased level of the unwanted substances. Step (5) is
not required in each washing cycle; however, it may be useful
to enhance washing by freeing contaminants which may be
20 trapped in the immobilized beads. Steps may be performed in
a different order, e.g., steps (2) and (3) may be reversed. Steps
in the washing protocol may be accomplished on a droplet
microactuator using droplet operations as described herein.
Another embodiment is illustrated in FIG. 12 and may
25 comprise a top plate 1201, bottom plate 1202, electrodes
1203, and a magnet 1204. The embodiment steps generally
may include:
(1) using droplet operations to combine a slug 1205 with a
droplet 1206 comprising magnetically responsive beads
so 1207 and unbound material 1208 inproximity withmagnet
1204;
(2,3) with the beads 1207 immobilized, using droplet opera-
tions to transport the resulting combined slug 1210 across
35	 the beads 1207 to separate unboundmaterial 1208 fromthe
beads 1207;
(4) using droplet operations to separate off a portion of the
combined slug 1210 to yield a portion 1212 comprising the
beads with a reduced concentration of unbound target sub-
40	 stance and a portion 1214 comprising unbound target sub-
stance;
(5) repeating steps (1)-(4) as needed to achieve the desired
reduction in unbound material.
In a related approach, the slug may be continuously supple-
45 mented by adding additional wash droplets and/or slugs as the
slug is being transported across the immobilized beads. The
process may continue until the desired reduction in unbound
material is achieved.
FIG. 13 illustrates an alternative embodiment which may
50 also comprise a top plate 1301, bottom plate 1302, electrodes
1303, and a magnet 1304. In this embodiment, the magnet
1304 is moved, such as in the direction ofAl, to separate beads
1305 from unbound material 1306 in a combined slug 1307
rather than moving the slug 1307. A similar approach
55 involves movement of both the magnet and the slugto achieve
separation (not shown). Yet another approach involves using
multiple magnets to move the beads (not shown).
In embodiments in which magnetically responsive beads
are used, the inventors have found that application of a mag-
6o netic field though useful for temporarily immobilizing beads,
moving beads and/or positioning beads, sometimes results in
unwanted aggregation of the beads. In one embodiment, a
surfactant is included to prevent or reduce bead aggregation.
Examples of surfactants suitable for this purpose include:
65 Tween® 20, Tween® 80, Triton X-100. Surfactants should be
selected and used in amounts which reduce or eliminate bead
aggregation and minimize non-specific adsorption while at
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the same time not resulting in significant loss of target ana-
lytes or reagents from the droplet.
Another approach to eliminating or reducing clumping
aggregation of beads involves the use of smaller numbers of
larger beads. Any number of beads which can be contained in
a droplet during one or more droplet operations may be used.
In some embodiments, the number of magnetically respon-
sive beads can range from I to several 100,000's. For
example, in one embodiment, the invention makes use of one
to 100 magnetically responsive beads per droplet. For
example, the invention may make use of 1, 2, 3, 4, 5, 6, 7, 8,
9, 10 ... 100 magnetically responsive beads per droplet. In
one embodiment, the number of magnetically responsive
beads is from one to 10. Use of smaller numbers of magneti-
cally responsive beads permits larger beads to be used. For
example, in one embodiment, the invention makes use of one
to 100 magnetically responsive beads per droplet, where the
beads have an average diameter of about 25 to about 100
microns. In another embodiment the invention makes use of
one to 10 magnetically responsive beads per droplet, where
the beads have an average diameter of about 50 to about 100
microns.
8.6.1.2 Washing Non-Magnetically Responsive Beads
A similar approach may be used with beads that are not
magnetically responsive or not significantly magnetically
responsive. As illustrated in FIG. 14, instead of using a mag-
netic fieldto immobilizebeads 1401, aphysical obstacle 1402
may be used to permit removal of some or all of droplet 1403
surrounding the beads 1401. The physical obstacle 1402 may,
for example, include a membrane, sieve, and/or projection
from the droplet microactuator (e.g., from the top plate 1404
and/or bottom plate 1405). Where a physical obstacle 1402
(projection or object) attached to the top plate 1404 and/or
bottom plate 1405 is employed, it should be arranged so as to
permit transport using one or more adjacent electrodes 1406
while preventing the beads 1401 from following, e.g., using a
projection from the top plate that leaves sufficient space for
droplet transport and/or a projection with one or more open-
ings that permits the droplet to be transported through the
opening while preventing the beads from following.
8.6.2 Washing Droplet Microactuator Surfaces
FIG. 15 illustrates an example of an approach for washing
• droplet microactuator surface. In this non-limiting example,
• surface 1501 is located on the interior of the top plate 1502.
In this approach, (1) a sample droplet 1503 including a target
substance 1504 having affinity for a surface component 1505
is (using droplet operations) brought into contact with the
surface 1501, causing (2) some portion or all of the target
substance to be immobilized. (3) A wash droplet 1506 and the
sample droplet 1503 are combined using droplet operations to
yield a combined wash-sample droplet 1507. (4) The com-
bined wash-sample droplet is then divided using droplet
operations to yield a portion 1508 in contact with the surface
and comprising a reduced concentration of unbound target
substance and a portion 1509 separated from the surface
comprising unbound target substance. Steps (3) and (4) may
be repeated as needed to achieve the desired reduction in
unbound material.
8.7 Cell Handling
Various protocols of the invention may make use of drop-
lets including cells. The droplets may include culture media
for maintaining cell viability and/or growing cell cultures.
In some cases, the invention makes use of droplets having
predetermined numbers of cells. For example, in some
embodiments, the invention may make use of droplets includ-
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ing single cells. For example, droplets with single cells may
be useful to product clonally pure cell populations and/or to
conduct experiments studying the reaction of single cells to
specific stimuli. Droplets with predetermined numbers of
5 cells may be provided by dispensing droplets from a cell
suspension onto a droplet transport pathway or network from
a suspension of cells and/or by dividing droplets with mul-
tiple cells into one or more subdroplets. The suspension may
be supplied from an external source or may be stored in a
io droplet microactuator reservoir. Droplets can be analyzed to
determine the number of cells in each droplet, and droplets
with a preselected number of cells can be routed downstream
for further processing. Dispensed droplets with multiple cells
may themselves be combined with one or more buffer drop-
15 lets and divided into two or more sub-droplets and analyzed
for the presence of single cells.
Sort decisions can be based on droplet analysis. For
example, light transmission may be used to identify droplets
with a predetermined number of cells. Sort decisions may be
20 made based on the measurement of transmitted light. Other
embodiments may employ automated image analysis and/or
or multi-color fluorescence and/or scattering analysis. Drop-
lets not meeting specifications can be reintroduced into the
sample reservoir for another attempt or transported to a waste
25 reservoir.
Droplets meeting cell count specifications may be trans-
ported to droplet microactuator reservoirs and/or transported
for sorting and/or enrichment. One approach to providing
reservoirs with enriched cell content is illustrated in FIGS.
30 16A and 16B. In this embodiment, droplets 1602 are dis-
pensed from a cell suspension 1604 and transported based on
their characteristics to reservoirs 1606 on droplet microactua-
tor 1600.
In other embodiments, droplets may be further manipu-
35 lated, e.g., as discrete droplets for analysis of the cells con-
tained within. Droplets including predetermined numbers of
cells may be used as inputs for various assay protocols
described herein. In some embodiments, gravity is not used as
40 
the motive force for transporting droplets.
In one specific embodiment, tumor cells maybe isolated on
the droplet microactuator. Cells may, for example, be isolated
from microliters of fine-needle aspirates (FNA). In another
embodiment, samples such as blood stem cells, bone marrow,
45 GI washes, and cryopreserved-thawed samples can be ana-
lyzed for cancer cells.
Immunogenic capture of relevant cells can be accom-
plished using antibody beads, such as anti-cytokeratin beads,
may be used to capture relevant cells from a sample prior to
50 introduction into the droplet microactuator and/or from a
droplet on a droplet microactuator. Binding may be enhanced
or incubation times reduced on the droplet microactuator by
actively shuttling the droplet or vortexing the droplet within a
reservoir. Beads can be isolated and washed as described
55 elsewhere herein. Target cells can be released into suspension
in a droplet on the droplet microactuator.
Uniform numbers of cells per droplet from can be dis-
pensed from an on-chip reservoir using cell dispensing
approaches described herein. Droplets with cells can be ali-
6o quoted into multiple on-chip reservoirs. Cells can be incu-
bated in on-chip reservoirs. Cell viability can be assessed,
e.g., using resazurin as a fluorescent redox indicator. Living
cells convert the non-fluorescent resazurin dye into resorufin
which fluoresces red. Non viable cells do not fluoresce. Cells
65 can be distributed to on-chip reservoirs and nucleic acid from
the cells can be amplified using approaches as described
herein.
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8.8 Droplet Microactuator Architecture and Operation
The system of the invention generally includes a droplet
microactuator controlled by a processor. For example, the
processor may, among other things, be programmed to con-
trol droplet manipulations on a droplet microactuator. A wide
variety of droplet microactuator configurations is possible.
Various illustrations are provided in FIGS. 1, 2, 6, 9, and 17.
Examples of components which may be configured into a
droplet microactuator of the invention include various filler
fluids which may be loaded on the droplet microactuator;
fluid loading mechanisms for introducing filler fluid, sample
and/or reagents onto the droplet microactuator; various res-
ervoirs, such as input reservoirs and/or processing reservoirs;
droplet dispensing mechanisms; means for controlling tem-
perature of the droplet microactuator, filler fluid, and/or a
droplet on a droplet microactuator; and magnetic field gener-
ating components for manipulating magnetically responsive
beads on a droplet microactuator. This section discusses these
and other aspects of the droplet microactuator and their use in
the systems of the invention.
8.8.1 Droplet Microactuator
The systems make use of a droplet microactuator. The
droplet microactuator will include a substrate with one or
more electrodes arranged for conducting one or more droplet
operations. In some embodiments, the droplet microactuator
will include one or more arrays, paths or networks of such
electrodes. A variety of electrical properties may be
employed to effect droplet operations. Examples include
electrowetting and electrophoresis.
In one embodiment, the droplet microactuator includes
two or more electrodes associated with a substrate, and
includes a means for permitting activation/deactivation of the
electrodes. For example, the electrodes may be electronically
coupled to and controlled by a set of manual switches and/or
a controller. The droplet microactuator is thus capable of
effecting droplet operations, such as dispensing, splitting,
transporting, merging, mixing, agitating, and the like. Droplet
manipulation is, in one embodiment, accomplished using
electric field mediated actuation. Electrodes will be electroni-
cally coupled to a means for controlling electrical connec-
tions to the droplet microactuator.
The basic droplet microactuator includes a substrate
including a path or array of electrodes. In some embodiments,
the droplet microactuator includes two parallel substrates
separated by a gap and an array of electrodes on one or both
substrates. One or both of the substrates may be a plate. One
or both substrates may be fabricated using PCB, glass, and or
semiconductor materials as the substrate. Where the substrate
is PCB, the following materials are examples of suitable
materials: Mitsui BN-300; Arlon I IN; Nelco N4000-6 and
N5000-30/32; Isola FR406, especially IS620; fluoropolymer
family (suitable for fluorescence detection since it has low
background fluorescence); polyimide family. Various mate-
rials are also suitable for use as the dielectric component of
the substrate. Examples include: vapor deposited dielectric,
such as parylene C (especially on Glass), and parylene N;
Teflon AF; Cytop; and soldermasks, such as liquid photoim-
ageable soldermasks (e.g., on PCB) like Taiyo PSR4000
series, Taiyo PSR AUS series (good thermal characteristics
for applications involving thermal control), and Probimer
8165 (good thermal characteristics for applications involving
thermal control); dry film soldermask, such as those in the
Dupont Vacrel family; and film dielectrics, such as polyimide
film (Kapton), polyethylene, and fluoropolymers like FEP,
PTFE. Some or all of the substrate may also include a hydro-
phobic coating. Suitable examples include Teflon AF; Cytop;
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coatings in the Fluoropel family; silane coatings; fluorosilane
coatings; and 3M Novec electronic coatings.
Where the droplet microactuator includes two plates, drop-
lets may be interposed in the space between the plates. Space
5 surrounding the droplets typically includes a filler fluid. The
droplet microactuator can conduct droplet operations using a
wide variety of fluid droplets, though conductive fluids are
preferred.
Surfaces of the droplet microactuator are typically coated
io with a hydrophobic coating. For applications involving ther-
mal cycling, a hydrophobic coating should be selected that is
resistant to thermal stress during prolonged thermocycling
operation. Examples of suitable thermal resistant materials
include soldermasks such as Probimer® 8165 whichhas been
15 developed for use in the automotive industry and has excel-
lent thermal shock resistance, and PCB board materials such
as Mitsui BN-300 which is resistant to high temperature and
warpage.
Droplet transport occurs along a path or network of control
20 electrodes. The array or path includes electrical connections
for electrically coupling electrodes to external circuitry. The
array or path may also include electrical connections for
electrically coupling certain electrodes together. The elec-
trodes are controlled via the external circuitry by a processor.
25 Droplet operations may be effected by supplying voltage to
the electrodes. While the preferred voltage varies depending
on the thickness of the dielectric, for a dielectric constant in
the range of 2-100 and thickness in the range of 1 nun to 10
mm, the preferred energy per unit area limits are in the range
30 of about 300 microjoule/sq meter to about 300000 micro-
j oule/sq meter. The preferred activation voltage is in the range
of about 1 mV to about 50 kV, or about IV to about 10 kV, or
about 5V to about 1000V, or about I OV to about 300V.
Typically, the electrodes are fired via a voltage relay. The
35 droplet microactuator operates by direct manipulation of dis-
crete droplets, e.g., using electrical fields. For example, a
droplet adjacent to an energized electrode with surrounding
electrodes grounded will transport to align itself with the
energized electrode, i.e., the droplet will be transported to the
40 position of that electrode. A series of successive transfers will
transport droplets along the path or network of control elec-
trodes. In addition to transport, other operations including
merging, splitting, mixing and dispensing of droplets can be
accomplished in the same manner by varying the patterns of
45 voltage activation.
It should be noted that electrodes can be activated in a
variety of ways. For example, an electrode can be activated by
applying a DC potential. Similarly, an electrode can be acti-
vated by applying an AC potential, so that the activated elec-
50 trode has an AC potential an unactivated electrode has a
ground or other reference potential. In another aspect, the
potential may be applied by repeatedly activating an electrode
and then inverting it. An AC mode can be effected by using
software to rapidly switch between polarities of the outputs.
55 In some embodiments the invention employs droplet
operation structures andtechniques described in U.S. Pat. No.
6,911,132, entitled "Apparatus for Manipulating Droplets by
Electrowetting-Based Techniques," issued on Jun. 28, 2005 to
Pamula et al.; U.S. patent application Ser. No. 11/343,284,
60 entitled "Apparatuses and Methods for Manipulating Drop-
lets on a Printed Circuit Board," filed on Jan. 30, 2006; U.S.
Pat. No. 6,773,566, entitled "Electrostatic Actuators for
Microfluidics and Methods for Using Same," issued on Aug.
10, 2004 and U.S. Pat. No. 6,565,727, entitled "Actuators for
65 Microfluidics Without Moving Parts," issued on Jan. 24,
2000, both to Shenderov et al.; U.S. Patent Publication No.
20060254933, entitled "Device for transporting liquid and
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system for analyzing" published on Nov. 16, 2006 by Adachi
et al., the disclosures of which are incorporated herein by
reference for their teachings concerning structures and tech-
niques for conducting droplet operations.
Droplet operations can be rapid, typically involving aver-
age linear velocities ranging from about 0.01 cm/s to about
100 cm/s, or from about 0.1 cm/s to about 10 cm/s, more
preferably from about 0.5 cm/s to about 1.5 cm/s. Moreover,
droplets may typically be manipulated at a frequency of
manipulation ranging from about 1 Hz to about 100 KHz,
preferably from about 10 Hz to about 10 KHz, more prefer-
ably from about 25 Hz to about 100 Hz. In addition to being
rapid, droplet manipulations using the droplet microactuator
are also highly precise, and multiple droplets can be indepen-
dently and simultaneously manipulated on a single droplet
microactuator.
Discrete droplet operations obviate the necessity for con-
tinuous-flow architecture and all the various disadvantages
that accompany such an architecture. For example, near
100% utilization of sample and reagent is possible, since no
fluid is wasted in priming channels or filling reservoirs. Fur-
ther, as noted above, droplet movement can be extremely
rapid. The droplet microactuator may in some cases be
supplemented by continuous flow components and such com-
bination approaches involving discrete droplet operations and
continuous flow elements are within the scope of the inven-
tion. Continuous flow components may be controlled by the
controller. Nevertheless, in certain other embodiments, vari-
ous continuous flow elements are specifically avoided in the
droplet microactuator of the invention and/or methods of the
invention. For example, in certain embodiments, one or more
of the following components is excluded from a droplet
microactuator and/or methods of the invention: microchan-
nels; fixed microchannels; networks of microchannels;
pumps; external pumps; valves; high-voltage supplies; cen-
trifugal force elements; moving parts.
Electric field mediated actuation also obviates the need for
other droplet operations and all the various disadvantages that
accompany such techniques. It will be appreciated that the
droplet microactuator may nevertheless be complemented or
supplemented with other droplet manipulation techniques,
such as electrical (e.g., electrostatic actuation, dielectro-
phoresis), magnetic, thermal (e.g., thermal Marangoni
effects, thermocapillary), mechanical (e.g., surface acoustic
waves, micropumping, peristaltic), optical (e.g., opto-elec-
trowetting, optical tweezers), and chemical means (e.g.,
chemical gradients). When these techniques are employed,
associated hardware may also electronically coupled to and
controlled by the controller. However, in other embodiments,
one or more of these droplet operation techniques is specifi-
cally excluded from a droplet microactuator of the invention.
The droplet microactuator can be manufactured in a highly
compact form and can be driven using a very small apparatus.
For example, droplet microactuator and apparatus may
together be as small as several cubic inches in size. The
droplet microactuator requires only small amounts of electri-
cal power and can, for example, readily be operated using
batteries. The droplet microactuator can perform droplet
operations using extremely small droplets. Droplets are typi-
cally in the range of from about 1 fL to about 1 mL, more
preferably from about 100 pL to about 1 µL, still more pref-
erably from about 10 nL to about 1 µL.
The use of discrete droplets for on-chip processing instead
of continuous flows provides several important advantages.
Since sample fluid need not be expended for priming of
channels orpumps virtually all of the sample fluid canbe used
for analysis and very small volumes of sample (e.g., less than
60
about 100 µL or less than about 50 µL or less than about 25
µL) can be analyzed. The same advantages apply to the use of
reagents where reducing the volume of reagents consumed
has the advantage of reducing the cost of the analysis. The use
5 of discrete small-volume droplets also permits a large number
of reactions to performed in a small footprint (e.g. greater
than 10 per cm2 or greater than 100 per cm2 or greater 1,000
per cm2 or greater than 10,000 per cm2).
10 Various components of the invention may be included as
components of the droplet microactuator. In fact, an entire
system of the invention may be provided as an integrated
droplet microactuator. In some embodiments, the droplet
microactuator includes various sensors and means for elec-
15 tronically coupling the sensors to external circuitry. In other
embodiments, the droplet microactuator includes heaters
and/or magnetic field generating elements and means for
coupling such elements to external circuitry. Further, a drop-
let microactuator including any one or more of the reagents
20 described herein in a reservoir or in droplet form is also an
aspect of the invention.
Optical windows can be patterned in the electrodes to
enhance the capability of performing optical detection on the
chip. Where the electrode is formed in an opaque material on
25 a transparent substrate, a window in the electrode can be
created permit light to pass through the substrate. Alterna-
tively, when the electrode material is transparent, a mask can
be created to eliminate stray light. Additionally, the opening
can be patterned as a diffraction grating. Adaptive optical
30 windows can be created as well, using a second electrowet-
tinglayer. For example, opaque oil (e.g. oil dyed black) can be
used with a transparent droplet to create an temporary and
movable optical window.
35 8.8.2 Cartridge
In some embodiments, the invention includes a cartridge
for coupling to the droplet microactuator. It will be appreci-
ated that a cartridge, while not necessary to the operation of
the invention, may be convenient in some circumstances.
40 When present, the cartridge may include a means for electri-
cally coupling the path or network of the droplet microactua-
tor to a processor, e.g., a processor of a droplet microactuator
system of the invention. In this embodiment, the electrical
connection is: electrodes	 art idge processor, where
45 there may be additional elements between the three. In
another embodiment, the cartridge may include means for
physically coupling to the droplet microactuator. In this
embodiment, the electrical connection may be: electrodes-
processor---cartridge. Alternatively, the cartridge may lack
50 electrical components altogether.
When present, the cartridge may include reservoirs for one
or more reagents, e.g., pre-loaded reagents. The droplet
microactuator may be configured so that a fluid path may be
established between the cartridge reservoirs and the interior
55 of the droplet microactuator for flowing reagents, sample
and/or filler fluid from the cartridge onto the droplet micro-
actuator. For example, preloaded cartridge reservoirs may be
dispensed into the droplet microactuator prior to, during, or
after coupling of the cartridge to the analyzer. The cartridge
60 may be sealed, self-contained and/or disposable. It may be
supplied with or without a droplet microactuator. Such car-
tridges can be used to ensure repeatable assay conditions,
permit safe handling and disposal of infectious or hazardous
material, and/or reduce cross-contamination between runs.
65 The cartridge may, for example, include a machined plastic
part. It may be affixed to and provided in combination with the
droplet microactuator.
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The cartridge materials are selected to provide storage of
reagents without degradation or contamination of the
reagents. Moreover, they should be selected to provide reli-
able operation at elevated temperature and to ensure compat-
ibility with the real-time chemistry. They may, for example,
include molded plastic components. In some embodiments,
sealed, disposable test cartridges enhance operator safety and
facilitate safe disposal.
Various components of the droplet microactuator system
may be included on the cartridge. For example, the top-plate,
which encloses the interior space of the droplet microactua-
tor, may be provided as a component of the cartridge. Various
sensors may also be included as components of the cartridge.
8.8.3 Filler Fluid
The droplet microactuator of the invention includes one or
more free (i.e. fluid-fluid) interfaces. Examples include a
liquid-liquid or liquid-gas interface. Typically chemistry is
performed in the primary (droplet) phase, and the secondary
phase serves as a filler fluid separating the droplets from each
other. The secondary phase can, for example, be a liquid, gel
and/or a gas. Where the secondary phase includes a liquid, the
liquid is sufficiently immiscible with the primary liquid phase
to permit the droplet microactuator to conduct one of more
droplet operations.
It should also be noted that the droplet microactuator may
include more than two phases. For example, in one embodi-
ment the droplet microactuator operates based on an aqueous-
oil-air three-phase system. In a related environment, the drop-
let microactuator may operate based on an aqueous-first oil-
second oil three-phase system, such as a system including an
aqueous droplet surrounded by silicon oil, which is in turn
surrounded by a fluorosilicon oil. Generally, three-phase sys-
tems will include three components which are mutually
immiscible or substantially immiscible.
In another embodiment, oil or another immiscible liquid
may be used as a droplet encapsulant for electrowetting. For
example, a droplet can be encapsulated in a shell of oil by
moving the droplet through an air/oil interface. Each droplet
would then have its own local bath of oil with the space
between encapsulated droplets filled with either air or a third
immiscible liquid. Among other advantages, this approach is
useful for minimizing the transfer of material between drop-
lets in the system by partitioning into the oil phase while
retaining the advantageous properties of the oil with respect
to evaporation and fouling of the surface. This approach may
also be used to facilitate electrowetting of non-electrowet-
table liquids which are immiscible with electrowettable liq-
uids. In a specific embodiment of this concept the immiscible
liquid can be chosen to be crosslinkable (by UV, heat, mois-
ture or chemically) to create capsules of liquids with solid
shells, for drug delivery synthesis applications.
Further, in some applications it may be desirable or neces-
sary to perform certain operations in an immiscible liquid,
such as oil, and others in air. The invention includes hybrid
systems in which droplet manipulation is performed both in
air and in an immiscible liquid filler fluid such as oil. For
example, samples may be processed under oil and then trans-
ported into an air-medium portion for evaporation for subse-
quent analysis by MS. Conversely, a sample could be col-
lected in air and then processed with droplets under oil. Thus,
the droplet microactuator may include a transport path for
moving droplets from a droplet microactuator surface in a
space filled with filler fluid to a droplet microactuator open to
the atmosphere or including a gaseous filler fluid.
The filler fluid may be any fluid in which the droplet micro-
actuator can, under the right conditions, conduct one or more
droplet operations. It should be noted that certain filler fluids
may be solids or highly viscous fluids under certain condi-
tions, e.g., during transport, while they are transformed into
fluids for operation, e.g., by heating. The filler fluid may be a
5 liquid or gas during operation of the droplet microactuator.
Examples of suitable liquid filler fluids include, without limi-
tation, silicone oils; fluorosilicone oils; hydrocarbons, includ-
ing for example, alkanes, such as decane, undecane, dode-
cane, tridecane, tetradecane, pentadecane, hexadecane;
io aliphatic and aromatic alkanes such as dodecane, hexade-
cane, and cyclohexane, hydrocarbon oils, mineral oils, paraf-
fin oils; halogenated oils, such as fluorocarbons and perfluo-
rocarbons (e.g. 3M Fluorinert liquids); mixtures of any of the
foregoing oils in the same class; mixtures of any of the fore-
15 going oils in different classes. Examples of suitable gas filler
fluids include, without limitation, air, argon, nitrogen, carbon
dioxide, oxygen, humidified air, any inert gases. In one
embodiment, the primary phase is an aqueous solution, and
the secondary phase is air or an oil which is relatively immis-
20 cible with water. In another embodiment, the filler fluid
includes a gas that fills the space between the plates surround-
ing the droplets. A preferred filler fluid is low-viscosity oil,
such as silicone oil. Other suitable fluids are described in U.S.
Patent Application No. 60/736,399, entitled "Filler Fluids for
25 Droplet-Based Microfluidics" filed on Nov. 14, 2005, the
entire disclosure of which is incorporated herein by reference.
The fluid may be selected to prevent any significant evapora-
tion of the droplets.
The phases of the fluids used in the protocols of the inven-
30 tion may be selected to facilitate protocols of the invention
without undue formation of bubbles, loss of reagent to the
filler fluid, and/or adherence of reagent to the droplet micro-
actuator surface.
In certain embodiments of the invention the filler fluid may
35 be selected to reduce or prevent evaporation of sample,
reagent, or other droplets utilized in the protocols of the
invention. The filler fluid may be selected to prevent sample,
reagent, or other droplets utilized in the protocols of the
invention from evaporating and becoming too small for fur-
40 ther effective manipulation. Similarly, the filler fluid can be
selected to prevent evaporation of sample, reagent, or other
droplets utilized in the protocols of the invention from detri-
mentally concentrating species within the droplets in a man-
ner which results in an unduly adverse affect on the intended
45 use of the droplet. Moreover, the filler fluid may be selected to
reduce or prevent transport of material from sample, reagent,
or other droplets utilized in the protocols of the invention
across the phase boundary to maintain droplet volume and/or
ensure reliable microfluidic operation and/or assay results.
50 Miscibility between phases can sometimes result in shrinking
(or swelling) of the droplet phase. To prevent or reduce this
problem, one or more phases of the system may be saturated
with the equilibrium concentration of another phase to reduce
shrinking or swelling. Thus, for example, the filler fluid may
55 be saturated with the equilibrium concentration of the solvent
for sample, reagent, or other droplets utilized in the protocols
of the invention, and/or one or more of the sample, reagent,
and/or other droplets utilized in the protocols of the invention
may be saturated with the equilibrium concentration of the
60 filler fluid.
In some embodiments, a liquid filler fluid is selected to
minimize contact between the droplet and droplet microac-
tuator surfaces. That is, a film of liquid may exist between the
droplet and surface which prevents material within the drop-
65 let from coming into contact with and adhering to the coated
surface. This approach helps to prevent fouling of the surface
and related interference with droplet transport. For example,
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it has been observed that high concentrations of certain pro-	 fluid. This approach can enhance visualization of the different
teins in water droplets readily stick to certain hydrophobic 	 phases, for example to distinguish droplets from filler fluid or
surfaces spoiling the hydrophobic nature of these surfaces; 	 from air bubbles. In optical applications, the differential
whereas, the same droplets can be moved across the same	 absorbance of the two phases can be used to modulate the
surfaces without appreciable adhesion of proteins if bathed in 5 color of light passing through the system. As another
an oil which minimizes contact between the two surfaces. 	 example, in applications where fluorescence measurements
This approach may also help to avoid cross-contamination	 are made within droplets it may desirable for the oil to include
between droplets caused by deposition of material from one 	 molecules, such as dyes, that absorb the emitted wavelength
droplet which is then picked up by a second droplet. In a	 oflightto minimize cross-talk between reactions occurring in
similar embodiment, a film between the droplet and droplet io adjacent droplets.
microactuator surface can be used to lubricate the droplet by 	 The filler fluid may be selected to have particular thermal
preventing friction-like physical interactions between the 	 properties that can either thermally insulate the droplets or
droplet and surface during droplet operations. 	 conduct heat away from the droplets. For example, in the
In one embodiment, the invention provides a thin coating 	 amplification protocols of the invention, a thermally conduc-
of a liquid filler fluid layer in an otherwise gas filled system. 15 tive or low heat capacity filler fluid may be desirable to permit
For example, the invention provides a microfluidic system 	 rapid changes in temperature. For applications where a steady
including an open or enclosed system including a thin layer of 	 temperature is required a thermally insulating or high heat
filler fluid, such as oil, layered on a droplet microactuator 	 capacity filler fluid can be used to provide temperature sta-
surface, wherein the system is otherwise filled with a gas. The 	 bility.
oil is of sufficient thickness to provide lubrication and con- 20	 The filler fluid may be selected to undergo a phase change
tamination of droplet microactuator surfaces and contamina-	 upon presentation of an appropriate stimulus. For example, a
tion of droplets via droplet microactuator surfaces. Preferably 	 wax-like filler fluid (e.g. paraffin wax or octadecane) can be
the oil is selected to minimize transport of material between 	 used where the filler fluid is changed from solid to liquid form
the droplet and oil phases. One advantage of this approach is 	 by application of heat. Lowering the temperature would
reduction of carry-over in the droplet microactuator. The 25 return the filler fluid to a solid so that droplets would be
surface may in some embodiments be treated by coating it	 contained within a solid matrix. Encapsulation of the liquid
with the filler fluid while operating in air. This approach is 	 phase within a solid may facilitate storage and handling of the
also useful for loading operations as a means to retain the 	 sample, reagent, and/or other droplets utilized in the proto-
lubricating effect of oil while avoiding trapping of oil bubbles	 cols of the invention and/or allow for safe and convenient
in the bulk filler fluid.	 3o disposal of the materials following use of the droplet micro-
Treatment of a Teflon AF surface with silicone oil can 	 actuator. The filler fluid can be stored as a solid on the droplet
provide some of the lubrication benefit of silicone oil filler 	 microactuator, in a cartridge-based reservoir, or elsewhere,
fluid even when operating in air. This approach can be used to 	 and heated to permit the fluid to flow into and fill the droplet
prime the droplet microactuator with a lubricating layer of oil, 	 microactuator. Or the immiscible filler fluid can be selected to
followed by replacement with air to allow samples to be 35 be crosslinkable (by UV, heat, moisture or chemically) to
loaded without introduction of bubbles, followed by re-intro- 	 create capsules of liquids within a solid shell.
duction of oil to prevent evaporation of the samples. Thus the 	 The filler fluid may be selected to have particular gas per-
benefits of each kind of system are available depending on the 	 meability or saturation properties. In certain applications a
type of microfluidic processing to be carried out. 	 reaction occurring inside the droplet may consume oxygen or
In another embodiment, the filler fluid can be completely 40 other gas which may need to be replenished by gas contained
exchanged at different steps within a protocol. For example, a	 within or transported through the filler fluid. For example,
gas filler fluid can be introduced during sample loading to 	 some fluorinated oils have useful gas permeability properties
prevent trapping of airbubbles and then a liquid filler fluid can 	 for such applications. Alternatively, the filler fluid may be
be pumped in to prevent evaporation of the liquid. Different 	 selected to exclude certain gases from the droplet, for
types of filler fluid can be pumped into or out of the system 45 example to maintain anaerobic conditions within the droplet.
depending on the particular assay steps to be performed. 	 The filler fluid may be selected to have a certain degree of
In yet another embodiment, multiple filler fluids can be	 miscibility or partitioning into the droplet phase. Usually,
used within a single system. For example, a droplet microac- 	 complete or substantially complete lack of miscibility
tuator can be selected to have separate gas filled and liquid
	
between the droplet and filler fluid is desired, but some appli-
filled regions. Operations or certain types of droplets can be 50 cations may benefit from some limited degree of miscibility
segregated between the different filler fluid regions. 	 between the phases or partitioning of particular molecules
The filler fluid may be selected based on its refractive index 	 between the phases, e.g., liquid-liquid extraction applica-
to either match the droplet to prevent refraction of light pass-	 tions. In certain applications where dissolved gases in the
ing through or near the droplet. Alternatively the filler fluid
	
filler fluid may be problematic, a means for degassing the
may be selected with a refractive index that differs from the 55 filler fluid prior to or during use may need to be provided. For
droplet to provide contrast for certain types of optical mea- 	 example, filler fluid may be degassed by incubation under
surements or optical manipulations. A filler fluid may be 	 vacuum, heating, sparging or by centrifugation.
chosen to have a lower index of refraction than the primary	 The filler fluid may be selected to have a particular surface
liquid so that light can be transmitted though the primary 	 or interfacial tension with the droplet phase or with the drop-
liquid by total internal reflection. The primary phase can 60 let microactuator surfaces. Surfactants can be added to the
include highly elongated droplets which can serve as "light	 filler fluid to stabilize liquid films that may be present
pipes" to convey light between two locations, e.g. to facilitate 	 between the droplet and solid phases. Examples of suitable
optical analyses.	 surfactants include nonionic low HLB (hydrophile-lipophile
The filler fluid may be selected based on its color to facili-	 balanced) surfactant. The HLB preferably less than about 10
tates direct or indirect visualization of the droplet, e.g., by 65 or less than about 5. Suitable examples include: Triton X-15
providing contrast between the sample, reagent, and/or other 	 (HLB=4.9); Span 85 (HLB 1.8); Span 65 (2.1); Span 83 (3.7);
droplets used in the protocols of the invention and the filler 	 Span 80 (4.3); Span 60 (4.7); and fluorinated surfactants.
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Surfactants are preferably selected and provided in an 	 selected so that any viscosity changes resulting from thermal
amount which (1) results in more droplet operations on the 	 cycling are not unduly detrimental to conducting droplet
droplet microactuator as compared to corresponding droplet 	 operations required for effecting the amplification protocols.
microactuator without the surfactant or (2) makes one or 	 The filler fluid may be selected to have particular electrical
more droplet operations possible on the droplet microactuator 5 properties. For example, certain applications including elec-
as compared to corresponding droplet microactuator without 	 trowetting favor the use of a filler fluid that is non-conductive
the surfactant or (3) makes one or more droplet operations 	 (e.g., silicone oil). Or the dielectric permittivity can be
more reliable on the droplet microactuator as compared to 	 selected to control the coupling of electrical energy into the
corresponding droplet microactuator without the surfactant. 	 system from external electrodes. In certain applications a
In a related example, surfactants are preferably selected and io non-conductive filler fluid can be employed as an electrical
provided in an amount which makes one or more droplet 	 insulator or dielectric in which the droplet floats just above
operations possible or more reliable for droplets including 	 the electrodes without physically contacting them. For
one or more specific reagents or mixtures on the droplet 	 example, in an electrowetting system a layer of filler fluid
microactuator as compared to droplet operations for the same	 (e.g., silicone oil) between the droplet and electrode can be
droplets including one or more specific reagents or mixtures 15 used to provide electrostatic control of the droplet. Filler
on a corresponding droplet microactuator without the surfac- 	 fluids may be deionized to reduce conductivity.
tant. In another related example, surfactants are preferably 	 The filler fluid may be selected to have a particular density
selected and provided in an amount which makes one or more	 relative to the droplet phase. A difference in density between
droplet operations possible or more reliable for one or more 	 the two phases can be used to control or exploit buoyancy
droplets including amphiphilic molecules on the droplet 20 forces acting upon the droplets. Examples of two-phase sys-
microactuator as compared to droplet operations for the same	 tems useful in this aspect of the invention include water/
droplets including amphiphilic molecules on a corresponding 	 silicone oil, water/flourinert, and water/fluorosilicone oil.
droplet microactuator without the surfactant. 	 When one phase is buoyant, then that effect can be exploited
In a preferred embodiment, the surfactant is added to the 	 in a vertical configuration as a means to transport one phase
filler fluid in an amount which ranges from about 0.001 to 25 through the other. For example, a waste or collection well can
about 10% w/w, or about 0.001 to about 1% w/w, or about 	 exist at the top or bottom of the droplet microactuator where
0.001 to about 0.1% w/w. For example, in one embodiment 	 droplets are delivered to that reservoir by simply releasing
the filler fluid is 2 cSt silicone oil and the surfactant is Triton 	 them at an appropriate point and allowing them to float or sink
X-15 in an amount which ranges from about 0.001 to about 	 to the target destination. Such an approach may be suitable for
10% w/w, or about 0.001 to about 1 % w/w, or about 0.001 to 30 use in removing reactant from a droplet microactuator, e.g.
about 0.1 % w/w. The solid-liquid interfacial tension may be	 removing fluid containing amplified nucleic acid for use in
adjusted to control the wetting of the filler fluid on the droplet 	 other processes. Density differences can also be used as a
microactuator surfaces, for example, to control the formation, 	 means to control or engineer contact between the droplets and
thickness or behavior of thin films of the filler fluid between 	 droplet microactuator surfaces. For example, a droplet not
the droplet and droplet microactuator surfaces or to control 35 normally contacting a top-plate can be released to sink or float
the wetting behavior of the fluid when filling or emptying it 	 to that surface to contact it. Density differences and buoyancy
from the droplet microactuator.	 effects can also be exploited for sensing applications in which
By doping filler fluid with surfactant the inventors have	 the movement of droplets is detected and related to a change
discovered that it is possible to increase the concentrations of
	
in position, orientation or acceleration.
compatible protein solutions by more than 3 orders of mag-  40	 The filler fluid is selected for material compatibility with
nitude, from mg/L to mg/mL. The inventors were able to 	 the droplet microactuator surfaces. For example, certain filler
reliably dispense and transport 25 nL droplets of 75 mg/mL 	 fluids can etch, dissolve, contaminate, absorb into or other-
lysozyme solution using the new filler fluid. For example, the 	 wise be incompatible with certain droplet microactuator
filler fluid may be a silicone oil doped with a surfactant such 	 materials. For example, fluorinated hydrocarbons, such as
as Triton X-15. Preferably the surfactant is a lipophilic sur- 45 Fluorinert, may be incompatible with Teflon AF or Cytop
factant. In one embodiment, we added 0.1% (w/w) Triton 	 surfaces because of their tendency to dissolve these materials,
X-15, a lipophilic surfactant to the oil so that high concen- 	 while silicone oils may be incompatible with PDMS surfaces
trations protein droplets could be formed or dispensed from 	 due to the tendency of these materials to dissolve each other.
on-chip reservoirs. Droplet transport for all compatible fluids	 The filler fluid is selected for biochemical compatibility
is fast (typically about 3-10 cm/sec) and reliable (>25,000 50 with sample and reagents used in the protocols of the inven-
operations). In one embodiment, the filler fluid includes a	 tion.
surfactant dopant in an amount which results in an increase in 	 The invention may include means for controlling the intro-
the concentration of a protein that can be reliably dispensed
	
duction or circulation of the filler fluid within the droplet
on the droplet microactuator. 	 microactuator, cartridge and/or system. In one mode of opera-
The filler fluid may be selected to have a particular viscos- 55 tion the filler fluid is injected once during the initialization of
ity or volatility. For example, a low viscosity liquid (e.g. 0.65 	 droplet microactuator operation. The filler fluid may be pro-
cSt. Silicone oil) facilitates transport of droplets while a low 	 vided from an external source using a syringe, dropper, pipet-
volatility filler fluid (e.g., 2, 5 or 10 cSt. Silicone oil) may be 	 tor, capillary, tube or other means. Alternatively, the filler
desirable to prevent loss of filler fluid by evaporation, particu- 	 fluid may be provided from a reservoir internal to the droplet
larly in nucleic acid amplification applications performed at 60 microactuator assembly or cartridge. As an example, the fluid
elevated temperature. In some applications, evaporation of 	 can be contained within a sealed pouch which is punctured or
the filler fluid can be desired, so a low volatility filter fluid 	 compressed to transfer the liquid into the droplet microactua-
may be selected. The filler fluid may be selected to have a 	 tor.
particular viscosity dependence on temperature, since the	 In another mode of operation a means can be provided for
viscosity of the filler fluid affects the fluid dynamics and the 65 multiple introductions or recirculation of one or more filler
temperature on the droplet microactuator may vary. In nucleic 	 fluids within the droplet microactuator. A secondary fluid-
acid amplification protocols of the invention, the filler fluid is	 handling system can be provided to inject and to remove fluid
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from within the droplet microactuator. Pressure, gravity or
other means such as the use of thermal gradients can be used
to transport the filler fluid into or out of the droplet microac-
tuator. Such a system can be used for the following purposes:
(1) To replenish filler fluid lost to evaporation or leakage over
time. A slow steady flow or periodic injection of filler fluid
can be employed to make up for any loss of filler fluid
volume.
(2) To provide "clean" filler fluid either continually or peri-
odically to reduce contamination between droplets. The
filler fluid can be cleaned either by completely replacing it
or by circulating it through a filter or bed of absorbent
material selected to remove contaminants.
(3) To provide a means for transporting droplets to waste. For
example, at the end of an assay, droplets can be released
and allowed to flow with the filler fluid to the outlet pro-
viding a means to "flush" the droplet microactuator. Flush-
ing the droplet microactuator can be performed to reset the
status of the droplet microactuator in preparation to per-
form additional assays.
(4) To exchange the filler fluid when different fluids may be
desired for certain steps, for example to replace oil with air
to allow drying of droplets, or to replace one oil with a
different oil.
(5) To provide a means of controlling the temperature of the
droplets by heating or cooling the fluid as it is circulated
through the droplet microactuator. For example, PCR can
be performed in droplets containing the appropriate PCR
reagents (e.g., primers, nucleotides, and polymerase) by
circulating temperature controlled filler fluid through the
droplet microactuator to perform thermocycling. The tem-
perature of the filler fluid entering and leaving the droplet
microactuator can be directly measured and the tempera-
ture and flow rate of the filler fluid can be adjusted to
provide optimal temperature control inside the droplet
microactuator.
Local regions of filler fluid or even individual units of filler
fluid for each droplet can be used. For example aqueous
droplets can be encapsulated in an individual shell of fluid,
such as oil, which moves along with that droplet. Each such
droplet would then have its own local fluid bath with the space
between encapsulated droplets filled with third immiscible
liquid such as air or fluorosilicone oil. This approach can be
used to minimize the transfer of material between droplets in
the system by partitioning into the oil phase while retaining
the advantageous properties of the oil with respect to evapo-
ration and fouling of the surface. The shells of oil can be
created by simply moving the droplet through an oil interface,
pinching off a unit of oil as the droplet creates a bulge along
the interface.
Hybrid systems can be implemented in which different
regions of the droplet microactuator are filled with different
fluids. For example, samples can be processed under oil and
then transported into an air portion to be evaporated for sub-
sequent analysis by MS. Conversely, a sample can be col-
lected in air and then processed under oil.
Magnetically responsive beads can be used to move mate-
rial between oil and water phases on a droplet microactuator.
Generally, water-soluble compounds or materials tend to
remain within the droplets, unable to cross the oil-water
meniscus in significant quantities, and oil-soluble com-
pounds or materials remain in the lipophilic filler fluid. When
the material is attached to magnetically responsive beads, a
magnetic field may be used to move the beads and attached
material across the oil-water boundary. The beads need to be
selected such that they have sufficient affinity for oil and
water so that they can readily cross the meniscus. This opera-
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tion is useful for drying or concentrating materials and can
also be used to facilitate washing and/or dilution. For
example, material bound to a magnetically responsive bead
can be removed from one droplet and transferred by way of
5 the filler fluid to another droplet.
Filler fluid can be circulated through the droplet microac-
tuator to reduce contamination during and/or between runs.
Filler fluid can be continually or periodically flowed through
the droplet microactuator, so that fresh filler fluid is con-
10 stantly supplied to the droplet microactuator. In addition to
removing contaminates contaminated oil, this technique
could be used at the end of a run to clear droplets from the
array by removing the voltage so that droplets are released
and flow with the oil to an exterior of the droplet microactua-
15 for and/or into a waste reservoir.
8.8.4 Droplet Microactuator Loading
The droplet microactuator generally includes one or more
input ports for the introduction of one or more filler fluids,
20 reagents and/or samples (e.g., reagents and/or samples for
conducting protocols and/or assays as described elsewhere
herein, e.g., in Sections 8.1, 8.2, 8.3, 8.4 and/or 8.5) into the
droplet microactuator. In some embodiments, samples or
reagents are loaded via the input ports using conventional
25 robotics. In one alternative embodiment, droplets of sample
or reagent are separated by plugs of oil in a long pre-loaded
glass capillary which when connected to the droplet micro-
actuator allows droplets of sample or reagent to be captured
and routed on the droplet microactuator as they are pumped
30 out of the capillary into the input port. Another loading tech-
nique involves pre-stamping reagents onto the droplet micro-
actuator and allowing them to dry, e.g., using a high-speed
reagent stamping or printing process. Yet another approach
involves the use of a direct plate-to-droplet microactuator
35 interface in which the contents of plates, e.g., 1536 or 384 or
96 well plates, are transported onto the droplet microactuator
in parallel by using pressure to force the contents through
input ports aligned with wells. Loading hardware may in
some embodiments be electronically coupled to and con-
40 trolled by the controller.
8.8.5 Reservoirs
The droplet microactuator includes various reservoirs,
such as input reservoirs and/or processing reservoirs.
45 8.8.5.1 Input Reservoirs
In some embodiments, the droplet microactuator includes
one or more input reservoirs in fluid communication with one
or more input ports, typically in direct fluid communication
with the input ports. The input reservoir(s) serve as reservoirs
50 for storage of bulk source material (e.g. reagents or samples)
for dispensing droplets (e.g. reagent droplets or sample drop-
lets). Thus, the input reservoir(s) may, for example, serve as
sample wells or reagent wells.
The input reservoirs generally include one or more well
55 walls defining an interior space and an opening. The interior
space defined by the well walls is at least partially isolated by
the well walls from the remainder of the interior of the droplet
microactuator. The well may be adjacent (in any direction,
e.g., vertically or laterally) to a port suitable for introduction
60 of fluid from an exterior of the droplet microactuator into the
input reservoir. One or more openings in the well walls may
be provided to enable fluid communication with the interior
volume of the droplet microactuator for dispensing of drop-
lets into this interior volume. The opening(s) may permit fluid
65 to flow or be transported into the interior volume of the
droplet microactuator onto the path or network of electrodes.
Input reservoirs may also include one or more vents for per-
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mitting displacement of filler fluid from the input reservoir as
fluid is introduced into or removed from the well via the port
or the opening.
The input reservoirs may further include one or more pla-
nar control electrodes in a top or bottom plate adjacent to or 5
within the space defined by the well walls. The planar elec-
trodes are electronically coupled to and controlled by the
controller. In a preferred embodiment, the planar electrode
has two or more branches or rays, such that activation of the
control electrode during droplet dispensing in the presence of 10
a fluid exerts a "pull" on the fluid in a direction which is
generally opposite to the direction of droplet dispensing. In
some cases, the shape of the electrode results in a multi-vector
pull having a mean vector which has a direction generally
opposite to the direction of the droplet being dispensed. 	 15
Well walls may, for example, be formed by protrusions
from the top or bottom plates, and/or may be formed by
deposition of a wall-forming material on a surface of the top
or bottom plate. For example, well walls may be formed from
a soldermask material or polymeric gasket material deposited 20
and patterned on the surface. In some embodiments a source
of continuous or semi-continuous sample or reagent flow is
coupled in fluid communication with one or more of the input
ports.
It should be noted that while droplet dispensing may be 25
conducted from defined reservoirs, in some embodiments,
droplet dispensing is conducted without the use of physically
defined reservoirs. Dispensing may proceed from source
droplet which is confined during droplet dispensing, e.g., by
electrowetting forces or by hydrophilic surfaces. 	 so
8.8.5.2 Processing Reservoirs
The droplet microactuator may also include one or more
processing areas or reservoirs. These areas or reservoirs serve
as a location for executing various droplet processing steps, 35
such as mixing, heating, incubating, cooling, diluting, titrat-
ing, and the like. The droplet microactuator includes one or
more paths or networks of control electrodes sufficient to
transport droplets from the one or more input ports to the one
or more processing areas or reservoirs. In some cases the 40
processing areas are simply components or sections of these
paths or networks. In other embodiments, the processing
areas are defined processing reservoirs. Such reservoirs may,
for example, be structured generally in the same manner as
the input reservoirs described above. However, the processing 45
reservoirs are typically not in direct fluid communication
with the input ports, i.e., droplet transport along the one or
more paths or networks of control electrodes is required add
reagent or sample to the processing reservoir(s). In some
cases, the processing reservoirs include a path or network of 50
reservoirs therein to permit droplet operations within the
processing reservoirs.
8.8.5.3 Droplet Operations
The droplet microactuator may conduct various droplet 55
operations with respect to a droplet. Examples include: load-
ing a droplet into the droplet microactuator; dispensing one or
more droplets from a source droplet; splitting, separating or
dividing a droplet into two or more droplets; transporting a
droplet from one location to another in any direction; merging 60
or combining two or more droplets into a single droplet;
diluting a droplet; mixing a droplet; agitating a droplet;
deforming a droplet; retaining a droplet in position; incubat-
ing a droplet; heating a droplet; vaporizing a droplet; cooling
a droplet; disposing of a droplet; transporting a droplet out of 65
a droplet microactuator; other droplet operations described
herein; and/or any combination of the foregoing.
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Droplet dispensing refers to the process of aliquoting a
larger volume of fluid into smaller droplets. Dispensing is
usefully employed at the fluidic interface, the input reser-
voirs, and at processing reservoirs. Droplets may be formed
by energizing electrodes adjacent to the fluid reservoir caus-
ing a "finger" of fluid to be extended from the reservoir. When
the fluid front reaches the terminal electrode, the intermediate
electrodes are de-energized causing the fluid to retract into the
reservoir while leaving a newly-formed droplet on the tenni-
nal electrode. As previously noted, one or more electrodes in
the reservoir may also be energized to assist in separating the
droplet being dispensed from the bulk fluid. Because the
droplet conforms to the shape of the electrode, which is fixed,
excellent accuracy and precision are obtained. Droplet dis-
pensing is controlled by the controller. In some embodiments
the invention employs droplet dispensing structures and/or
techniques described in U.S. Pat. No. 6,911,132, entitled
Apparatus for Manipulating Droplets by Electrowetting-
Based Techniques," issued on Jun. 28, 2005 to Pamula et al.;
U.S. patent application Ser. No. 11/343,284, entitled "Appa-
ratuses and Methods for Manipulating Droplets on a Printed
Circuit Board," filed on filed on Jan. 30, 2006; U.S. Pat. No.
6,773,566, entitled "Electrostatic Actuators for Microfluidics
and Methods for Using Same," issued on Aug. 10, 2004 and
U.S. Pat. No. 6,565,727, entitled "Actuators for Microfluidics
Without Moving Parts," issued on Jan. 24, 2000, both to
Shenderov et al., the disclosures of which are incorporated
herein by reference.
In some embodiments, droplet operations are mediated by
electrowetting techniques. In other embodiments, droplet
operations are mediated by electrophoresis techniques. In
still other embodiments, droplet operations are mediated by
electrowetting techniques and by electrophoresis techniques.
In one embodiment, separations may be performed using a
combination of electrowetting and electrophoresis. Elec-
trowetting microactuation can be used to create a channel to
perform electrophoresis; to deliver a sample to the channel or
capture a sample fraction from channel following an electro-
phoretic separation. For example, forforming a channel, elec-
trowetting can be used to deform (stretch) a droplet of sepa-
ration medium in a long thin shape followed. In some cases,
the channel may be polymerized, e.g., using UV polymeriza-
tion. In other cases, the channel may be formed by using
droplet operations to add droplets into a physically confined
microchannel. In a related embodiment, the effective length
of an electrophoresis channel can be increased by capturing
the fraction of interest in a droplet at the output and then
returning it to the input in a cyclical fashion. Using the same
principle, a series of progressively finer separation can be
performed. Separations may also be accomplished using mul-
tiple different separation mediums at the same time.
Droplet splitting or dividing of droplets generally involves
separating a droplet into two or more sub-droplets. In some
cases, the resulting droplets are relatively equal in size.
Transporting involves moving a droplet from one location
to another in any direction. Droplets may be transported on a
plane or in three dimensions. It will be appreciated that a
variety of droplet operations, such as dispensing and/or split-
ting may include a transporting element, in which on droplet
is transported away from another droplet.
Merging involves combining two or more droplets into a
single droplet. In some cases, droplets of relatively equal size
are merged into each other. In other cases, a droplet may be
merged into a larger droplet, e.g., combining droplet with a
larger volume present in a reservoir.
Mixing a droplet involves various droplet manipulations,
such as transporting or agitating, that result in a more homog-
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enous distribution of components within the droplet. In one
mixing embodiment, a droplet positioned over an electrowet-
ting electrode is rapidly and cyclically deformed in place by
activating and deactivating the electrode, inducing fluid cur-
rents within the droplet which facilitate mixing. Frequency- 5
dependent effects such as mechanical resonances may be
used to tune the quality and speed of mixing. Compared to
techniques whichrequire transport of droplets on a surface for
mixing this approach minimizes the area required for mixing.
This mixing scheme can be employed without the presence of 10
a top plate. Due to space-saving advantage, this scheme could
provide for simplified mixing in reaction wells since only one
electrode is needed.
Reagents or samples from reservoirs may be dispensed as
discrete droplets for transport to other locations on the droplet
microactuator.
The invention includes droplet operations using droplets
comprising beads. A variety of such operations are described
elsewhere herein. In one embodiment, beads are used to con-
duct droplet operations on reagents that are prone to interfere
with droplet operations. For example, certain proteins may be
prone to bind to surfaces of a droplet microactuator and/or to
partition into the filler fluid. Immobilizing such compounds
on hydrophilic beads can be used to facilitate droplet opera-
tions using the compounds. The compounds can be bound to
the beads, and the beads can contained with a droplet which is
subjected to droplet operations.
In one particular dispensing operation, coagulation is used
to separate serum from whole blood. Whole blood is loaded
onto the chip and combined with a droplet comprising a
coagulating agent. Following coagulation, droplets are dis-
pensed from the sample. Because cells and platelets are
trapped in place, the liquid dispensed from the sample will
contain only serum.
8.8.6 Thermal Control
The droplet microactuator of the invention may include a
means for controlling the temperature of the droplet micro-
actuator or a region of the droplet microactuator. Among
other things, thermal control is useful for various protocols
requiring heating or cooling steps. Examples include ampli-
fication protocols requiring thermal cycling and various
assays that require incubation steps.
8.8.6.1 Thermal Control Designs
In general, thermal control may be provided in three ways:
(1) thermal control of the entire droplet microactuator; (2)
thermal control of a region of a droplet microactuator using a
heater that is in contact with or in proximity to the controlled
region; and (3) thermal control of a region of the droplet
microactuator using a heater that is integrated into the droplet
microactuator (e.g., in the substrate comprising the path or
array of electrodes and/or in a top plate of the droplet micro-
actuator, when present). Combinations of the foregoing
approaches are also possible. Two approaches previously dis-
cussed are illustrated in FIG. 2.
In an integrated heater approach, temperature zones can be
created and controlled using thermal control systems directly
integrated into the droplet microactuator. Integration of ther-
mal control through thin-film heating elements fabricated
directly on the droplet microactuator is also useful to maxi-
mize the speed, throughput and quality of amplification reac-
tions on the droplet microactuator. Due to their small thermal
mass, droplets can be thermally cycled extremely rapidly.
Thermal control is enhanced by locating the heating elements
proximate to the droplets and reducing the parasitic thermal
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losses between the heater and the droplet. Heating elements
can be integrated into the top plate and/or bottom plate of the
droplet microactuator.
Integrating heating elements onto the droplet microactua-
tor also enables the use of multiple distinct thermal zones
within the droplet microactuator. This permits multiple steps
in an analysis, such as sample preparation and thermal
cycling, requiring different temperatures to be performed
simultaneously on different portions of the droplet microac-
tuator. Droplets can be physically transported or "shuttled"
between zones of different fixed temperatures to perform the
thermal cycling aspects of the amplification reaction. This
approach can produce even faster reactions, since heating and
cooling of the entire thermal zones is no longer rate-limiting.
Instead, heating and cooling rates are determined by the time
required to transport the droplets between the zones and the
time required for the droplet temperature to equilibrate to the
temperature of the zone once it arrives within the zone, both
of which are expected to be very fast. A further advantage is
that reaction steps can be "queued" rather than "batched" to
permit greater operational flexibility. For example, discrete
samples can be continuously fed into the droplet microactua-
tor rather being delivered at a single point in time.
Droplets may be thermally cycled in batch mode using a
single heater or in flow-through mode by circulating the drop-
lets through distinct temperatures zones created by the heat-
ing elements. The essential difference between batch and
flow-through modes is that in batch mode thermal control is
effected by varying the temperature of the heater while in
flow-through mode, thermal cycling is effected by transport-
ing the droplets among distinct constant temperature zones.
In the "batch" method a single integrated thin-film heater on
the droplet microactuator was used to thermally cycle static
droplets located within the heater zone. In the "flow-through"
method, two distinct fixed temperature zones were created on
the droplet microactuator and thermal cycling was performed
by shuttling the droplets between the two zones.
In the "batch" case, the thermal mass of the heater itself as
well as thermal losses may be minimized through the use of
thin-film heaters placed directly adjacent to the droplets.
Because the thermal masses, including the droplet itself, are
so small, rapid temperature changes can be effected. Passive
cooling (in filler fluid) is also rapid because the total energy
input into the system is extremely small compared to the total
thermal mass.
For "flow-through" heating, a larger thermal mass is desir-
able because it helps to stabilize the temperature while a
slower ramp rate is tolerable because the heater temperature is
not varied once it reaches its set point. A flow-through system
can, for example, be implemented using block heaters exter-
nal to the droplet microactuator which were more accurate
and easier to control than thin-film heaters although, in prin-
ciple either type of heater could be used to implement either
method.
In another embodiment, temperature is controlled by flow-
ing or recirculating heated filler fluid through the chip and
around the droplets.
The droplet microactuator layout is scalable, such that a
droplet microactuator may include a few as one heating zone
up to tens, hundreds or more heating zones.
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8.8.6.2 Heater Types
Heaters may be formed using thin conductive films.
Examples of suitable thin films include Pt heater wires and
65 transparent indium-tin-oxide (ITO). ITO provides better
visualization of the droplets for real-time observation. A
remotely placed conventional thermocouple (TC) for tem-
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perature regulation can also be used. In one embodiment, tiny
metal (e.g., copper) vias in the PCB substrate are used to
create tight thermal junctions between the liquid and the
remote TC. Further, sample temperature can be determined
by monitoring the copper via using a surface mount ther- 5
mistor or an infrared sensor. One advantage of using a ther-
mistor is that they are small enough (2x2 mm) to be soldered
directly on the droplet microactuator, while an advantage of
using IR is that it is non-contact method which would sim-
plify the interfacing. Because the thermal conductivity of io
copper is at least 700 times greater than the FR4 substrate
(350-390 W/m•K versus 0.3-0.5 W/m•K) the temperature of a
Cu via will accurately represent the temperature inside the
liquid. Heaters may be integrated on the bottom and/or top
(when present) plate of the droplet microactuator and on the 15
bottom and/or top surface of either plate, or integrated within
the structure of either plate.
In one flow-through embodiment, reduced thermal gradi-
ents can be provided by using heaters to create a continuous
temperature gradient across the droplet microactuator (e.g., 20
from 100 to 50° C.). The use of a continuous gradient will
eliminate the need to overcome the steep temperature gradi-
ents found along the edge of the heater blocks. A controlled
temperature gradient would also significantly enhance the
functionality of the device by allowing protocols with arbi- 25
trary numbers of temperature points to be implemented. Fur-
thermore, each reaction can be performed with a custom
thermal protocol while only the temperatures of the two or
more blocks would need to be thermally regulated. The drop-
lets will be transported to and held at the appropriate location 30
between the heaters to achieve a target temperature. The
fluorescence of the droplets can be imaged using a fluores-
cence sensor as they are transported over a detection spot. The
temperature of the upper and lower target temperatures can be
varied by changing the location of the droplets. 	 35
In some embodiments, heaters located above the droplets
may obscure the droplets thus interfering with real-time opti-
cal measurements. In such cases, the droplets can be trans-
ported out from underneath the heaters to a location which is
preferred for optical detection (i.e. a detection spot). Droplets 40
may be periodically transported out from underneath the
heaters to a detection spot on the droplet microactuator detec-
tion purposes, e.g. detection by fluorescence quantitation.
Droplets may be routed into proximity with a sensor while
cycling them from one temperature zone to another. 	 45
8.8.7 Droplet Microactuator Fabrication
Droplet microactuators can be made using standard micro-
fabrication techniques commonly used to create conductive
interconnect structures on microdroplet microactuators and/
or using printed-circuit board (PCB) manufacturing technol-
ogy. Suitable PCB techniques include those described in U.S.
patent application Ser. No. 11/343,284, entitled "Apparatuses
and Methods for Manipulating Droplets on a Printed Circuit
Board," filed on Jan. 30, 2006, the entire disclosure of which
is incorporated herein by reference. These techniques permit
the droplet microactuator to be manufactured in bulk at very
low cost. Low cost manufacture enables economical produc-
tion of droplet microactuators, even for use as one-use dis-
posables. Thus, the invention provides a method in which
droplet microactuators are supplied to users as components of
disposable cartridges for use in systems of the invention.
Designs can also be implemented on glass or silicon using
conventional microlithography techniques with the capabil-
ity of producing much smaller features than are typical in a
PCB process. Even, for example, for a 1,572,864-reservoir
droplet microactuator with 70 µm reservoir spacing and 3 IL
74
reservoir volume, the minimum required lithographic feature
size is —0.5 µm which is well within the capabilities of con-
ventional microlithographic techniques currently used in the
semiconductor industry.
8.9 Systems
Fluid loading may be accomplished using droplet micro-
actuator systems, such as illustrated in FIG. 18. Steps of a
fluid loading protocol may be conducted using a droplet con-
trol system 1801. A set of computer executable instructions
may be written which can be loaded into a controller for
execution of a loading protocol. Integrated systems including
the droplet control system 1801 and the protocol execution
system 1802 may also be used. The droplet control system
1801 permits a user to control droplet microactuator system
functions, such as droplet operations and sensor operations
for fluid loading protocols. The protocol execution system
1802 permits a user to execute software routines that control
droplet microactuator system functions, such as droplet
operations and fluid loading operations. The invention also
provides a method or computer useable instructions for con-
ducting fluid loading processes or protocols. The program-
mable flexibility of the platform permits assays to be rapidly
optimized and allows conditional execution steps to be imple-
mented. For example, calibrations, confirmatory tests, or
additional controls can be executed if triggered by a particular
test result. In some embodiments, the system can integrate
sample preparation steps. Automation of the system and on-
droplet microactuator operations enhance portability and
enable assays to be performed more quickly and by personnel
with minimal training, thereby reducing human error.
Referring further to FIG. 18, at a high level, each of the
systems of the invention typically includes a processor or
controller 1803, a droplet microactuator 1804, a sensor or
detector 1805, input device(s) 1806, output device(s) 1807,
and software. U.S. Patent Application No. 60/806,412,
entitled "Systems and Methods for Droplet Microactuator
Operations," filed on Jun. 30, 2006, the entire disclosure of
which is incorporated herein by reference, describes droplet
microactuator systems which may be employed in conjunc-
tion with the droplet microactuator aspects of the invention.
The droplet control system includes droplet control software
run on a computer 1808 and programmed to display a droplet
control interface for controlling droplet microactuator system
functions. The protocol execution system includes protocol
execution software programmed to facilitate execution of a
set of computer executable or computer useable instructions
for controlling droplet microactuator system functions to
conduct fluid loading.
50 8.9.1 Controller
The system of the invention may include a controller 1803.
The controller serves to provide processing capabilities, such
as storing, interpreting, and or executing software instruc-
tions. The controller may, for example, be comprised of a
55 digital signal processor (DSP) with memory, a microcontrol-
ler or an application specific integrated circuit (ASIC). An
example of a suitable DSP processor is the Analog Devices
Blackfin DSP processor.
The controller is electronically coupled to various hard-
60 ware components of the invention, such as the droplet micro-
actuator, any sensors, and any input and/or output devices.
The controller may be configured and programmed to control
data and/or power aspects of these devices. For example, with
respect to the droplet microactuator, the controller controls
65 droplet manipulation by activating/deactivating electrodes.
This aspect of the invention is discussed further in Section
8.8.
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The controller may further be electronically coupled to a
separate computer system including a processor, input and
output devices, data storage medium, and other components.
This arrangement is particularly useful in the droplet control
system, in which the computer system is programmed to
operate a droplet control user interface. In this arrangement,
the processor of the computer system may accept input via the
user interface and transmit instructions to the controller, e.g.,
to activate/deactivate electrodes, to read electrodes, memory,
and/or sensors, and the like.
In the protocol execution system, software for controlling
the system may be loaded directly into and executed by the
controller to cause the controller to control the droplet micro-
actuator system functions. In this embodiment, the system
can run autonomously, e.g., as a portable or handheld system.
8.9.2 Droplet Microactuator
The system may include a droplet microactuator 1804, as
described further in Section 8.8. The droplet microactuator is
electronically coupled to the processor such that the proces-
sor can control various operations of the droplet microactua-
tor, such as droplet manipulation operations.
8.9.3 Sensor
Various embodiments of the invention make use of sensors
or detectors 1805. Sensors may include sensors which are
coupled to the droplet microactuator for the purpose of mea-
suring parameters of interest on the droplet microactuator
such as the fluorescent or luminescent intensity at a location
on the droplet microactuator where a reaction product may be
located. Sensors may also include sensors which monitor the
status of the system such as droplet microactuator insertion
sensors, lid latch sensors, ambient temperature sensors and
the like. Output from each sensor may be mapped to a specific
memory location, and the processor must only query the
mapped location to obtain a reading from the sensor. The
sensor is mounted relative to the droplet microactuator and/or
electronically coupled to the droplet microactuator such that
the sensor can detect signals, such as electrical or light sig-
nals, from the droplet microactuator. Sensors are discussed in
more detail elsewhere in this specification, e.g., see Section
8.11.
8.9.4 Input and Output Device(s)
Systems of the invention also include various input devices
1806 and output devices 1807. In certain embodiments, such
as the protocol execution system, certain input and output
devices may be controlled using a human-machine interface
(HMI) controller.
8.9.5 Software
Each of the systems of the invention includes software. The
software provided on a storage medium is one aspect of the
invention. Examples of suitable storage mediums include
magnetic storage, optical storage, phase-change memory,
holographic storage, molecular memory storage, battery or
capacitor-backed SRAM and flash memory storage. The soft-
ware may be loaded in memory and/or in a processor. A
system in which software of the invention is present in
memory and/or a processor and/or a storage medium is also
an aspect of the invention.
The software of the invention may be written in any of a
variety of programming languages, such as Visual C, Java
and/or Python. The system may include an interpreter for
translating droplet manipulation and other instructions from
the high-level language into an intermediate language for
execution by the processor. Alternatively, software written
according to the invention may be compiled into machine
language using a compiler. The software interpreter and com-
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piler for the language of the invention are themselves novel
aspects of the invention. As such, all forms of data storage,
memory, and processors containing the interpreter and/or
compiler are aspects of the invention.
5 The system can be programmed to execute a wide variety
of protocols involving any number of droplet manipulations.
Multiple droplets can be independently and simultaneously
manipulated on a single droplet microactuator. The capacity
to independently manipulate multiple droplets in parallel
io enables execution of complex protocols as a series of basic
microfluidic instructions. Systems are scalable and may con-
trol tens, hundreds, thousands or more parallel droplet
manipulations per droplet microactuator. For example, at any
one moment, up to a maximum of every control electrode on
15 the droplet microactuator may be engaged in a droplet opera-
tion.
The system can be programmed to enable users to input
instructions for the execution of protocols. Existing protocols
may be monitored and adjusted according to user require-
20 ments. Complex protocols can be implemented in which the
outcome of one or more steps determines the selection of one
or more subsequent steps. For example, a droplet in which a
certain measured result is positive may be transported for
further processing, while a droplet in which a result is nega-
25 tive may be discarded, or vice versa.
8.9.6 Portability
Referring to FIGS. 19A and 1913, in some embodiments,
the analyzer is provided as a portable device, such as a hand-
held device 1900. FIG. 19A shows the exterior of handheld30 device 1900 and FIG. 19B shows a slot 1902 for insertion of
a droplet microactuator (not shown), an optical sensor 1904
for sensing optical signals from the droplet microactuator,
and a lid latch 1906, which may be coupled to the system to
indicate whether the lid is open or closed. It is envisioned that35 the portable analyzer may also be a tabletop device. The
portability of the droplet microactuator systems of the inven-
tion facilitates point of care or point of sample collection use
in a wide variety of settings in clinics, operating rooms,
40 
emergency rooms, small laboratories, and in the field (emer-
gency response teams, accidents, disasters, battlefield, biot-
errorism sites etc.) for rapid diagnostics that can lead to quick
turn around times in critical situations.
8.10 User Interface
45 The droplet control system includes droplet control soft-
ware programmed to display a droplet control interface for
controlling droplet operations on the droplet microactuator,
controlling the sensor, when present, and controlling other
hardware associated with the droplet control system. The
50 system may also include software to facilitate creation of a set
of software or computer useable instructions for controlling
droplet microactuator system functions, such as droplet
operations and/or sensor operations.
As illustrated in FIG. 20, the system may include a user
55 interface 2000. The user interface is described further in
related U.S. Patent Application No. 60/806,412, entitled
"Systems and Methods for Droplet Microactuator Opera-
tions," filed on Jun. 30, 2006, the entire disclosure of which is
incorporated herein by reference. The user interface may
6o display a map 2001, preferably an interactive map, of a drop-
let microactuator. The map may be used to interact directly
with the droplet microactuator to manipulate droplets on the
droplet microactuator to conduct a fluid loading protocol
according to the invention. The map may be used in a virtual
65 mode to manipulate virtual droplets 2011 in a programming
mode to develop and record subroutines for controlling drop-
let microactuator functions and related hardware.
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8.10.1 Droplet Control System and User Interface 	 To facilitate user interaction, a moused over or selected
	
The droplet control system includes droplet control soft- 	 electrode 2002 or other component may also cause the elec-
	
ware. The droplet control software is programmed to display	 trode or other component to be highlighted on the droplet
	
a droplet control interface for controlling droplet operations 	 microactuator map. This capability permits a user who is
on the droplet microactuator, controlling the sensor, when 5 directly controlling droplet microactuator operations to
	
present, and controlling other hardware associated with the	 review information about each potential step by mousing over
	
droplet microactuator system. The droplet control software 	 the droplet microactuator component prior to actually select-
	
permits a user to manipulate droplets on a droplet microac- 	 ing and activating the droplet microactuator component. The
	
tuator via a software driven user interface. As described 	 system may be programmed to highlight a moused over com-
above, an example of such an interface is illustrated in FIG. io ponent and a selected component differently so that a user
	
20. Among other things, the user interface may permit a user 	 may differentiate between the two.
	
to view information about a droplet microactuator. The user 	 The system may include a means 2007 for permitting a user
	
interface may also facilitate input by the user which controls 	 to select the mode of operation, e.g., select between a virtual
	
functions of the droplet microactuator and associated devices,	 or programming mode in which a program can be written for
such as associated sensors.	 15 controlling a droplet microactuator, and an operation mode in
	
With respect to controlling droplet operations on a droplet	 which droplets are controlled directly on a droplet microac-
	
microactuator, the software is programmed and the system is 	 tuator.
	
configured to, among other things, drive control andreference 	 The system may include a means 2012 for permitting a user
	
electrodes on the droplet microactuator to conduct the droplet 	 to select a droplet microactuator design for display. Alterna-
operations. Droplet operations, which are discussed further in 20 tively, data identifying the droplet microactuator design may
	
Section 8.8 above, are effected by applying a voltage to 	 be included as a component of the droplet microactuator
	
selected electrodes. The software and system may be config- 	 assembly or cartridge accessible by the system upon coupling
	
ured to permit software loaded in the processor to control 	 of the droplet microactuator assembly or cartridge to the
	
activation of the selected electrodes by controlling the opera-	 system.
tion of relays associated with the electrodes. 	 25	 It should be noted that in some designs, more than one
	
As shown in FIG. 20, the user interface 2000, which is	 electrode may be coupled to the same electrical output. Such
	
displayed on an output device, maybe programmed to display 	 designs can be used to simplify the design of the droplet
	
a graphical illustration or map 2001 of a droplet microactua- 	 microactuator. In such designs, selecting or mousing over one
	
tor design. The map 2001 may be based on a matrix or other	 electrode from a common set may result in selection, high-
configuration that defines the position of each of the control so lighting and activation of all electrodes in the set.
	
electrodes and/or reservoirs. Components of the map may be 	 Thus, in one embodiment, the system is programmed so
	
differentiated by appearance, e.g., by shape, color, bright- 	 that when a user selects an unactivated electrode 2002 on a
	
ness, symbols, icons, etc. For example, in the map displayed 	 microactuator map 2001, the system activates the electrode.
	
in FIG. 20, unactivated droplet manipulation electrodes 2002 	 For example, the system may be programmed and configured
can be shown in a first color (such as gray), activated droplet 35 so that clicking on a representation of an electrode on the map
	
manipulation electrodes and reservoirs 2003 can be shown in	 causes a voltage to be applied to a corresponding actual
	
a second color (such as red), and unactivated reservoirs 2004	 electrode on the droplet microactuator, thereby activating the
can be shown in a third color (such as blue). 	 selected electrode. In this way, a user can directly manipulate
	
In a simple embodiment, the matrix is defined in a control
	
droplets on the droplet microactuator using the interface.
file which identifies a row and column for each electrode 40 The droplet control system may permit a user to transport
	
and/or reservoir. When a control file is loaded, the system 	 a droplet by sequentially clicking on a series of adjacent
	
reads in the matrix definitions and displays the corresponding 	 electrodes. Similarly, the system may permit a user to trans-
map of the matrix on the user interface. 	 port a droplet by selecting a virtual on-screen droplet 2011
	
The interface may display information about components 	 and dragging the droplet to a virtual electrode at a desired
of the map, which may also be stored in the control file. In one 45 location on the droplet microactuator map. Moreover, the
	
embodiment, the system displays information about a com- 	 system may permit a user to transport a droplet by selecting a
	
ponent when it is moused over, selected, or otherwise elec- 	 virtual on-screen droplet 2011, then clicking a virtual elec-
	
tronically identified by a user. Information displayed may, for 	 trode at a desired location on the droplet microactuator map.
example, include some or all of the following information: 	 Other droplet microactuator components may be similarly
component type, e.g., droplet manipulation electrode, 50 controlled via a user interface.
reagent reservoir, sample reservoir, etc.;	 The system may be programmed to display a representa-
	
electrical connectivity information, e.g., electrode enu- 	 tion of the electrical control lines 2005 electronically coupled
meration, grounds, pinout number etc.; 	 to the droplet microactuator components, so that when a user
	
adjacency relationships, e.g., in a polygonal electrode 	 mouses over and/or selects a component, the system high-
arrangement;	 55 lights the electrical signal that is activated as a result of being
	
representative geometry, for rendering the map in the user 	 mapped to the component.
interface;	 The droplet microactuator may be visually monitored, e.g.,
design notes and/or other comments; 	 using a microscope and video capture device. The user inter-
part numbers;	 face may be programmed to display a real-time image of the
column and/or row position.	 6o droplet microactuator from the video capture device. Further,
	
The system may also record the history of the activation of	 the droplet microactuator map may be superimposed over the
	
each electrode, so that the user may track the number of times 	 real-time droplet microactuator image so that a user can visu-
	
an electrode has been activated. History information may, for	 alize droplet operations on the droplet microactuator as he or
	
example, be displayed by mousing over or selecting an elec- 	 she interacts with the droplet microactuator via the user inter-
trode. The system may be programmed to accept input from a 65 face.
	
user instructing history information to be displayed simulta-	 Similarly, the system may be programmed to display vir-
neously for all electrodes. 	 tual droplets 2011 on the droplet microactuator map which
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illustrate actual behavior of droplets on a droplet microactua-
tor which is being controlled by the system, and/or the system
may be programmed to display virtual droplets 2011 on the
droplet microactuator map which illustrate predicted behav-
ior of droplets on a droplet microactuator, even though a
droplet microactuator is not being directly controlled by the
system.
The system may also be programmed to effect an "inverse
output' 2006 operation. In typical operation, the droplets are
constantly connected to a ground voltage/ground line. In the
"inverse output" operation, the signals are inverted so that the
droplet is at a high voltage and the electrodes are activated by
setting them to ground potential. In other words, the "inverse
output' operation switches the polarity of the signals.
The system may also facilitate creation of a set of software
or computer useable instructions for controlling droplet
operations on the droplet microactuator and controlling other
functions of a droplet microactuator and related hardware.
The software instructions may, for example, include instruc-
tions for executing a protocol for processing and analyzing a
sample and outputting results of the analysis. The system may
facilitate writing programs for controlling droplet microac-
tuator functions and related components, such as sensor com-
ponents without interacting with an actual droplet microac-
tuator.
The system may, for example, include means for permit-
ting a user to create a program with a set of instructions for
execution by the droplet microactuator. Examples of suitable
instructions include:
"on" for identifying electrodes that are to be actuated;
"frequency" to set the rate at which the steps are executed,
e.g., the timing of electrode activation/deactivation;
"wait" to permit the instructions to pause for a predeter-
mined period;
"loop" to loop steps in the program;
"voltage" to set the voltage being applied to the outputs.
Instructions can be provided as a byte-coded language
which includes instructions needed to conduct droplet
manipulations and control other aspects of the system. The
instructions prepared by the system can be recorded in the
assembly language and assembled into byte codes. The byte
codes can be loaded into a system of the invention, e.g., a
protocol execution system, for execution. The system may
include a software interpreter for interpreting the language
for execution, e.g., in a protocol execution system.
In a preferred embodiment, the system displays a series of
buttons or icons 2008 that can be selected to add, insert,
update, modify or delete instructions from a subroutine. The
buttons or icons may, as appropriate, be accompanied by
fields 2009 for the entry of parameters associated with the
instructions. For example, by clicking the "add" button, a
command can be added at the end of a subroutine. By clicking
an "insert" button, a command can be inserted within a sub-
routine. By clicking a "modify" button, a command present in
a subroutine can be modified. By clicking a "delete" button, a
command can be deleted. Further, a display field 2010, which
may be editable, may be included for viewing, entering and/or
editing code.
The system may display a simulated execution of a sub-
routine on the droplet microactuator map, which outputs to
the user a visual display of the effects of the command series
selected. In other words, in a simulated execution mode, the
software executes the steps of a subroutine but does not send
an electrical signal to the droplet microactuator. In a preferred
simulation mode, simulated droplets are displayed on the
screen to illustrate to the user the actual effect of the program.
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In this way, a user can readily troubleshoot a subroutine
without requiring interaction with a droplet microactuator.
8. 10.2 Protocol Execution System and User Interface
5 The invention provides a protocol execution system. The
protocol execution system includes protocol execution soft-
ware programmed to facilitate execution of a set of software
instructions for loading fluid, controlling droplet operations
on the droplet microactuator and/or other functions of a drop-
10 let microactuator and related hardware. The protocol execu-
tion system provides the ability to execute protocols on a
free-standing system, typically a portable or handheld sys-
tem.
The protocol execution system is configured to control the
15 droplet microactuator and any associated components. Pre-
programmed instructions may be loaded into the controller
which controls the system and any associated components.
The protocol execution system may include various compo-
nents for permitting a user to provide input to and obtain
20 output from the processor. The human-machine interface may
be facilitated using a HMI board. The HMI board typically
includes a controller and various electronic components, such
as buses and ports for electronically coupling input and output
devices with the processor.
25 8.11 Sensors
The droplet microactuators and systems include sensors
for measuring droplet properties, such as physical properties,
chemical properties, and electrical properties. In some
30 embodiments, the sensors will include a sensing element
arranged to interact with a droplet and/or a signal from a
droplet; a transducing element, which converts output from a
sensor into a measurable signal; a means for transmitting the
signal to the processor. The processor may convert the signal
35 into an output recognizable to a user.
The sensor element may be a component of the droplet
microactuator, e.g., mounted on a top or bottom plate, posi-
tioned in the interior space of a droplet microactuator
between top and bottom plates, or manufactured as an integral
40 component of the droplet microactuator, e.g., an integral
component of top or bottom plates. In other embodiments, the
sensor element may be exterior to the droplet microactuator
but arranged within the system in a manner which permits the
sensor to receive a signal from on the droplet microactuator,
45 e.g., from a droplet on a droplet microactuator. For example,
a sensor element for sensing photons may be arranged to
receive photons from a droplet on a droplet microactuator.
Where the system has a top plate capable of transmitting
photons from a droplet, the sensor may be arranged in prox-
50 imity to the top plate for sensing the photons. Where the
system has a top plate not capable of transmitting photons
from a droplet, the top plate may be provided with a window
capable of transmitting photons, and the sensor may be
arranged in proximity to the window for sensing the photons.
55 Illustrative examples of sensor configurations are provided
in FIGS. 21A-21D wherein the sensors may be provided in
association with a bottom plate 2102, a top plate 2104, and
electrodes 2106. FIG. 21A illustrates an optical sensor which
may include use of a setup including an LED 2108 and a
60 photodiode 2110 for monitoring absorbance. FIG. 21B illus-
trates a luminometric sensor which may include use of a
photomultiplier tube (PMT) 2112. FIG. 21C illustrates a
potentiometric sensor 2114 which typically functions based
on the measurement of a potential under no current flow. FIG.
65 21D illustrates an amperometric sensor 2116 which typically
functions by the production of a current when a potential is
applied between two electrodes.
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It is important to keep in mind that, as noted elsewhere in
this disclosure, the droplet microactuator may be supplied as
a separate component which can be coupled to a system by a
user. Where sensors are exterior to the droplet microactuator,
those sensors may in some embodiments be aligned such that
upon coupling to the droplet microactuator system, the sens-
ing elements are appropriately aligned to detect signals from
the droplet microactuator, e.g., the photon sensor is aligned
with the appropriate window and/or with the appropriate
location on the droplet microactuator where the sensing step 10
will be accomplished in the course of a droplet protocol.
In various embodiments, the droplet microactuator and/or
system may be configured with sensor components enabling
the implementation of one or more types of sensing.
Examples of suitable sensing types include physical sensing, 15
electrochemical sensing, and optical sensing.
8.11.1 Physical Approaches
A droplet microactuator and/or system of the invention
may include one or more physical sensors arranged to sense a
property of a droplet on a droplet microactuator. Examples of 20
physical sensing include temperature and droplet size (e.g.,
by thermally measuring the footprint of the droplet).
8. 11.2 Electrochemical Approaches
The droplet microactuator system of the invention makes 25
use of a variety of optical detection approaches. A droplet
microactuator and/or system of the invention may include one
or more electrochemical sensors arranged to sense a property
of a droplet on a droplet microactuator. Examples of suitable
electrochemical sensing types include potentiometric sen-  30
sors, amperometric sensors, voltametric sensors, and conduc-
tometric sensors. The various components of the sensors
(e.g., electrodes, counter electrodes, reference electrodes,
etc.) may be provided on the same or separate substrates,
arranged to permit contact with a droplet on the droplet 35
microactuator. For example, in embodiments in which the
droplet microactuator includes two substantially parallel sub-
strates, various components of the sensor assemblies may be
comprised on one or both of the substrates. In some embodi-
ments, an electric circuit may be used to amplify signals into
a measurable voltage. Various aspects of these approaches are
discussed in the ensuing sections.
8.11.2.1 Amperometry Sensor
The droplet microactuator device or system may include an
amperometry sensor and an electrical source arranged to per-
mit a droplet on the droplet microactuator to be transported
into contact with electrical source and the sensor to permit
detection of electric current flowing through the droplet.
8.11.2.2 Potentiometry Sensor
The droplet microactuator device or system may include a
potentiometry measuring and reference electrode arranged to
permit a droplet on the droplet microactuator to be trans-
ported into contact with the measurement and reference elec-
trodes to permit measurement of equilibrium electrode poten-
tial of a droplet.
8. 11.3 Optical Approaches
The droplet microactuator system of the invention makes
use of a variety of optical detection approaches.
A droplet microactuator and/or system of the invention
may include one or more optical sensors arranged to sense a
property of a droplet on a droplet microactuator. Examples of
optical sensing include absorbance, chemiluminescence, and
fluorescence. Optical sensors may in some cases be accom-
panied with an appropriate light source, e.g., for exciting
fluorescence or conducting absorbance measurements. These
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sensors may be provided as components mounted on a droplet
microactuator and/or as integral parts of a droplet microac-
tuator, e.g., using semiconductor manufacturing techniques.
Optical sensors may include various optics designed to
direct optical signals, and may be coupled to various image
processors for analyzing optical images. For example, droplet
size may be detected by processing an image of a droplet.
Similarly, droplet size may be obtained by measuring a ther-
mal footprint of the droplet. Electrical sensors may also be
used to measure droplet size, e.g., by measuring impedance of
the droplet footprint.
In some cases, surfaces of the droplet microactuator may
be modified to enhance optical sensing. For example, elec-
trodes with reflective surface finishes may beused to facilitate
optical measurements of droplets. The use of reflective elec-
trodes increases the path length for absorbance measurements
and is also compatible with reflectance spectroscopy. For
auto-fluorescent substrates, such as PCB, coating a droplet
microactuator surface with a non-fluorescent coatings can be
used to provide a non-fluorescent detection zone.
Various aspects of these approaches are discussed in the
ensuing sections.
8.11.3.1 Photosensor
The droplet microactuator device or system may include an
absorbance detection components including a light source
and a photosensor arranged to permit a droplet on the droplet
microactuator to be transported into proximity with the light
source and photosensor such that light or energy passing
through the droplet can be detected by the photosensor.
The droplet microactuator device or system may include
chemiluminescence detection components including a pho-
tosensor (such as a photodiode, avalanche photodiode, pho-
tomultiplier tube) or photon sensor (such as a photon-count-
ing photomultiplier tube) arranged to permit a droplet on the
droplet microactuator to be transported into proximity with
the photosensor or photon sensor such that photons emitted
by chemical species in the droplet can be detected by the
photosensor or photon sensor.
40 8.11.3.2 Fluorescence Sensor
The droplet microactuator device or system may include
fluorescence detection components including a light excita-
tion source with appropriate filters, if necessary, and a pho-
tosensor (such as a photodiode, avalanche photodiode, pho-
45 tomultiplier tube) or a photon sensor (such as a photon-
counting photomultiplier tube) with appropriate filters and
dichroic mirrors, if necessary, arranged to permit a droplet on
the droplet microactuator to be transported into proximity
with the light excitation source and the photosensor or photon
So sensor such that photons emitted by fluorescent species in the
droplet can be detected by the photosensor or photon sensor.
8.11.3.3 Surface Plasmon Resonance
In another embodiment, surface plasmon resonance (SPR)
55 sensing is employed to detect interactions between an anti-
body and any target analyte. SPR sensing is useful to detect
and quantify such interactions. Typically, one interactant in
the interactant pair (i.e., antibody or analyte) is immobilized
on an SPR-active gold surface on a glass substrate. The inter-
6o actant may be immobilized using a droplet-based approach
wherein a droplet is transported into contact with the gold
surface to deposit the interactant thereon. A droplet including
the other interactant may be transported into contact with the
immobilized interactant, thereby permitting the other inter-
65 actant to bind to the immobilized interactant. When light
(e.g., visible or near infrared) is directed through the glass
substrate and onto the gold surface at angles and wavelengths
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near the surface plasmon resonance condition, the optical
reflectivity of the gold changes very sensitively with the pres-
ence of biomolecules on the gold surface or in a thin coating
on the gold. The optical response may be highly sensitive due
to the fact that it involves an efficient, collective excitation of
conduction electrons near the gold surface. The extent of
binding between the solution-phase interactant and the
immobilized interactant may be observed and quantified by
monitoring this reflectivity change. The invention also
includes a droplet microactuator including a gold surface
thereon, and a path or network of electrodes arranged to
permit the execution of droplet manipulations sufficient to
bring a droplet into contact with the gold surface. Further, the
invention includes a system including such droplet microac-
tuator and further including a light source capable of directing
light onto the gold surface at angles and wavelengths near the
surface plasmon resonance condition. Similarly, the inven-
tion includes a system including such a droplet microactuator
and further including a means for detecting changes in reflec-
tivity of the gold surface. Moreover, the invention includes a
droplet microactuator device and/or system having loaded
thereon reagents sufficient to conduct some or all steps of an
SPR protocol.
8.11.3.4 Raman Spectroscopy
In one embodiment, the droplet microactuator and/or sys-
tem includes Raman spectroscopic detection capability. In
general, this capability includes a Raman signal-generating
light source, a Raman signal detection surface, and a Raman
spectrophotometer.
The Raman signal generating light source may, for
example, be a monochromatic light, e.g., a laser source with
excitation in the visible wavelength range. The light source is
arranged to irradiate a Raman signal detection surface on a
droplet microactuator. The surface may, for example, be a
surface of the droplet microactuator and/or a surface of a
particle on a droplet microactuator. For example, the surface
may be the surface of a particle in a droplet on a droplet
microactuator. The droplet microactuator may have the capa-
bility of conducting droplet operations using a droplet includ-
ing such particles in order to effect various protocols which
employ Raman signal detection methods.
The Raman signal detection surface may include any sur-
face appropriate for Raman scattering. Examples include
gold or silver surface. The surface may be roughened. The
droplet microactuator may in some cases include multiple
metallic surfaces (e.g., surfaces of the droplet microactuator,
beads, particles, nanoparticles, etc.), including surfaces
labeled with a different Raman reporter molecules. Antibod-
ies or analytes bound to the surface may be identified by the
characteristic Raman spectra of the Raman reporter mol-
ecules. The Raman detection surface may, for example, be an
electrode, a coating on the electrode, or a layer on any chip
surface. In operation, a droplet is positioned using droplet
operations on the Raman detection surface, and is irradiated
with a laser beam. Scattered light from the irradiated surface
is collected with a spectrometer. In another embodiment, the
Raman detection surface is a particle in a droplet on a droplet
microactuator. The particle may, for example, be a nanopar-
ticle, such as a silver or gold nanoparticle. For example, silver
nanoparticles can be prepared as monodispersed colloidal
suspensions, which can be manipulated on a droplet micro-
actuator using droplet operations. In some embodiments, the
particles may be aggregated into clusters using aggregation
additives, such as inorganic salts such as sodium chloride or
sodium nitrate, acids such as nitric or hydrochloric or organic
amines such as poly-L-lysine. These aggregation additives
can be combined with a droplet including the sample and the
particles using droplet operations, e.g., using droplet opera-
tions to combine a droplet including the aggregation additive
with a droplet including the particles and sample. Surfaces of
5 the droplet microactuator associated with the Raman spectro-
scopic region are selected to minimize the background fluo-
rescence signal.
A Raman spectrophotometer is arranged to detect Raman
scattered light emitted from the sample droplet. The Raman
io spectrophotometer may be integral with the droplet microac-
tuator arranged exterior to the droplet microactuator in a
manner whichpermits it to detect Raman scattered light emit-
ted from the sample droplet on the droplet microactuator.
In operation, a droplet microactuator is provided having a
15 Raman detection surface thereon. An analyte is brought into
association with the Raman detection surface using droplet
operations. The surface is irradiated with a Raman signal
generating light source. Raman scattered light signals are
detected correlated with expected signals in order to deter-
20 mine the identity and/or quantity of an analyte.
In another embodiment, surface-enhanced Raman scatter-
ing (SERS) is employed to detect interactions between an
antibody and any target analyte. In general, this method
involves monitoring an analyte mediated binding event in a
25 sample droplet which includes the analyte, a specific binding
member, a Raman-active label, and is in contact with a sur-
face, such as a bead or a surface of the droplet microactuator,
and which is capable of inducing a surface-enhanced Raman
light scattering. The sample droplet is illuminated with a
3o radiation sufficient to cause the Raman-active label in the test
mixture to emit a detectable Raman spectrum. The differ-
ences in the detected surface-enhanced Raman scattering
spectra are dependent upon the quantity of the analyte present
in the test mixture. The presence and/or quantity of the ana-
35 lyte in the sample droplet may be determined by monitoring
the Raman scattering spectra. The invention includes a drop-
let microactuator device and/or system having loaded thereon
reagents sufficient to conduct some or all steps of an SERS
protocol.
40 In a related embodiment, the invention provides a method
for determining the presence or quantity of an analyte in a
sample droplet by monitoring an analyte-mediated ligand
binding event on a droplet microactuator. The method gener-
ally includes reacting the analyte with an antibody coupled to
45 a Raman active label. The reaction is conducted using drop-
lets on a droplet microactuator and is effected under condi-
tions permitting specific binding of the antibody to the ana-
lyte, if present, to yield a first complex in the sample droplet.
Sequentially or simultaneously the first complex is contacted
50 with a surface capable of inducing a surface-enhanced Raman
light scattering and having attached thereto an antibody spe-
cific for the analyte to form a second complex. The second
complex is illuminated with a radiation sufficient to cause the
Raman-active labels in the complex to produce a detectable
55 Raman spectrum. Differences in the surface-enhanced
Raman scattering spectra are indicative of the presence and/or
quantity of the analyte present in the test mixture.
A variety of surfaces may be appropriate for the droplet-
based SERS protocols of the invention. Examples include
6o roughened metal electrodes, aggregated, films, metal islands
of different morphology, semicontinuous films near the per-
colation threshold, and vacuum-evaporated nanostructured
metal films. Accordingly, the invention includes a droplet
microactuator including an SERS substrate. The droplet
65 microactuator is suitably arranged such that a droplet maybe
transported along a path or network of electrodes into contact
with the SERS substrate.
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In DNA detection methods of the invention, a Raman label
may be used. A label may be a non-sequence specific inter-
calator or a specific label covalently attached to a unique
probe sequence. Negatively charged labels may require the
use of a charge neutralizing agent, such as Spermine, to facili-
tate association of the label with a negatively charged surface,
such as silver nanobeads with a citrate surface layer. Aggre-
gating agents may also be used in order to improve signal.
Spermine may also serve as an aggregating agent.
8.11.3.5 Multisensor Capabilities
Preferred sensors are sensors for detecting absorbance,
fluorescence, chemiluminescence, as well as potentiometric,
amperometric, and conductometric sensors. The droplet
microactuator device and/or system of the invention includes
one or more of these detection capabilities. In one embodi-
ment, a droplet microactuator includes components for facili-
tating 2 or more of these detection methods on a single droplet
microactuator. In another embodiment, the droplet microac-
tuator includes one detection module, but the system is pro-
grammed to conduct more than one test using the module. In
this embodiment, processed sample droplets requiring testing
are sequentially moved into position for testing. Thus, mul-
tiple samples may be multiplexed over a detection spot where
a single sensor is used.
8. 11.4 Sensor Electronics
The detection capabilities may be provided as one or more
components of a sensor board. The sensor board may include
one or more sensors. The sensor board may include additional
electronic circuitry such as amplifiers, A/D converters, read-
out circuits and the like for conditioning or amplifying the
signal received from a droplet. The sensor board may include
control elements or other off-droplet microactuator compo-
nents of the detection protocol, such as control of motors for
moving components of the system.
In one embodiment, the sensor board includes a servo
motor controller for controlling a servo motor that moves a
magnetic field source into and out of proximity with the
droplet operation surface, thereby applying/removing the
magnetic field to/from the droplet microactuator. This
embodiment is useful for manipulating magnetically respon-
sive materials. The sensor board may also include power
supply elements and communication elements, including
without limitation, elements required to electronically couple
the sensor components or control components of the board to
the processor.
The optical detection location may include specialized
coatings, electrode designs, or other features that facilitate
optical detection. For example, the detection spot may
include a specialized pad and/or coating that facilitates its
operation as a background surface for optical measurement.
In certain embodiments, such as nucleic acid amplification
applications, the preferred optical detection method is fluo-
rescence quantitation. In such embodiments, the detection
spot may be selected to shield background fluorescence
present in the microactuator substrate or coatings disposed on
the microactuator substrate. For example, in one embodi-
ment, the microactuator is comprised of a printed circuit
board substrate and the detection spot is comprised of a gold
pad which shields the background fluorescence of the sub-
strate from the sensor thereby facilitating fluorescent mea-
surement of a droplet positioned on the pad. The pad may be
formed in a metal layer disposed directly on the substrate or
disposed on an intervening layer disposed on the substrate.
Preferably, the metal layer in which the pad is formed
should be disposed on top of any layers exhibiting significant
background fluorescence. In one embodiment the pad is dis-
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posed directly on a printed circuit board substrate being
formed in the same metal layer as the electrodes for control-
ling the droplet. In this embodiment, the dielectric material
(which may also exhibit background fluorescence) may be
5 disposed above the metal layer and is selectively removed
from the detection pads, but not the control electrodes.
Thus, a low background fluorescence detection spot may
be achieved through a combination of selective removal of
fluorescent material above the detection pad and optical
10 shielding of fluorescent material located below the pad. The
pad is preferably designed to minimize its interference with
other droplet microactuator functions. In the embodiment
described above, the pad may be formed in the same metal
layer as the control electrode but is separate and electrically
15 distinct from the control electrodes. The pad therefore
8.11.5 Detection Approaches
The invention provides a variety of approaches for sensing/
detecting signals or attributes of droplets. Many of these
20 approaches are described elsewhere in this specification. Thi s
section describes additional approaches that may be useful in
various settings.
An advantage of the droplet microactuator approach of the
invention includes the ability to decouple reaction steps in a
25 particular assay. Many biochemical assays use common end
reactions to generate a color, light or other detectable quan-
tity. Droplet-based protocols of the invention can be used to
combine the assay droplet with a droplet containing the end
reaction reagents at the point of detection. Decoupling of the
30 assay steps permits each to be separately optimized and sepa-
ration of the steps in time provides greater flexibility when
one of the reaction steps is rate limiting. For example chemi-
luminescence assays typically have better results at a basic
pH. For an assay which is optimal at an acidic pH assay
35 reaction can be completed first at the acidic pH, and the light
generation aspect of the reaction can be performed at a basic
pH.
The droplet microactuators of the invention are useful in
the study of rate kinetic reactions. Sample droplets can be
40 periodically dispensed from a reservoir in which a reaction is
occurring. The droplets can then be individually analyzed to
determine the time course of the reaction. The droplets can be
analyzed in real-time or mixed with another reagent for later
analysis. Electrowetting may also be used to rapidly mix
45 droplets for the purpose of studying fast reaction kinetics.
Changes in viscosity of a droplet can be measured as a
means for assessing the state of a chemical reaction inside the
droplet. For example, a coagulant can be added to a droplet of
blood followed by transporting the droplet and monitoring of
50 the ease of transport of the droplet. Greater degrees of coagu-
lation would make transport of the droplet more difficult
which can be detected as used as a measure of the degree of
coagulation.
Preferred sensors include optical sensors for sensing opti-
55 cal signals, such as absorbance, fluorescence, and chemilu-
minescence, and electrochemical sensors for sensing electro-
chemical properties, such as potentiometric properties,
amperometric properties, conductometric properties.
Accordingly, the droplet microactuator system of the inven-
60 tion includes components arranged to facilitate detection of
one or more of these properties. In one embodiment, 2 or
more of these properties are detected on one or more droplets
on a single droplet microactuator or otherwise accomplished
using a single droplet microactuator system. In another
65 embodiment, the droplet microactuator includes one sensor
of a particular type, and the system is programmed to conduct
more than one test using the sensor. In this embodiment,
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processed sample droplets requiring testing are sequentially
moved into position for testing, i.e., moved into sufficient
proximity to the requisite sensor to enable detection. Thus,
multiple samples may be multiplexed over a detection spot
for detection by a single sensor. Multiple sensor types may be
supplied on a single droplet microactuator using this
approach.
The droplet microactuator system may in some embodi-
ments be configured to deposit a droplet or sample to a loca-
tion that is exterior to the droplet microactuator for detection.
For example a droplet including (or potentially including) an
analyte can be deposited on a substrate for MALDI-TOF
analysis.
Droplets can be cyclically transported past a common
detection point in proximity to an appropriate sensor to allow
multiple reactions to be simultaneously monitored. For
example the droplet microactuator can include two or more
"tracks" that connect high and low temperature zones in a
flow-through PCR reaction chamber. A single detector is
placed at the intersection of the tracks. Droplet traffic can be
timed to cause droplets to sequentially pass over the detection
spot.
Examples of assays suitable for execution in the droplet-
based protocols of the invention on the droplet microactuator
of the invention include optical assays, such as absorbance
assays, fluorescence assays, bioluminescence assays and
chemiluminescence assays; and electrochemical assays, such
as potentiometric assays, amperometric assays, and conduc-
tometric assays. For example, various combinations of one or
more of the foregoing assay types can be used to identify
and/or quantify one or more analytes, such as proteins,
enzymes, nucleic acids, metabolites, electrolytes, gasses
(e.g., blood gases) and hematocrit. A system of the invention
may be programmed to conduct on a single droplet microac-
tuator various combinations of these assay types.
In one embodiment, a single droplet microactuator or sys-
tem includes detection capabilities for 2, 3, 4, 5, 6 or more
different kinds of assays. For example, the droplet microac-
tuator device, system and/or other components of a droplet
microactuator system may separately or together include one
or more detection components, such as components for
amperometry, potentiometry, conductometry, absorbance,
chemiluminescence, fluorescence, and/or temperature. Fur-
ther, a droplet microactuator system may be programmed to
execute assay protocols for conducting 2, 3, 4, 5, 6 or more
different kinds of assays on the same or multiple samples or
sample types.
Within the droplet microactuator, the droplet manipulation
components and the detection components may in some
embodiments be decoupled by providing them on separate
substrates. Similarly, various detection components may be
provided as part of a droplet microactuator device or system,
but separate from the droplet microactuator. Thus, for
example, a sensor may be provided on a cartridge to which the
droplet microactuator is coupled. The coupling is arranged so
that when the droplet microactuator is coupled to the car-
tridge, suitable components are aligned to permit detection.
Thus, for example, a photon sensor may be aligned with a
window or other transparent substrate so that when the drop-
let microactuator is properly mounted on the cartridge, pho-
tons emitted from a droplet on the droplet microactuator may
pass through the window or substrate for detection by the
photon sensor. Similarly, where a light source is necessary to
cause fluorescence of a molecule in a droplet on the droplet
microactuator, the light source may be mounted to the car-
tridge or other component of the droplet microactuator device
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or system and aligned so that the light source can reach the
droplet to produce the desired fluorescence.
In one embodiment, the droplet microactuator includes
electrodes for performing electrochemistry. Electrodes can
5 be patterned onto the electrowetting substrate to permit elec-
trochemical measurement of droplets in contact with the elec-
trodes. In a two-substrate droplet microactuator, the elec-
trodes for performing electrochemistry can be formed either
or both substrates. In some embodiments, transport elec-
io trodes and electrochemical measurement electrodes are pro-
vided on different substrates. The electrodes may include
membranes for fabricating ion-selective analyses.
8.12 Other Methods
The invention includes a method in which components of ai5 bench-top system are offered to or provided to a customer in
exchange for consideration. In one embodiment, the compo-
nents offered to or provided to the customer do not include the
PC. The software of the invention may be provided to the user
20 on a storage medium or made available for download via a
network, such as the Internet. The user may obtain other
components of the system, couple the components to a PC,
load the software on a PC, and thereby assemble system of the
invention.
25 The invention includes a method in which a bench-top
system is used to generate code for executing a protocol. Code
is uploaded into a separate system, such as a portable or
handheld system, which is offered to or provided to a cus-
tomer in exchange for consideration. The user may use the
30 system for executing the protocol.
The invention also includes a method in which program-
ming and/or system control is effectuated remotely via a
network, such as a telephone system or the internet. Thus, for
example, a system may be sold to a user, a programmer may
35 connect to the system via a user interface displayed via the
Internet to control the system, create programs using the
system, load programs on the system, and/or repair programs
on the system. As another example, the invention includes a
process whereby a remote user accesses a droplet microac-
40 tuator via a network and performs one or more droplet
manipulations on the system.
8.13 Kits
A further aspect of the invention is a kit including reagents,
sample collection devices, and/or a droplet microactuator or
45 cartridge for conducting the methods of the invention.
8.14 Concluding Remarks
The foregoing detailed description of embodiments refers
to the accompanying drawings, which illustrate specific
50 embodiments of the invention. Other embodiments having
different structures and operations do not depart from the
scope of the present invention.
As will be appreciated by one of skill in the art, the present
invention may be embodied as a method, system, or computer
55 program product. Accordingly, the present invention may
take the form of an entirely hardware embodiment, an entirely
software embodiment (including firmware, resident software,
micro-code, etc.) or an embodiment combining software and
hardware aspects that may all generally be referred to herein
6o as a "circuit," "module" or "system." Furthermore, the
present invention may take the form of a computer program
product on a computer-usable storage medium having com-
puter-usable program code embodied in the medium.
Any suitable computer useable medium may be utilized.
65 The computer-usable or computer-readable medium may be,
for example but not limited to, an electronic, magnetic, opti-
cal, electromagnetic, infrared, or semiconductor system,
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apparatus, device, or propagation medium. More specific
examples (a non-exhaustive list) of the computer-readable
medium would include some or all of the following: an elec-
trical connection having one or more wires, a portable com-
puter diskette, a hard disk, a random access memory (RAM),
a read-only memory (ROM), an erasable programmable read-
only memory (EPROM or Flash memory), an optical fiber, a
portable compact disc read-only memory (CD-ROM), an
optical storage device, a transmission medium such as those
supporting the Internet or an intranet, or a magnetic storage
device. Note that the computer-usable or computer-readable
medium may even be paper or another suitable medium upon
which the program is printed, as the program can be electroni-
cally captured, via, for instance, optical scanning of the paper
or other medium, then compiled, interpreted, or otherwise
processed in a suitable manner, if necessary, and then stored
in a computer memory. In the context of this document, a
computer-usable or computer-readable medium may be any
medium that can contain, store, communicate, propagate, or
transport the program for use by or in connection with the
instruction execution system, apparatus, or device.
Computer program code for carrying out operations of the
present invention may be written in an object oriented pro-
gramming language such as Java, Smalltalk, C++ or the like.
However, the computer program code for carrying out opera-
tions of the present invention may also be written in conven-
tional procedural programming languages, such as the "C"
programming language or similar programming languages.
The program code may execute entirely on the user's com-
puter, partly on the user's computer, as a stand-alone software
package, partly on the user's computer and partly on a remote
computer or entirely on the remote computer or server. In the
latter scenario, the remote computer may be connected to the
user's computer through a local area network (LAN) or a
wide area network (WAN), or the connection may be made to
an external computer (for example, through the Internet using
an Internet Service Provider).
The present invention is described with reference to flow-
chart illustrations and/or block diagrams of methods, appa-
ratus (systems) and computer program products according to
embodiments of the invention. It will be understood that each
block of the flowchart illustrations and/or block diagrams,
and combinations of blocks in the flowchart illustrations and/
or block diagrams, can be implemented by computer program
instructions. These computer program instructions may be
provided to a processor of a general purpose computer, spe-
cial purpose computer, or other programmable data process-
ing apparatus to produce a machine, such that the instruc-
tions, which execute via the processor of the computer or
other programmable data processing apparatus, create means
for implementing the functions/acts specified in the flowchart
and/or block diagram block or blocks.
These computer program instructions may also be stored in
a computer-readable memory that can direct a computer or
other programmable data processing apparatus to function in
a particular manner, such that the instructions stored in the
computer-readable memory produce an article of manufac-
ture including instruction means which implement the func-
tion/act specified in the flowchart and/or block diagram block
or blocks.
The computer program instructions may also be loaded
onto a computer or other programmable data processing
apparatus to cause a series of operational steps to be per-
formed on the computer or other programmable apparatus to
produce a computer implemented process such that the
instructions which execute on the computer or other program-
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mable apparatus provide steps for implementing the func-
tions/acts specified in the flowchart and/or block diagram
block or blocks.
This specification is divided into sections for the conve-
5 nience of the reader only. Headings should not be construed
as limiting of the scope of the invention.
It will be understood that various details of the present
invention may be changed without departing from the scope
of the present invention. Furthermore, the foregoing descrip-
io tion is for the purpose of illustration only, and not for the
purpose of limitation, as the present invention is defined by
the claims as set forth hereinafter.
We claim:
1. A droplet microactuator system comprising:
15	 (a) a cartridge comprising:
(i) a droplet microactuator comprising a substrate com-
prising electrodes configured to conduct droplet
operations in a gap formed by the substrate of the
droplet microactuator and a second substrate;
20	 (ii) a cartridge reservoir and a fluid path from the car-
tridge reservoir into the gap;
(iii) a mechanical mechanism, electrical mechanism,
pressure source and/or vacuum source for forcing
fluid through the fluid path; and
25	 (iv) a droplet inthe gap comprising magnetically respon-
sive beads;
(b) a magnetic field source arranged to immobilize the
magnetically responsive beads in the droplet in the gap
during a droplet operation mediated by the electrodes;
30 (c) an optical sensor configured in a sensing relationship
with the droplet microactuator, such that the sensor is
capable of sensing an optical signal from and/or an opti-
cal property of one or more droplets on the droplet
microactuator; and
35	 (d) one or more processors electronically coupled to the
droplet microactuator and programmed to:
(i) control the droplet operations on the droplet micro-
actuator, wherein the droplet operations conduct one
or more droplet-based assay protocols using droplet
40 
operations comprising one or more electrowetting-
mediated droplet operations and the droplet-based
assay protocols comprise one or more electrowetting-
mediated bead-washing protocols; and
45	
(ii) process electronic signals from the optical sensor.
2. The system of claim 1 wherein:
(a) the system further comprises a light excitation source
arranged to direct light at an excitation wavelength to a
fluorescent species in a droplet on the droplet microac-
50	 tuator thereby causing such species to fluoresce; and(b) the optical sensor is configured to sense fluorescence
from fluorescing species in the droplet.
3. The system of claim 1 wherein:
(a) the droplet comprises a biological fluid;
55	 (b) the system further comprises a light source arranged to
direct light through a droplet; and
(c) the optical sensor is configured to sense light from the
droplet.
4. The system of claim 1 wherein the optical sensor is
60 configured to sense bioluminescence or chemiluminescence
from a droplet on the droplet microactuator.
5. The system of claim 1 wherein the optical sensor is
configured to sense light scattering from a droplet on the
droplet microactuator.
65 6. The system of claim 1 wherein the optical sensor is
configured to sense turbidity from a droplet on the droplet
microactuator.
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7. The system of claim 1 wherein the optical sensor com-
prises a sensing component selected from the group consist-
ing of photosensors and photon sensors.
8. The system of claim 1 wherein the optical sensor com-
prises a sensing component selected from the group consist-
ing of photodiodes, avalanche photodiodes, photomultiplier
tubes and photon-counting photomultiplier tubes.
9. The system of claim 1 comprising two or more types of
sensors.
10. The system of claim 1 programmed to execute droplet
operations for sequentially presenting single droplets to mul-
tiple sensors.
11. The system of claim 1 programmed to execute droplet
operations for presenting multiple droplets to multiple sen-
sors.
12. The system of claim 1 programmed to execute droplet
operations for presenting multiple droplets to multiple sen-
sors in a substantially parallel manner.
13. The system of claim 1 programmed to execute droplet
operations for presenting multiple droplets to multiple sen-
sors for conducting a single assay type.
14. The system of claim 1 programmed to execute droplet
operations for presenting multiple droplets to multiple sen-
sors for conducting multiple assay types.
15. The system of claim 1 wherein the system is pro-
grammed to execute two or more different droplet-based pro-
tocols for conducting a droplet-based assay.
16. The system of claim 1 wherein the system is pro-
grammed to execute two or more different droplet-based pro-
tocols for conducting multiple tests starting with a single
sample droplet.
17. The system of claim 1 wherein the system is pro-
grammed to execute two or more different droplet-based pro-
tocols for conducting tests on multiple sample droplets.
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18. The system of claim 1 wherein the droplet-based pro-
tocols comprise an immunoassay protocol for a human diag-
nostic test making use of the magnetically responsive beads.
19. The system of claim 1 wherein the droplet-based pro-
s tocols comprise a protocol for amplifying and capturing a
nucleic acid on the magnetically responsive beads and elec-
trowetting-mediated bead-washing of the magnetically
responsive beads.
20. The system of claim 1 wherein the droplet-based pro-
10 tocols comprise a protocol which makes use of a sample
droplet comprising a fluid selected from the group consisting
of whole blood, serum, plasma, sweat, tear, saliva, sputum,
cerebrospinal fluids, amniotic fluids, seminal fluid, vaginal
excretions, serous fluid, synovial fluid, pericardial fluid, peri-
15 tonal fluid, pleural fluid, transudates, exudates, cystic fluid,
bile, urine, gastric fluids, intestinal fluids, fecal samples,
swabs and washes.
21. The system of claim 1 wherein one or more of the
droplet operations is dielectrophoresis-mediated.
20 22. The system of claim 1 wherein the droplet microactua-
tor is configured and the system is programmed to conduct 2
or more tests beginning with a single droplet of sample rang-
ing from about 1 nL to about 10 lLL.
25 23. The system of claim 1 wherein the droplet microactua-
tor is configured and the system is programmed to conduct 5
or more tests beginning with a single sub-microliter droplet of
sample ranging from about 1 nL to about 10 µL.
24. The system of claim 1 wherein the droplet microactua-
30 for is configured and the system is programmed to conduct 10
or more tests beginning with a single sub-microliter droplet of
sample ranging from about 1 nL to about 10 µL.
